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Abstract
Risk of cardiac conduction slowing (QRS/PR interval prolongations in mon-
itored electrocardiograms) is assessed in nonclinical studies, where the current As-
traZeneca strategy involves ensuring high margins to in vitro effects and statistical
tests to identify in vivo effects. This thesis aims to improve QRS/PR risk assessment
using pharmacokinetic-pharmacodynamic modelling for describing QRS/PR effects
and evaluating translation to human effects.
Data for six compounds were collected from the literature and previously
performed in vitro (sodium/calcium channel), in vivo (guinea pig/dog) and clin-
ical AstraZeneca studies. Mathematical models were developed and evaluated to
describe and compare effects across compounds and species.
Key results were that proportional drug effect models often suffice for small
QRS/PR changes (up to 20%), while larger effects require nonlinear models. Heart-
rate correction and circadian rhythm models reduced residuals primarily for de-
scribing baseline PR intervals, with highest impact in humans followed by dogs and
guinea pigs. Meaningful (10%) human QRS/PR changes correlated to low levels of
sodium channel block (3-7%) and calcium channel binding (13-21%) and to small
effects in guinea pigs and dogs (QRS 2.3-4.6% and PR 2.3-10%). This suggests that
worst case human effects can be predicted by assuming four times greater effects at
the same concentration from dog/guinea pig.
Small changes in vitro and in vivo consistently translate to meaningful PR/QRS
changes in humans across compounds. Accurate characterisation of concentration-
effect relationships therefore require a model-based approach. Although the pre-
sented work is limited by the small number of investigated compounds, it provides
a starting point for predicting human risk using routine QRS/PR data to improve
the safety of new drugs.
xix
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Chapter 1
Introduction
Adverse cardiovascular (CV) effects caused by abnormal function of the heart are a
major cause of the withdrawal of marketed small molecule drugs and of late stage
attrition in drug development [5, 6]. Important biomarkers for heart function include
the duration of key intervals monitored in the electrocardiogram (ECG), such as
the QT, QRS and PR intervals. Most known is the prolongation of the heart-rate
corrected QT (QTc) interval, corresponding to delayed ventricular repolarisation.
Nonclinical and clinical observations have linked QTc prolongation to inhibition of
the human potassium channel encoded by the ether-a-go-go-related gene (hERG)
and to risk of the potentially lethal arrhythmia Torsades des Pointes (TdP) [7, 8].
Numerous investigations provide insights for identifying and predicting risk of QTc
prolongation in the clinic [9, 10, 11, 12, 13, 14]. However, much less is known of the
nonclinical to clinical translation of conduction liabilities manifested in the ECG as
QRS and PR prolongations [15]. QRS widening is linked to sudden cardiac death in
healthy males [16] and PR prolongations are associated with increased risk of atrial
fibrillations and death in risk populations [17]. Identifying QRS/PR risks of drug
candidates already in nonclinical studies is therefore vital for the progression of safe
compounds into first clinical trials.
As most quantitative investigations prior to this work had focused on QTc„
QRS and PR intervals were selected as the focus for this thesis. Established mod-
elling and simulation (M&S) methods allows the identification, quantification and
prediction of nonclinical and clinical QTc effects [1, 10, 14] and similar models and
methods may be useful also for QRS and PR. Applying M&S methods to QTc has
been shown to improve the power to detect and quantify small effects in simulated
pre-clinical studies [18]. Furthermore, incorporation of factors predictive of baseline
effects such as sex, age, heart rate corrections and circadian rhythms has been shown
to reduce unexplained residual variability and improve the estimation of drug effects
[10, 14]. In addition to improved sensitivity to detect risks, M&S has been used to
investigate the relative sensitivity of nonclinical assays compared to the clinic, pro-
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viding information on the translational relationship and allowing quantitative risk
assessment and prediction to humans. For example, investigations into the dog to
human translation of clinical QTc effects have suggested that 2-8 ms QTc change in
dogs translate to 10 ms change in humans [12]. Similar M&S analyses could provide
a framework for improved identification, prediction and mitigation of risks related
to changes in QRS/PR durations.
Nonclinical CV safety assays for detection of conduction slowing include
molecular-, cell- and tissue-based in vitro assays and in vivo telemetry studies. Func-
tional ion channel inhibition assays and binding assays are used to assess the potency
to inhibit or bind to cardiac ion channels in vitro, and are typically conducted in early
discovery phases. The major ion channels studied to assess risk of conduction slow-
ing are the sodium (Nav1.5) and L-type calcium (Cav1.2) channels. Drug-induced
QRS widening is primarily linked to Nav1.5 inhibition, and recent studies suggest
that QRS widening may occur already at exposures corresponding to low inhibitions
in vitro. A margin of 30-100-fold between potency to human Nav1.5 (hNav1.5) and
maximum free (unbound) plasma concentrations have been suggested to reduce risk
of QRS widening in the clinic [19]. Another study found that <10% block of hNav1.5
may lead to QRS widening in humans [20]. The primary mechanism for drug-induced
PR prolongation is AV block through Cav1.2 inhibition [15], however, safety margins
for Cav1.2 were not identified in the literature. Early CV safety assessment could
thus be improved by increased quantitative understanding of the in vitro to clinical
translation of QRS and PR prolongations.
In vivo investigations of drug-induced effects on ECG intervals are typically
conducted in anaesthetised and/or conscious rats, guinea pigs and dogs [21, 22, 23].
At AstraZeneca, CV safety rodent animal studies are typically conducted at the lead
optimisation phase, providing the first data on CV effects in complete systems. For
the development of small molecule drugs, the lead optimisation stage involves the
optimisation of lead compound series, and the final compound is yet to be selected.
CV safety information is therefore available at a time of (relatively) low accumulated
cost and high chemical choice. CV safety studies in dogs or non-human primates are
conducted following candidate selection, and are required for all compounds prior to
first time in human (FTIM) studies, primarily to evaluate potential effects on QTc
[24]. While QTc modelling is routinely conducted at AstraZeneca, allowing quanti-
tative risk assessment, effects on QRS and PR intervals are primarily evaluated by
point-wise statistical tests. As QRS and PR effects similar to QTc may be smaller in
dogs compared to humans, safety risks may not be detected as effectively as possible
in the nonclinical and clinical studies. Also, this method does not allow for quantita-
tive comparisons between candidates and to competitors nor clear evaluations of the
therapeutic window. Improved methods for analysing the nonclinical and clinical
data may thus improve risk assessment, reduce unnecessary animal usage and risk
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to humans and increase efficiency in drug discovery and development.
1.1 Aims and objectives
Ultimately, the goal within safety pharmacology is to mitigate safety risks as early
in drug discovery and development as possible in order to reduce risk of exposing
volunteers and patients to unsafe drugs and to spare animal lives. A new modelling
framework for quantifying and predicting drug-induced QRS and PR effects in hu-
mans may lead to earlier identification of conduction liabilities, and consequently to
reduced risk to humans and to more efficient drug discovery and development. The
aim of this thesis is therefore to increase the understanding of how drug-induced
cardiac conduction slowing in humans, reflected by QRS and PR prolongations in
monitored ECGs, may be predicted and mitigated using nonclinical in vitro and in
vivo data, with the following objectives:
1. Apply and develop models to quantify QRS and PR intervals monitored in
nonclinical species and in humans at baseline conditions and during drug treat-
ment.
2. Investigate the translation between nonclinical in vitro and in vivo effects and
clinical QRS and PR prolongations.
3. Develop a model framework to quantitatively predict QRS and PR prolonga-
tions in humans using nonclinical data, that can be adopted by the pharma-
ceutical industry to improve safety assessment.
1.2 Thesis outline
This thesis will present novel methods for prediction of QRS and PR effects in
humans using nonclinical in vitro and in vivo data, where the resulting predictions
can help inform and improve decisions for compound selection, progression and
development. The work is divided into separate chapters as detailed below:
• Chapter 2 provides relevant background information regarding M&S tech-
niques within pharmacology, a brief discussion of the mechanisms of car-
diac electrophysiology relevant to this work and a review of current M&S
approaches used within CV safety assessment.
• Chapter 3 presents work performed related to parameter identifiability of a
set of pharmacodynamic models. Several of these models were later applied in
3
this thesis.
• Chapter 4 presents the compounds that were investigated in this thesis and
the studies from which data were collected. These studies include nonclinical
assays previously performed or outsourced by AstraZeneca, a clinical Phase I
study performed by AstraZeneca and published studies identified from litera-
ture searches.
• Chapter 5 presents the development of mathematical models using the col-
lected in-house data for each investigated compound and species, including
guinea pigs, dogs and humans. These models were developed with the higher
purpose of performing translational analyses, but the results also provides
useful information on appropriate models for characterising these effects in
animals and humans.
• Chapter 6 presents the development of mathematical models for the clinical
effects observed in the collected literature data. These models were developed
with the higher purpose of performing translational analyses.
• Chapter 7 presents translational analyses performed using the models devel-
oped in Chapters 5 and 6, but also using additional mechanistic methods.
Investigations into the translations were conducted between in vitro, in vivo
and clinical effects. This chapter also presents how the results of these analyses
can be used to predict effects in humans using the nonclinical data.
• Chapter 8 concludes the work conducted for this thesis and addresses how
far the aims and objectives of this thesis have been met. In addition, future
work to further advance nonclinical risk assessment of cardac conduction are
suggested.
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Chapter 2
Background
2.1 Introduction
This chapter aims to provide background information of relevance to this thesis.
It comprises a brief overview of M&S methodologies within pharmacology, a brief
discussion of the mechanisms of cardiac electrophysiology and a review of the M&S
approaches that are currently used within CV safety assessment.
2.2 Modelling & simulation within pharmacology
Many different types of data are collected during drug discovery (nonclinical phase)
and development (clinical phase), and integration and understanding of these data
is key to making the right decisions at any stage of this process [25, 26, 27]. Ap-
plying M&S can impact both drug discovery and development. For example, M&S
is in drug development used to quantify and explain sources of variability, inform
study design, make comparisons to competitor compounds, refine dosing schedules
and to predict effects in untested populations, such as paediatrics [28]. In drug dis-
covery, M&S can impact target validation through improved understanding of the
hypothesised biological mechanism of action, predict exposure and effect in healthy
volunteers or patients and optimise experimental design both for further nonclini-
cal studies and FTIM [28, 29]. Also, M&S can in drug discovery be an integrated
part of the design-make-test cycle, where modelling results can be used to compare
effects of candidate compounds. These effects can be both desired (efficacy) and
unwanted (off-target, potentially toxic), thereby quantifying the therapeutic index
of the compounds (the margin between efficacy and toxicity). M&S can thus, in
addition to improving integration of efficacy data, inform and improve the identifi-
cation, evaluation, prediction and mitigation of safety liabilities [1]. QRS and PR
prolongations, which are the topic of this work, are for non-arrhythmic indications
typically undesired off-target effects that should be mitigated.
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2.2.1 Pharmacokinetic and pharmacodynamic modelling
M&S approaches within pharmacology are traditionally centred around pharma-
cokinetic (PK) and pharmacodynamic (PD) modelling. PKPD modelling allows the
integration of data across subjects, doses and time points, as well as the capture of
delayed effects, effects in noisy data and baseline variations over time; all of which
would be more difficult to analyse through the application of standard statistical
approaches.
2.2.1.1 Modelling the pharmacokinetics
The pharmacokinetics of a drug describe the processes that govern drug exposure,
such as drug absorption, distribution, metabolism and excretion (ADME), and phar-
macokinetic models aim to quantitatively link dose administration to drug exposure
(concentration in whole blood or plasma). Drug concentrations at the site of ac-
tion would be preferred as these are likely to more accurately predict drug effects,
however, plasma concentrations are typically used as a substitute for effect site con-
centrations as these are more readily obtained. PK data typically consist of plasma
concentrations measured at specific time points following the administration of one
or several doses.
Empirical PK models may consist of a series of exponentials, consistent with
the number of linear phases visible when plotting the observed concentration data
over time on a logarithmic scale. Though useful for interpolation, the parameters of
these models are difficult to interpret physiologically. Through re-parameterisation,
these models can also be described by compartmental models. Compartmental mod-
els are simple models incorporating the concepts of drug absorption, distribution and
elimination where features of the model, such as number of compartments or non-
linear terms, tend to be driven by the experimental data. Typically, first-order rate
constants define the exchange of drug between well-mixed compartments represent-
ing different regions of the body where the drug equilibrates at different rates. An
example of a linear two-compartment model with first order absorption is provided
in Figure 2.1.
In this example, c1 is the plasma drug concentration (which is typically
observed), a0, a1 and a2 the amounts of drug in the gut, central and peripheral
compartments (where the peripheral compartment represents slowly equilibrating
tissues), f the oral bioavailability, V the volume of distribution of the central com-
partment, ka the rate-constant for first-order absorption of drug from the gut to the
central compartment, ke the rate constant for first order elimination of drug from
the central compartment and k12 and k21 controls the distribution to the periph-
eral compartment. Experimental plasma concentration data typically support the
fitting of 1-3 compartments. Also, it is not uncommon to see non-linear absorption
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Corresponding system equations:
a˙0 = −ka ∗ a0
a˙1 = ka ∗ f ∗ a0 − (k12 + ke) ∗ a1 + k21 ∗ a2
a˙2 = k12 ∗ a1 − k21 ∗ a2
(2.1)
with observations
y = c1 = a1/V
Figure 2.1 Example of a 2 comparment PK model with iv and oral administration
or elimination rates, typically visible upon dosing with a large range of doses. The
plasma concentrations seldom match the concentrations where the pharmacological
effects occur, as this is often in target tissues and may also be inside cells. However,
although imperfect, plasma concentrations are extremely important biomarkers for
pharmacological and toxicological effects.
While the compartments of data-driven PK models are abstract and rarely
represent specific parts of the body, physiology-based (PB) PK models connect com-
partments to specific tissues, incorporating physiological properties such as tissue
volumes and blood flow rates as well as drug-specific parameters such as partition
fractions [30]. Such models are more complex to parameterise, and are therefore
more costly to develop. PB-PK models have improved predictions of drug disposi-
tion between species as individual parameters can often be scaled using physiological
values specific to each species [31].
2.2.1.2 Modelling the pharmacodynamics
While the pharmacokinetics of a drug in simple terms describes the link between
dose and plasma concentrations, the pharmacodynamics is concerned with the effects
the drug has on the body. This includes both desired and unwanted effects, where
the measured effects may be sensitive biomarkers or clinical outcomes. Clinical
outcomes are direct measures of the effects of drug treatment, such as the cure of
disease, adverse events or survival, and can therefore take a long time to manifest.
Biomarkers are directly or indirectly linked to drug concentrations and/or the clinical
outcome, and may be biochemical measurements such as levels of specific proteins
or chemicals, or physiological measurements such as heart rate or blood pressure.
A useful classification of biomarkers, separating biomarkers into intermediary steps
which may be incorporated into mathematical models, is described in [32] and shown
in Figure 2.2. Biomarkers are often used as surrogates for clinical outcomes as the
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readout typically is faster, allowing shorter and more efficient assays and trials.
Figure 2.2 Biomarker classification based on their relation to clinical effects of drugs.
Adapted from [32].
The processes from drug exposure to physiological effects, such as changes
in biomarkers, can be described by pharmacodynamic (PD) models. Empirical PD
models aim to describe the data without including details of the processes leading to
the effects, thus limiting the number of assumptions required when developing the
model. A strictly empirical model may be any mathematical function, however, it is
common to use descriptive models derived from receptor theory. Many pharmaco-
logical and toxicological effects occur after interaction between a drug molecule and
a receptor, and these effects tend to saturate at high drug concentrations. This is
often modelled with the Emax model given by
E = EmaxC
γ
ECγ50 + Cγ
(2.2)
where E is the pharmacological effect, Emax the maximal effect, EC50 the concen-
tration at half-maximum effect and γ a shape parameter determining how steep the
curvature is (Hill factor). The shape of this model is illustrated in Figure 2.3, where
Emax reflects the efficacy of the drug while EC50 reflects its potency.
Figure 2.3 Shape of the Emax model curve, illustrating the influence of each parameter.
At low concentrations, the concentration term in the denominator becomes
negligible and therefore the model can be approximated by the power model, given
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by
E = EmaxC
γ
ECγ50
= a ∗ Cγ (2.3)
where a is the ratio of Emax/ECγ50. Furthermore, when γ equals 1, the effect is at
low concentrations proportional to Emax/EC50, resulting in the proportional model
given by
E = EmaxC
EC50
= slopeC (2.4)
where slope is the proportional drug effect. Proportional and power models are
commonly used to describe small effects. These alternative concentration-driven
PD models can be tested to see which best describes the observed data.
2.2.1.3 Accounting for time delays
Time delays may be present between plasma concentrations and observed effects.
These may be identified in hysteresis plots of concentrations plotted against response,
showing the timing of the observations as illustrated in Figure 2.4.
Figure 2.4 Time delays between plasma and effect can be visualised in a hysteresis plot. In
this example, the purple dots are observations and the black line reflect the order of data
collection. At similar drug concentrations, the effect appear to be greater when measured
at late time points compared to early time points.
Short time delays that are assumed to arise from a delay in distribution to the
target tissues may be modelled with an effect compartment model [33]. This model
assumes that the effect occurs at a hypothetical “effect site”. The distributional
delay between the plasma concentrations Cc and the concentrations at the “effect
site” Ce is given by
(dCe)/dt = ke0(Cc − Ce) (2.5)
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where ke0 governs the distribution rate. Importantly, plasma concentrations are
typically assumed to be unaffected.
Pharmacodynamic models may also incorporate assumptions of the mecha-
nisms of drug action. If the kinetics of dissociation from the receptor is the rate-
limiting step, the system can for example be modelled applying a receptor model
according to
R˙C = kon · (Rtot −RC) · C − koff ·RC
E = ke ·RC
(2.6)
where RC is the drug-receptor complex, Rtot the total receptor concentration, C
the drug concentration at the effect site, kon and koff the rates of binding and
dissociation of the drug-receptor complex and ke the proportional effect elicited by
the receptor-bound drug. This model relates to the Emax model by EC50 = koff/kon
and Emax = Rtot ·ke. Contrary to the receptor model, the Emax model assumes rapid
receptor binding kinetics compared to the time scale on which data are collected.
In this model, the relationship between drug-receptor complex and pharmacological
effect is assumed to be proportional. Alternative models may easily be applied to
describe this relationship.
Pharmacological responses may also be slow due to the processes that occur
between receptor binding and response. A drug may act by increasing the pro-
duction or elimination rate of the target protein, or cascades of events may occur
that eventually lead to the pharmacological effect. Such slow processes in the signal
transduction can sometimes be modelled using indirect response (turnover) mod-
els [34]. For these models, the response is assumed to be defined by a differential
equation given by
E˙ = kin − kout · E (2.7)
where kin is the zero-order (constant) rate of production of response, kout is the
first order rate of loss of response and the baseline level of response is the fraction
kin/kout. Concentration-driven drug effect models may be added to the rate param-
eters defining enhanced or inhibited rates dependent on drug concentration by for
example proportional or Emax type equations [34]. An example of a turnover model
where the drug enhances the production of response is given by
E˙ = kin(1 +
EmaxC
EC50 + C
)− kout · E (2.8)
where Emax and EC50 describe the drug-induced effect on kin. Series of turnover
models may also be used based on known mechanisms (and measured data or known
rate parameters) for signal transductions with several steps.
The benefit of including mechanistic understanding when developing models
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is the distinction between parameters of different type, such as species-, disease- or
compound-specific, enabling the improved integration of information from different
sources, such as in silico, in vitro and in vivo studies or knowledge. Importantly,
these approaches allow continuous refinement of hypotheses as more data become
available.
2.2.1.4 Operational model of pharmacological agonism
The relationship between the concentration of the drug-receptor complex and the
pharmacological response may be assumed to saturate with the bound receptor to
a physiological maximum of response. This is assumed in the operational model of
pharmacological action [35] given by
E = Em ·RC
n
RCn50 +RCn
=
Em
RtotC
Kd+C
n
RCn50 + RtotCKd+C
n =
Em(RtotC)n
(Kd + C)nRCn50 + (RtotC)n
, (2.9)
so, if τ = Rtot/EC50, then
E = Em(τC)
n
(Kd + C)n + (τC)n
(2.10)
where Em is the maximum response possible in the system, τ the transducer ratio,
n describes the sigmoidicity of the relationship between the drug-receptor complex
and the response and Kd the equilibrium constant for drug binding to the recep-
tor. The transducer ratio τ is the fraction of the total receptor concentration Rtot
divided by the concentration of RC that induces a half-maximum response. As
such, τ is a measure of the efficiency of the transduction from receptor binding to
pharmacological effect. For translational modelling, receptor models such as the op-
erational model separate the drug-specific parameters (Kd) from the system-specific
parameters (Em, τ, n) [9]. With some assumptions, for example that the modelled
mechanism is the sole mechanism of the effect and that the concentrations in the
in vitro and in vivo settings are equivalent, the drug-specific parameters may be
estimated in vitro. Also, the system-specific parameters are (in theory) the same
for drugs that act by the same mechanism. This may potentially be used to predict
responses between species or for new compounds, once the system properties are
known and Kd has been generated.
Through pharmacodynamic (PD) models, the concepts and processes of the
pharmacokinetics and pharmacodynamics of a drug can be combined and stud-
ied in an integrated way, quantifying individual processes from dose administration
through exposure to physiological effects.
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2.2.2 Non-linear mixed effects modelling
An important aspect of modelling physiological processes is to understand and quan-
tify variability. The same dose may result in different exposure if given to different
subjects, or even to the same subject twice. Similarly, the same exposure may lead
to different pharmacodynamic effects for different subjects. This occurs as a result
of differences in the processes involved, absorption rates may change after a meal,
and the density of metabolising enzymes may differ between subjects. Quantifying
and understanding the sources of variability is important to improve drug efficacy
and reduce the risk of unwanted effects.
Simple approaches that have been used to model changes in a population
rather than in an individual include estimating parameter values to averaged data,
pooling the data and treating them as if measured in a single individual (naive pooled
approach) and modelling each individual separately and averaging the estimated pa-
rameters (two-stage approach) [28]. However, these methods have been shown to
potentially lead to biased results [36] (Table 2.1). Also, none of these approaches
takes prior assumptions about the variability into account. A better approach is to
incorporate the assumption of variability directly into the model definitions, adopt-
ing a mixed effects approach [37]. Mixed effects models comprise of fixed effects,
defined by a deterministic model structure, and random effects, defined by statisti-
cal models allowing parameter values to vary in a population following pre-defined
distributions. In some cases the two-stage approach gives similar results as a mixed
effects approach, e.g. when modelling a small number of individuals with rich data
for each individual.
Table 2.1 Benefits and limitations of different approaches to deal with population data.
Approach + −
Average data Can result in biased structure and
estimates
Naive pooled Easy to implement No measure of variability between
subjects
Quick first estimates Difficult to deal with missing data
or varied sample sizes
Two-stage Easy measure of variability be-
tween subjects
Requires rich data for each subject
Difficult to deal with missing data
or varied sample sizes
Variability may be overestimated
Mixed effects Can quantify different sources of
variability
Requires specialised software
Reduces residual variability Time intensive
All data used simultaneously
Sparse or missing data can be in-
formed by remaining subjects
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In mixed effects models, the fixed effects describe the trends in the popu-
lation through a set of “population” parameters, which correspond to the average
parameter values (such as Emax or EC50) in the investigated population. The ran-
dom effects contain information on different types of variability in the population,
such as between-subject variability (BSV) or inter-occasion variability (IOV) in the
parameter values and residual unexplained variability (RUV). The RUV describes
the variance between the observed data and individual model predictions, and may
include for example measurement error, within-subject variability and model mis-
specification error. Quantifying known sources of variability using BSV and IOV
reduces the RUV, which is typically required. A general mixed effects model includ-
ing BSV and RUV is given by
yij = f (θi, xij) + ij , ij ∼ N
(
0, σ2
)
(2.11)
θi = θ + ηi, ηi ∼ N
(
0, ω2
)
(2.12)
where yij is the jth observation for subject i, f represents the structural model
with independent variables xij and parameter vector θi for subject i, and residual
variability ij . The parameter vector for subject i (θi) relates to the population
parameter vector θ by ηi. ij and ηi are assumed to be normally distributed with
mean 0 and standard deviations σ and ω, respectively. This implies that θi is
normally distributed with mean θ and standard deviation ω. Normal distributions
may be appropriate for parameters which can take positive and negative values.
Instead, log-normal distributions are often selected to describe variability of rate
parameters, as these often are assumed to be non-negative, and is given by
θi = θ + eηi , ηi ∼ N
(
0, ω2
)
(2.13)
where ηi is normally distributed with mean 0 and standard deviation ω. The dis-
tribution for the RUV is in the example above assumed to be normally distributed
and additive. Other commonly applied RUV models are the proportional and com-
bined error models. The combined error model comprise both an additive and a
proportional part. It is given by
y = f + (a+ b |f |)e (2.14)
where y is the observation, f the model function value, a the additive error, b the
proportional error and e are normally distributed random variables with mean 0 and
variance 1. For an additive error model, b is assumed to be 0, while for a proportional
error model, a is assumed to be 0.
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2.2.2.1 Estimating parameter values for mixed effects models
Parameters values of mixed effects models may be estimated using for example
parametric maximum likelihood (ML) approaches (implemented in NONMEM [38],
Phoenix [39] and Monolix [40]) or Bayesian methods (implemented in WinBUGS
[41]). The ML approach involves estimating the parameters values that maximise
the log of the likelihood of the observed data (given the model structure). Calculat-
ing this likelihood analytically is highly complicated even for simple mixed effects
models, and the parameter estimation is therefore accomplished by numerical meth-
ods [42].
Monolix 4.3.2 was used through-out this thesis for estimating the parame-
ter values of mixed effects models. The ML approach implemented in Monolix is
stochastic approximation expectation maximisation (SAEM) [43, 44]. This approach
is based on the expectation maximisation (EM) method [45], which can be used to
find ML estimates for the parameters θ of a model when the data are incomplete.
This is the case for mixed effects models, as the complete data consist of both the
observations for each individual subject y (known) and the individual parameter val-
ues ψ (unknown). The EM method iteratively updates estimates for the unknown
data and the parameter values to arrive at the ML estimator by separating each
iteration k into two steps; the expectation step where the function for the loglikeli-
hood of the complete data is created using the current estimate of the parameters
(θk), and the maximisation step where this function is maximised with respect to
θ to update the estimate of θ (θk+1). The EM method requires that the expecta-
tion of the loglikelihood is created in closed form, which limits its use to estimate
parameters of mixed effects models as these rarely can be solved analytically. In
the SAEM method, the expectation step is therefore replaced by two steps in order
to solve the system numerically, namely simulation and stochastic approximation.
Each iteration (k) in the SAEM algorithm thus consists of three steps:
1. Simulation: A Markov Chain Monte Carlo (MCMC) procedure using the
Hastings-Metropolis algorithm is used to generate a sequence of random sam-
ples for the individual parameters ψ (ψk) given the current approximation of
θ (θk). To improve convergance, more than one Markov Chain can be run.
2. Stochastic approximation: The approximation of the complete data likelihood
is updated using ψk and (with a reducing step-size when the number of itera-
tions increases) the expectation from the previous iteration.
3. Maximisation step: The estimation of θ is updated by maximising the approx-
imated complete data likelihood, resulting in the updated parameters θk+1.
This method was first implemented in Monolix, and has later been imple-
mented in other software, including NONMEM and Matlab. In addition to the
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estimated parameter values for the fixed effects and variance components of the
models, Monolix produces an estimate of the covariance matrices for the parame-
ters and estimates for the individual parameter values. The covariance matrices are
estimated by approximating the Fisher information matrix either by a linearisation
or a stochastic approximation approach. Also, the likelihood of the data given the
parameter values is approximated either by a Monte Carlo approach (importance
sampling) or by linearisation and is used to calculate summary statistics such as
minus twice the log of the likelihood (-2LL) and the Akaike information criterion
(AIC [46]), given by
AIC = −2LL+ 2P (2.15)
where P is the total number of parameters that are estimated. The AIC thus adds
a penalty to increasing the number of parameters.
2.3 Assessing cardiovascular (side) effects
The heart is the pump driving the CV system, supplying tissues with blood contain-
ing oxygen and vital nutrients while removing carbon dioxide and waste products.
This is accomplished by two loops of vasculature (arteries, veins, capillaries) joined
at the heart. The pulmonary circulation ensures the replenishment of oxygen while
the systemic circulation distributes oxygen to all cells in the body. The CV system
is essential for the survival of each cell and ultimately the organism. CV function is
controlled by the nervous and the endocrine systems to maintain homeostasis and
respond to stimuli, such as the increased oxygen need during exercise or changed
blood pressure caused by laying down. Side effects of drugs on the CV system may
cause long-term damage, potentially putting the patient at greater risk of mortality
and morbidity. Minimising drug-induced CV side effects is therefore essential for
the development of safe drugs.
2.3.1 Cardiac electrophysiology
The heart is divided into four chambers: The two right chambers pump blood
through the lungs while the two left chambers pump blood through the remain-
ing tissues. Blood is first loaded into the atria, which contract to load the ventricles,
followed by ventricular contraction to pump the blood around the body. The human
heart beats at a rate of about 60 bpm at rest, and the duration between the initia-
tion of each heart beat is thus around 1 s. These regular contractions are controlled
by electrical signals called action potentials (AP). Each heart beat is initiated at
the sino-atrial (SA) node, followed by propagation of the AP across the cardiac
tissues to ensure that different parts of the heart contract in a coordinated fashion
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and in the correct order. This AP propagation can be monitored using the ECG,
which measures the electrical stimulation across the body surface (Figure 2.5). The
standard 12-lead ECG is constructed from 10 electrodes placed across the subject’s
body, where 12 angles (leads) are measured simultaneously and combined to form
the standard ECG. Following initiation of the heart beat at the SA node, the AP
propagates through the atrial tissue. The PR (or PQ) interval corresponds to the
series of events from depolarisation and activation of the atria, leading to contrac-
tion of the atrial tissue, through the atrio-ventricular (AV) node, the His-Purkinje
system and the bundle branches and ends when the AP has reached the Purkinje
fibres. PR intervals are often monitored due to the large R wave being a more robust
measure compared to the smaller Q wave, although PQ intervals more accurately re-
flect atrial depolarisation and conduction through the AV node as PR intervals also
include a short initial part of the ventricular depolarisation (QR). After reaching
the Purkinje fibres, ventricular depolarisation follows as the AP conducts through
the ventricular tissues, giving rise to the QRS complex in the ECG. Finally, the
ventricles relax in the repolarisation phase, with the QT interval representing the
duration of the full ventricular action potential.
Figure 2.5 The ECG of normal sinus rhythm, highlighing the basic electrophysiology of a
heart beat. Initial activation of the sino-atrial (SA) node is followed by atrial depolarisation
and contraction, and conduction to the atrio-ventricular (AV) node. From the AV-node,
the action potential conducts through the Purkinje fibres to the ventricles, followed by
ventricular depolarisation and contraction. Finally, the ventricles relax in the repolarisation
phase.
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In the contractile cells of the heart (myocytes), the AP is controlled by ion
fluxes through membrane channels (Figure 2.6). Many different ion channels are
involved in the AP, and their prevalences vary between different parts of the cardiac
tissues (myocardium) to ensure optimal CV function, such as maintaining the delay
between atrial and ventricular contraction. This delay ensures the proper filling of
the ventricles and in turn a high cardiac output.
Figure 2.6 Opening and closing of ion channels in the myocyte membrane control the dif-
ferent phases of the cardiac action potential [47]. Phase 0: Depolarisation by rapid inward
INa current through the Nav1.5 channel. Phase 1: Early repolarisation through transient
outward IK current through the Kv4.3 channel. Phase 2: Plateau phase by balanced in-
ward ICa current through the Cav1.2 channel and outward IK current through the Kv11.1
(hERG) and Kv7.1 channels. Phase 3: Dominance of the repolarisation due to closing of
the hCav1.2 channels. Phase 4: Maintained resting potential due to outward IK current
through the Kir2.1 channel.
2.3.2 Biomarkers for cardiovascular safety
The importance of CV safety assessment is highlighted in a recent study, implicating
CV complications as the leading cause of drug withdrawals from the EU market be-
tween 2002 and 2011 [48]. CV risks of potential new drugs are routinely assessed in
drug discovery and development, aiming to identify CV risks early in order to min-
imise risks to volunteers and patients and to avoid costly late-stage drug attrition.
A panel of functional biomarkers is tested in clinical and nonclinical assays, and
typically includes heart rate (HR) and blood pressure (BP), ECG, indices of car-
diac contractility and, in nonclinical studies, structural damage by histopathological
changes of the heart and/or vessels (Figure 2.7).
The ECG is investigated by visual assessment and/or automated software
to find signs of arrhythmias and irregularities, to assess the amplitudes of peaks
and to identify changes in the durations of the intervals between specific peaks.
Key intervals are QT, PR and QRS, which, as described previously, correspond
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to different and specific events in the heart beat. Changes in the durations of
these intervals indicate undesired side effects for most new drugs, with the possible
exception of antiarrhythmic drugs.
As was mentioned in the introduction, the most known safety risk is prolon-
gation of the QTc interval, to which abundant observations have linked inhibition
of the hERG channel and risk of the potentially lethal arrhythmia Torsades des
Pointes (TdP) [7, 8]. QTc liabilities are regulated in the specific ICH guidelines for
pre-clinical (S7B, [24]) and clinical (E14, [49]) development, and QTc is the only
ECG biomarker for which a clear regulatory threshold of concern for clinical use has
been established. This threshold is stated in the E14 guidelines, where the upper
bound of the 95 % confidence interval around the mean QTc effect should be <10 ms
for all time points, measured in a thorough QT/QTc (TQT) study [49]. Since the
update of the E14 guidelines in December 2015, QTc effects may also be investigated
by PK-PD or PD modelling of other clinical data, where the upper bound of the
90% confidence interval should be <10 ms at the highest clinically relevant exposure
[50].
The focus of this thesis is however not QTc, but QRS and PR prolongations,
reflecting drug-induced slowing of cardiac conduction. Prolonged QRS and PR in-
tervals are linked to increased mortality and morbidity in cardiac risk populations
[15]. PR interval prolongations are primarily caused by delays in conduction through
the AV node and are associated with increased risk of atrial fibrillations and death
in risk populations [17]. Widening of the QRS complex represents slowed conduc-
tion through the ventricles and is linked to sudden cardiac death in healthy males
[16]. Early identification of these cardiac conduction liabilities is therefore vital for
effective nonclinical CV safety assessment. Contrary to QTc, QRS and PR intervals
are only regulated by the general requirement to evaluate undesirable pharmacody-
namic effects in the general in vivo safety pharmacology guidelines (ICH S7A [51]).
Also, no regulatory thresholds for acceptable levels of effects in clinical studies have
been established.
2.3.2.1 Nonclinical studies to assess conduction liabilities
Identification and mitigation of cardiac conduction liabilities is at AstraZeneca per-
formed using multiple nonclinical in vitro and in vivo assays (Figure 2.8). In vitro
assays primarily involve assessing the interaction of compounds with the cardiac
ion channels that are known to control the heart beat, where conduction slowing is
primarily studied by assessing effects on the sodium (Nav1.5) and L-type calcium
(Cav1.2) channels. Inhibition of Nav1.5 leads to reduced Na+ influx which slows ven-
tricular depolarisation, causing widening of the QRS complex (Figure 2.9) and/or
prolongation of the PR interval (reviewed in [19, 52]). In early discovery phases such
as the lead generation and lead optimisation phases, automated or conventional func-
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tional human Nav1.5 (hNav1.5) whole-cell voltage clamp assays are typically used
to identify compounds that inhibit hNav1.5 and reduce the Na+ flux in vitro. Safety
margins of 30-100 fold between predicted maximal exposures in humans (predicted
Cmax) and IC50 measured in vitro have been suggested for hNav1.5-QRS based on
collected information of in vitro potencies and clinical findings [19].
Potential mechanisms for PR prolongations are more complex, as the PR
interval represents action potential propagation through the atria, the AV node,
the His-Purkinje system and the bundle branches to reach the Purkinje fibres. The
major mechanism for drug-induced PR prolongation is AV block through inhibi-
tion of the cardiac L-type calcium (Cav1.2) channel (reviewed in [15], Figure 2.9).
Cav1.2 is activated following the fast Na+ depolarisation, initiating an influx of
Ca2+ that in turn triggers the release of intra-cellular Ca2+ deposits, provoking my-
ocyte contraction. Cav1.2 inactivates slowly and counter-acts repolarisation of the
myocytes through continued influx of Ca2+, and is thus also vital for maintaining
the plateau in the ventricular myocyte action potential influencing the QT inter-
val. Functional human Cav1.2 (hCav1.2) assays may be used to detect potential
conduction liabilities [53]. However, both conventional and automated functional
hCav1.2 assays have been shown to correlate poorly [54] to an in vitro contractility
assay using dog myocytes [55], showing low sensitivity with many false negative re-
sponders. Alternatively, radioligand binding to rat Cav1.2 (rCav1.2) may be used
to detect compounds that bind to Cav1.2. Two binding sites predictive of cardiac
contractility have been identified, namely the verapamil and diltiazem sites [54]. In
addition to hCav1.2 inhibition, rCav1.2 binding to these sites is therefore typically
analysed at AstraZeneca. In addition, PR prolongation may be caused by hNav1.5
inhibition e.g. through reduced conduction through the His-Purkinje system [56].
Contrary to hERG and hNav1.5, safety margins have not to the authors knowledge
been suggested for hCav1.2 inhibition or rCav1.2 binding.
In vivo investigations of drug-induced effects on ECG intervals may be con-
ducted in anaesthetised and/or conscious rats, guinea pigs and dogs [21, 22, 23].
Rodent animal studies are typically conducted early, at the lead optimisation phase,
providing the first data on cardiovascular effects in complete systems at a time of
(relatively) low cost and high chemical choice. Animal studies in dogs, or sometimes
minipigs or non-human primates, are conducted during pre-clinical development to
confirm the safety of compounds before first time in man (FTIM) studies as part of
regulatory requirements. Both conscious and unconscious animal telemetry studies
are used, as conscious animal studies enable long term safety assessment, while un-
conscious (open chest) animal studies enable measurement of additional variables,
reduce noise and allow for higher doses. ECGs are typically generated using auto-
matic systems for calculating the durations of the intervals, often followed by manual
checks at pre-defined time-points around which data are averaged to reduce noise
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Figure 2.8 Assays for cardiac conduction risk assessment at AstraZeneca. Cardiac con-
duction risk is mitigated during lead generation/optimisation by in vitro assays, primarily
assessing effects on Nav1.5 and Cav1.2. During lead optimisation, rodent in vivo studies
are conducted to assess cardiac safety, including QRS/PR interval prolongations in moni-
tored ECGs. Cardiac safety, including QRS/PR changes, is also evaluated in a large animal
telemetry study during pre-clinical development, and prior to human testing.
Figure 2.9 The ECG informs on electrophysiological changes in heart function as changes in
ion fluxes cause predictable changed in the ECG. Inhibition of the Cav1.2 calcium channel
slows down conduction through the AV node, leading to prolonged PR interval. Inhibition
of the Nav1.5 sodium channel leads to reduced rate of depolarisation across the myocyte
membrane, causing widening of the QRS complex. Figure by Matt Skinner, AstraZeneca.
and extracted for analysis. Any drug-induced effects on QRS and PR intervals are
typically identified by statistical tests, e.g. pair-wise comparison to the vehicle group
at each time point and evaluated considering additional information, such as drug
exposure and time point of the identified effects.
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2.3.3 Modelling & simulation for cardiovascular risk assessment
The following section describes the history and current status for a selection of
modelling approaches to assess CV safety in drug discovery and development, partly
published previously in Collins, Bergenholm et al. 2015 [1].
2.3.3.1 PKPD modelling of QTc, QRS and PR
PKPD modeling of QT prolongation began in the late 1970s and is arguably the
most characterized of all PK-ECG relationships, with numerous published models
in pre-clinical species and human [1]. Currently, PKPD modeling of clinical or
non-clinical data is routinely modeled using population (mixed effects) approaches
rather than individual or pooled datasets [57, 58], typically with direct models or
fast equilibrating effect compartments. The following factors have been identified
as important considerations in the modelling of QT [10, 14], and could also remain
relevant for QRS and/or PR intervals:
1. Heart rate correction, preferably individual specific in humans and animals
[59, 60].
2. Variability of the baseline including between subject variability, inter-occasion
variability and within-subject variability (e.g. a circadian rhythm modelled
using single or multiple cosine functions).
3. Subject demographic information such as age, sex.
4. Genetics.
5. Environmental or other factors such as obesity, physical activity, electrolyte
levels, blood pressure, blood glucose and alcoholism.
Modelling baseline variability of intervals in the ECG
QT interval duration is strongly dependent on HR and the use of correction methods
aim to remove the influence of heart rate, providing a more stable measure: QTc.
HR correction formulas include linear, fixed exponential (Bazett, QTcB, Fridericia,
QTcF) and individual exponential (exponents estimated to data, QTcI). QTcI and
QTcF has been shown to perform best in humans, while QTcI performed best in
pre-clinical species including dogs, guinea pigs and cynomolgus monkeys [59]. In ad-
dition to QT, QRS and PQ intervals have been shown to correlate to RR intervals
in a subject-specific manner [61], with PQ showing primarily positive correlations
and QRS small positive or negative correlations. Correcting to RR intervals may
therefore reduce variability also for modelling of QRS and PR intervals. Cosine
functions [62] have been used to account for within-subject variability in baseline
due to homeostatic mechanisms, external factors or circadian rhythms (regular di-
urnal fluctuations), either using typically single or where necessary multiple cosine
functions [12, 58, 63]. While early models were primarily developed by individual or
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pooled data modelling, population models are commonly applied today (reviewed in
[1]). Inter-individual variability is often included both for baseline and drug effect
parameters. This reflects the availability of high quality, rich ECG data combined
with more readily available software to conduct these analyses.
Modelling drug-induced effects on intervals in the ECG
Both empirical and systems level models have been used to investigate and predict
drug-induced ECG (primarily QT) effects. Empirical models that have been used
include both proportional and Emax models (Equations 2.2 and 2.4). In many cases,
proportional models described the drug effect adequately [1]. While it is expected
that drug effects will eventually saturate with exposure, proportional models may
be more prevalent for ECG changes, as maximal effects are often not achieved in
safety studies where doses are selected based on margins to the therapeutic exposure
and not to characterise full concentration-response relationships. Studies can also be
halted before reaching a maximum level due to lack of tolerability at these exposures.
However, Emax models can sometimes be fitted when the effects of anti-arrhythmic
compounds with intended effects on the ECG are evaluated. Once in the clinic,
concentrations required to reach maximal effect are less often reached for these same
reasons, leading to even fewer saturable models being observed. Where Emax models
have been utilised for clinical QTc changes, the maximal activity level appears to
be compound-specific rather than reaching a system specific or physiological upper
limit [1].
It is very common to observe a delay between blood or plasma drug concen-
trations and CV effect, resulting in hysteresis observable in a concentration-effect
plot. This time delay is often short, and of the order of minutes. Under these cir-
cumstances, an effect compartment model (Equation 2.5) is often applied to describe
the delay between the measured plasma concentrations and the distribution of drug
to the effect site [62]. Almost half of the ECG models reviewed in [1] included a time
delay, primarily using the effect compartment model and where the estimated time
delays rarely exceeded 30 minutes. The use of indirect response models (Equation
2.8) which describe the physiological turnover of the response parameter in terms
of synthesis and degradation is uncommon for ECG intervals. One potential reason
for this is that the effect of the drug on ion channel activity is expected to be rapid
once the compound has reached the myocytes, not requiring a turnover process to
have an effect. Although PK-PD modelling examples of intervals other than QT
are limited, it appears most other endpoints are typically treated similarly to QT.
The concentration-QRS relationship of a number of compounds has been investi-
gated in dogs [57] using a population approach, and this enabled comparison across
compounds and investigation of therapeutic window. The data were modelled as
percent change from baseline and the size of the estimated Emax for QRS change
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varied from 8 to 57 %.
2.3.4 Approaches to predict CV effects in humans
Methods to translate and predict CV risk in humans that incorporate different
levels of mechanistic insight are used and continously developed. Depending on the
questions asked, the current level of understanding of the system and the available
data, translational approaches involving models including different levels of detail
may be optimal. Three broad categories for modelling physiological systems to
describe pharmacodynamics can be defined:
1. Top-down (data-driven) models: Empirical models used to describe and quan-
tify data may be used to investigate translations by comparing effects between
species.
2. Systems pharmacology “middle-out” models: Systems-based models incorpo-
rating physiological processes and mechanism of action at targets may poten-
tially be used to predict effects in new species.
3. Mechanistic or systems biology models: Detailed models that combine knowl-
edge of the system from cellular targets to their impact at a cellular, tissue or
whole body level may potentially be used in combination with for example in
vitro data to predict effects in humans.
2.3.4.1 Empirical (top-down) translational approaches
In order to predict human effects from animal data, some assumptions must be made
considering the effect of the drug in humans compared to animals. Using PKPD
modelling, data can be integrated across subjects, doses and time points in order
to achieve good estimates of the effect in animals and humans, to be applied to
investigate empirical relationships between drug effects across species (Figure 2.10).
The most simple translational model would assume that the effect in the animal
species and humans are the same (either the absolute or relative effect compared
to baseline). Estimated drug effects from PKPD modelling can then be applied to
generate human predictions using predicted human drug concentrations. However,
the assumption of equal responses between animals and humans at the same drug
concentrations may not be ideal as animals and humans have different physiology.
Where simple physiological determinants control the drug effects, allometric
scaling may be used to quantify differences between animals and humans. Allometric
scaling may be used when the effects can be assumed to depend on a physiological
measure such as body mass, heart rate etc. The allometric relationship can for
example be given by
Y = a ∗M b (2.16)
24
Figure 2.10 Comparative assessment between species using descriptive PK-PD modelling and
simulation to identify predictive in vitro/in vivo assays and quantify empirical translational
relationships. Figure adapted from [1].
which implies that
log Y = b logM + log a (2.17)
where Y is the physiological parameter of interest,M is the body mass and a defines
the origin and b the slope of the logarithmic relationship. For example, while organ
weights scale proportionally to body mass, many biological rates (e.g. HR, breath
frequency) scale with b ≈ −0.25 and volume-rates (e.g. cardiac output, ventilation)
scale with b ≈ 0.75 [64]. Allometric relationships can also be used to extrapolate
to drug properties in humans through regression of a and b from data in multiple
nonclinical species.
Another method for translation using PK-PD models is by identifying inter-
species transducer functions using species-specific dose-response curves. This con-
cept is used in [12], where the translation from a pre-clinical species to man is found
using a three-step process (Figure 2.11). First, species-specific PK models are de-
veloped and time-matched exposure data points for the response data extracted.
Second, a model for the response is identified and fitted for both species, and the
species-specific dose response curves estimated. Finally, the response in humans is
plotted as a function of the response in the nonclinical species at matched unbound
drug concentrations. Within safety pharmacology, this approach can be used to
define nonclinical thresholds of effects, compare translational relationships between
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compounds and to compare the relative sensitivity of different models to humans.
This method was used to compare QTc prolongations in dogs and humans for four
different drugs [12], and suggested that average QTc prolongations of 2-8 ms (≈
1-3%) in dogs compare to 10 ms (≈ 2.8%) in humans. However, prior to the work
presented in this thesis, the translational relationship and relative sensitivity of
drug-induced PR and QRS prolongations in animals and humans were not known.
Figure 2.11 Translational modelling to find the translational relationship between pre-clinical
species and man. A possible goal may be to define how a safety margin in man translates
to pre-clinical results.
QTc risk has also been assessed by the probability of QTc prolongation as a
function of plasma concentration [13]. Here the probability of QTc prolongation was
assessed using Bayesian modelling. The posterior distribution of QTc changes was
used to create a cumulative probability of QTc change above 10 ms (Figure 2.12).
Such probability curves were derived for three different compounds and for both
dogs and humans. It was found that the slope of the drug effect was smaller in dogs
compared to humans for the investigated compounds, and also that the probability
of a 10 ms increase in humans occurred at lower exposure levels compared to dogs.
In this example, the drug-induced effects in dogs were found to be 0.5-1.5 ms at
concentrations where the effect in humans were 10 ms. This relationship indicates
an even lower sensitivity in dogs compared humans when contrasted to the results
in [12].
An important limitation is that these models do not inherently take into
account underlying physiological differences across species, such as ion channel ex-
pression levels and heart structure and size. This limits the possibility of using these
empirical modelling methods to understand the mechanisms behind the reduced sen-
sitivity in animals compared to humans.
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Figure 2.12 Using the posterior distribution of QTc effects to find the probability of QTc
change above 10 ms for different concentrations. Adapted from [63]. It may be possible to
relate the predicted QTc distribution in dog to that in man to find the translation.
2.3.4.2 Bottom-up systems pharmacology modelling
Drug-induced effects on cardiac ion channels have been modelled to predict mor-
phology changes in the AP or ECG in detailed, “bottom-up” mechanistic models
(Figure 2.13). Whilst models to translate a single in vitro experiment to in vivo
change are standard in integrated pre-clinical risk assessment [9], these in silico
predictions allow assessment of the combined effects on multiple molecular targets.
These models represent the relevant electrophysiological aspects of the cellular sys-
tem: transmembrane conductance, ion channels and their inhibition by drugs, as
well as other pumps/exchangers and intracellular ion concentrations, and integrate
the influence of these factors over time on cellular ion concentrations. Drug ef-
fects are modelled by altering the ion conductance term which represents the gating
(open/closed etc.) of the relevant ion channel.
Cellular cardiac AP models have been developed for different species includ-
ing humans [65, 66], dogs [67] and guinea pigs [68]. Such cardiac AP models have
been applied to predict the effects of anti-arrhythmic drugs that alter ion channel
activities [69, 70, 71] and better describe the effects of multiple ion channel inhibition
rather than focusing purely on potency values. Mirams et al. [70] showed that a
human AP model could be trained to classify TdP risk based on predicted therapeu-
tic maximal concentrations (predicted Cmax) and Nav1.5, Cav1.2 and Kv4.3 channel
IC50 values with markedly improved accuracy compared to safety margins between
hERG IC50 and therapeutic Cmax alone. A recent comparison of the predicted effect
of ion channel block in AP models from humans and nonclinical species highlights
the importance of cautious extrapolation between species [72]. For example, a 70%
block of the hERG ion channel resulted in an 80% AP prolongation in humans,
but only a 30% and 20% change in dogs and guinea pigs respectively. So, detailed
species-specific models may better explain and predict differences in the sensitivity
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Figure 2.13 Bottom-up systems pharmacology approach using in vitro potency to predict
clinical effects based on mechanistic knowledge. Figure adapted from [1].
to drugs between species.
While these ion flux models can capture information relating to the mem-
brane potential in a single cell, the resulting ECG measurements are at the tis-
sue/whole body level (Figure 2.14) and depend in part on the spatial orientation of
myocytes in the heart and the AP propagation in tissue. Models of cardiac tissue
have therefore been constructed to describe the propagation of the AP in 1, 2 and
3 dimensions [73] by linking multiple cellular models in a spatially relevant way.
These tissue models have been used to study the effects of single and multiple ion
channel blockade on Purkinje fibres [74]. At the whole heart level, cardiac structure
and electrophysiology have been integrated with whole body geometry to translate
ion channel effects through the simulation of cardiac AP propagation to calculate
12-lead ECG and QRS widening and QT prolongation as measured in the torso [75].
Similarly, 12-lead ECGs derived from simulated body surface potentials have been
used to compare the two QTc-prolonging drugs cisapride (pro-arrhythmic) and amio-
darone (anti-arrhythmic) [76], identifying the effect AP conduction of amiodarone
alone as the mechanism behind the drug being anti- rather than pro-arrhythmic.
However, with increasing model complexity, it becomes more difficult to evaluate if
the model structure correctly describes the system, is structurally and practically
identifiable and also that fixed parameters are correct.
The usefulness of mechanistic in silico models in drug discovery and devel-
opment needs to be further demonstrated, as a recent study investigated the ability
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Figure 2.14 Spatial and temporal scales at which ECG systems models operate. At each
level, different assumptions and variabilities need to be addressed, to meet the ultimate goal
of predicting cardiovascular liabilities in patient populations. Figure adapted from [1].
of AP models to predict the QT change in TQT studies and showed that the mod-
els in general under-predicted the TQT outcome [77]. However, evaluating a 10-
to 100-fold therapeutic window led to much improved predictions, suggesting that
something related to tissue or cellular concentrations may be missing in the systems
models. One tool built specifically to do this is the Cardiac Safety Simulator (Cer-
tara), a commercially available tool designed to increase the ability of non-modellers
to test the effect of ion channel activity on the ECG incorporating population vari-
ability on both exposure (through SimCYP, Certara) and ECG prediction. As a test
of predictivity of the simulator, the QTc effects of 6 anti-psychotic drugs [78] were
investigated using the Cardiac Safety Simulator showing good agreement between
predicted and observed mean QTc change, though the predictions did not account
for all of the observed variability. Also, PK and PD effects of combination treat-
ment with doinperidone and ketoconazole were predicted from in vitro data using in
silico models [79]. To date, this approach has been used to demonstrate translation
largely for ion channel inhibition and QTc effects [78, 79].
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2.3.4.3 Middle-out systems pharmacology modelling
The final type of approach represents a middle-out [80] approach which attempts
to combine the best properties of the purely descriptive top-down and reductionist
bottom-up approaches (Figure 2.15). For example, comprehensive in vivo systems
pharmacology models are in existence for CV system behaviour, particularly for
haemodynamics [81, 82, 83] but these have so far only been implemented in a single
species making translational predictions from pre-clinical species to human difficult.
We do not have feedback from the clinic yet to understand how successful human
predictions have been and there are no reports of cross-species comparisons with
these models. Alternatively, simplified model structures can be applied that cap-
ture the relevant process governing information flow without over-parameterisation
[57, 84]. Models of cardiovascular function with similar structure, but with species
specific parameters could allow for further refinement of the predictive power of
these approaches. In these approaches, substituting human physiological parame-
ters into the preclinical model is a key part of the translation. For example, when
HR changes have been translated from dogs to humans using a PKPD approach [84],
the sensitivity to drug in addition to a baseline typical for humans were applied. In
another example where BP was translated using an indirect response model, human
baselines and rates of turnover (kout) for SBP and DBP were obtained from the
literature and combined with a PK prediction and the drug sensitivity obtained in
dog to successfully predict the effects in first-time-in-human studies [57].
Mechanistic models may be used to quantify the relationship between in
vitro data and the physiological response in the clinic using the operational model of
pharmacological action (Equation 2.10). This has been done for hERG-QTc, where
the authors in [9] estimated that only 10% hERG inhibition induced by the selective
hERG blocker dofetilide translates to 20 ms (95% confidence interval 12-32 ms) QTc
prolongation in humans. Mechanistic PD models can also be used to distinguish
between different mechanisms for the drug effect. As an example, a mechanistic
model of drug effects on blood pressure (BP) has been used for this purpose. The
fundamental relationships between mean arterial pressure (MAP), total peripheral
resistance (TPR) and cardiac output (CO) were used for the development of the
structural model [82] given by
d
dt
CO = kin_CO ∗ (1− f1 ∗MAP )− kout_CO ∗ CO
d
dt
TPR = kin_TPR ∗ (1− f2 ∗MAP )− kout_TPR ∗ TPR
MAP = CO ∗ TPR+
10∑
n=1
An ∗ cos
(
n ∗ (t+ τ)2pi24
)
.
(2.18)
where TPR and CO are modelled using two linked turnover equations with “pro-
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Figure 2.15 Systems pharmacology approach to predict clinical effects based on systems
knowledge and in vitro/in vivo data. Figure from [1].
duction rates” kin_CO and kinTPR and negative feedback parameters f1 and f2 by
the MAP. The MAP in turn depends on CO and TPR and also incorporates circa-
dian variations modelled with a set of up to 10 cosine functions selected if inclusion
significantly improved fit to data. System-specific parameters such as production
rates, feedback strengths and circadian effects were estimated by challenging the
model with six compounds that affect either TPR or CO by different (established)
mechanisms. Several biomarkers were measured to collect data to populate and
parameterise the model, including HR, MAP, CO, stroke volume (SV) and TPR.
Drug exposure was not measured, and therefore modelled using PK models from the
literature. In theory, the developed model may be used to predict the mechanism(s)
of novel drugs affecting BP.
Importantly, model selection must be based on the type of questions to be
addressed, available resources, system knowledge and available data. A systems
approach may be preferable for translational purposes, but requires understanding
of the drug effect mechanism and important processes in the system. When a drug
effect mechanism is understood and well characterised, systems translational models
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can be adopted to generate robust predictions, while less understood mechanisms
are more challenging and simpler approaches may be preferred.
2.4 Summary
Current methodologies and best practices for assessing CV risk in drug discovery
and development are most advanced for the prediction and translation of QTc. For
other ECG parameters such as the QRS and PR intervals, little is known of the
translation from pre-clinical ion channel blockade or in vivo ECG changes to the
clinic. M&S methods and techniques to predict clinical QTc interval changes range
from empirical cross-species scaling to highly detailed multi-level models describ-
ing cardiac function starting at the ion channel level controlling the cellular AP,
propagation of the AP in different cardiac tissues and through the torso to predict
the 12-lead ECG response. These methods may also be useful for describing and
predicting effects on other ECG intervals.
This chapter identifies a gap in the current strategies for assessing cardiac
safety, as the quantitative translations from nonclinical to clinical effects of biomark-
ers for cardiac conduction slowing were largely unknown at the time of initiating
this work. In addition, despite the wealth of published examples of PKPD modelling
of drug-induced prolongations of the QT interval, few publications were identified
where drug-induced QRS and PR interval effects were described using PKPD mod-
els. The aims of this thesis are therefore to address this gap by developing models
to quantify QRS and PR intervals monitored in nonclinical species and in humans,
and to investigate the translation between nonclinical and clinical effects. Relevant
background information for performing these tasks has also been presented.
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Chapter 3
Parameter identifiability
3.1 Introduction
This chapter introduces the concepts of structural and practical identifiability and
investigating parameter identifiability of commonly applied pharmacodynamic mod-
els. Some models were applied in further chapters of this thesis, and the results of
these investigations are therefore of high relevance to this thesis. The work presented
in this chapter was performed in collaboration with Early Stage Researcher David
Janzén, and is based on a journal publication (Janzén and Bergenholm et al. [2]).
3.2 Structural and practical identifiability
M&S within pharmacology often involves the estimation of model parameter values
using experimental and/or literature data. The model with the estimated parameter
values may be used to predict new data and scenarios such as outcomes across dif-
ferent populations or with new dosing schedules. Such predictions may not always
be valid: In particular, the estimated parameters may not be possible to identify.
Within the concept of parameter identifiability, there are two distinct types: struc-
tural identifiability [85] and practical identifiability [86].
Structural identifiability concerns the inherent identifiability of the parame-
ters in a model given its structure and observed outputs [85]. If a model is struc-
turally identifiable, it means that all parameters can in theory be identified, given
perfect (e.g. noise free, continuous) data. However, an unidentifiable model has at
least one parameter that can take any value without changing the model output (al-
beit with possible readjustment of remaining parameters). A well-known structurally
unidentifiable problem is the linear model commonly used for estimating bioavail-
ability F and volume of distribution V from plasma concentrations measured after
oral drug administration. The most simple case is the one compartment PK model
with first order absorption, where the plasma drug concentration C following a single
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dose is defined according to
C(t) = F ·DOSE · ka
V (ka − ke)
(
e−ke·t − e−ka·t
)
(3.1)
where F is the bioavailability of the drug, DOSE is the orally administered dose,
V is the volume of distribution, ka is the rate of absorption and ke is the rate of
elimination. It has been shown that only the fraction FV can be identified, and
any estimate of F will therefore inversely correlate to V and both values will be
biologically meaningless [87]. Importantly, predictions of C(t) are still valid as these
depend on the identifiable fraction FV .
Practical identifiability is a measure of the amount of information contained
in the experimental data and how this information is translated to parameter un-
certainty and subsequent prediction uncertainty. Practical identifiability is analysed
by, for example, assessing standard errors and correlation matrices.
The structural identifiability of a model is preferably analysed prior to pa-
rameter estimation, ensuring that any uncertainty in the estimated parameters is
related to the quality of the data and how well the model can describe them (Fig-
ure 3.1). However, parameter identifiability is unfortunately often only investigated
and considered at the level of practical identifiability using more simple measure-
ments such as standard errors or correlation matrices rather than more sophisticated
approaches such as the profile likelihood approach [86].
This is problematic for several reasons. The primary reason is that it can-
not be guaranteed that the estimated parameter values are uniquely determined by
just looking at the estimation results. In addition, if the structural identifiability
of a model is unknown, it means that the source of uncertainty in the parameter
estimates may be either due to the experimental data, the model structure, or both
(Figure 3.1). Thus, increasing the quality of the data may or may not improve the
precision of the parameter estimates. On the contary, if structural identifiability
analysis has concluded that the model is identifiable, the uncertainty in the model
parameters is directly linked to the quality of the data and how well the model
can describe them. In this scenario, the uncertainty of the model parameters can be
improved by increasing the quality of the data. However, there will always be uncer-
tainties in the parameter estimates, even if the model is structurally identifiable and
the quality and quantity of the experimental data are relatively high. An approach
to further strengthen the plausibility of the model predictions under such conditions
is to divide the experimental data into two parts: data used for parameter estima-
tion and data used for model validation, i.e. by estimating the unknown parameters
using a subset of the experimental data and using the resulting estimates to predict
the validation data.
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The difference between structural and practical identifiability and the im-
portance of proper analyses are highlighted in Figure 3.2. The parameters of an
unidentifiable and a reparameterised version of a model (Model 5, presented later)
was estimated in three separate runs. Parameters in the unidentifiable version of the
model were estimated in two different runs using different initial estimates. For the
third parameter estimation run, the model was reparameterised following insights
from the structural identifiability analysis.
Investigating the estimated parameters shows that standard errors of uniden-
tifiable parameters differ significantly between the two estimation runs, and are
larger than the standard error of the product of the parameters. For one of the
estimation runs the magnitude of the standard errors (37.6 and 33.7 %) did not
clearly indicate a structural identifiability problem. In the second estimation run
the standard errors are much higher (163 and 154 %) and did indicate a structural
identifiability problem. However, for both estimation runs the estimated correla-
tions between Rtot and ke were close to -1 (-0.9 and -0.99), indicating a potential
structural identifiability problem. Analysing the models using the profile likelihood
approach [86] would also potentially indicate a problem with structural and practical
identifiability.
Although estimation of an unidentifiable model in theory should lead to in-
finitely large uncertainty for the structurally unidentifiable parameters due to a
flat likelihood function in the directions representing those parameters, this did not
happen in practice. The reason why this did not happen can be explained by mea-
surement and numerical noise. In real-world problems, the likelihood function is
never completely flat which introduces false local minima where the optimisation
routine may become “stuck” depending on the initial guesses used for the model
parameters and the optimisation algorithm itself. This example shows the poten-
tial danger of using practical identifiability analysis as a tool to deduce structural
identifiability.
3.2.1 Structural identifiability of 16 pharmacodynamic models
Commonly used PD models such as the effect compartment model, indirect response
models and drug-receptor binding models were described in Section 2.2.1.2. How-
ever, despite frequent use, relatively few PD models have been analysed from a
structural identifiability perspective. An example of a published structural identi-
fiability analysis is for an approximation of the receptor binding model. Receptor
binding often occurs over very fast timescales relative to the PK, and sometimes
also with respect to the effects elicited by the receptor once bound. In such cases,
the receptor binding model may be approximated by a quasi- or pseudo-steady
state approximation. When using such an approximation, it has been shown that
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the individual on and off rates of drug binding to the receptor cannot be uniquely
identified [88]. Another example is the target-mediated drug disposition model [89]
applicable to the modelling of biologics, which has been shown to be structurally
identifiable [90]. However, the identifiability of the effect compartment model and
the operational model have, to the author’s knowledge, not previously been anal-
ysed. Furthermore, mixed effects (“population”) models are often used to account
for and quantify known sources of variability in data sets, such as between-subject
variability (BSV). Such models are combined structural and statistical models, with
additional statistical parameters describing the variance of a postulated distribution
of the model parameter values across e.g. subjects. The structural identifiability of
mixed effects models describing BSV has not been investigated previously.
The parameter identifiability was investigated in [2] for 16 commonly applied
PD models comprising combinations of sub-models representing different potential
delays, including receptor binding, distribution through a hypothetical effect com-
partment and direct or indirect transduction (see Figure 3.3 and Table 3.1). Details
of the methods applied for the structural identifiability analyses are described else-
where [2], as these analyses were not performed by the author of this thesis and
therefore are outside the scope of this work. Briefly, the input-output approach
[91] was applied, allowing to distinguish globally identifiable, locally identifiable and
unidentifiable models. This approach involves step-wise derivation of the model writ-
ten in state-space form and substitution of all state variables on order to identify
if all parameters have a single, finite or infinite number of solutions. By definition,
a model is structurally globally identifiable only if all parameters are structrually
globally identifiable.
Figure 3.3 Schematic of the investigated pharmacodynamic models. A. The 16 investigated
models are constructed by combining the following submodels: Direct or delayed biophase
concentration through distribution to a hypothetical effect compartment, dynamic or direct
receptor binding using the steady-state approximation and direct proportional or sigmoid
signal transduction or delayed signal transduction applying a turnover model. B. Example
of a full model where all three processes are assumed to be dynamic and cause delay between
plasma concentration and drug effect. Figure from [2].
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Table 3.1 Summary of the 16 PD fixed effects and mixed effects models for which the structural identifiability was investigated. Adapted from [2].
Fixed effects models Mixed effects models
N Model equations I/O ICs Fixed effect parameters Fixed effect parametersa Random effect parametersb
1 E = ke RtotCpKd+C Cp/E Rtot, ke,Kd ke,Kd ηke, ηKd
2 E = Em(RtotCp)
n
(Kd+Cp)nRCn50+(RtotCp)
n Cp/E Rtot, Em, RC50, n,Kd Em, RC50, n,Kd ηEm, ηRC50, ηn, ηKd
3 E˙ = kin(1 + ke RtotCpKd+Cp )− koutE Cp/E E(0) = kout/kin Rtot, kin, kout, ke,Kd kin, kout, ke,Kd ηkin, ηkout, ηke, ηKd
4 E˙ = kin − kout(1 + ke RtotCpKd+Cp )E Cp/E E(0) = kout/kin Rtot, kin, kout, ke,Kd kin, kout, ke,Kd ηkin, ηkout, ηke, ηKd
5 R˙C = kon(Rtot −RC)Cp − koffRC Cp/E RC(0) = 0 Rtot, kon, koff , ke kon, koff , ke ηkon, ηkoff , ηke
E = keRC
6 R˙C = kon(Rtot −RC)Cp − koffRC Cp/E RC(0) = 0 Rtot, kon, koff , Em, kon, koff , Em, ηkon, ηkoff , ηEm,
E = EmRCn
RCn50+RC
n RC50, n RC50, n ηRC50, ηn
7 R˙C = kon(Rtot −RC)Cp − koffRC Cp/E RC(0) = 0 Rtot, kon, koff , kin, kon, koff , kin, ηkon, ηkoff , ηkin,
E˙ = kin(1 + keRC)− koutE E(0) = kout/kin kout, ke kout, ke ηkout, ηke
8 R˙C = kon(Rtot −RC)Cp − koffRC Cp/E RC(0) = 0 Rtot, kon, koff , kin, kon, koff , kin, ηkon, ηkoff , ηkin,
E˙ = kin − kout(1 + keRC)E E(0) = kout/kin kout, ke kout, ke ηkout, ηke
9 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, ke,Kd ke0, ke,Kd ηke0, ηke, ηKd
E = ke RtotCeKd+Ce
10 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, Em,Kd, ke0, Em,Kd, ηke0, ηEm, ηKd,
E = Em(RtotCe)
n
(Kd+Ce)nRCn50+(RtotCe)
n RC50, n RC50, n ηRC50, ηn
11 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, kin,Kd, ke0, kin,Kd, ηke0, ηkin, ηKd,
E˙ = kin(1 + ke RtotCeKd+Ce )− koutE E(0) = kout/kin kout, ke kout, ke ηkout, ηke
12 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, kin,K,d ke0, kin,Kd, ηke0, ηkin, ηKd,
E˙ = kin − kout(1 + ke RtotCeKd+C )E E(0) = kout/kin kout, ke kout, ke ηkout, ηke
13 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, kon, koff , ke ke0, kon, koff , ke ηke0, ηkon, ηkoff , ηke
R˙C = kon(Rtot −RC)Ce − koffRC RC(0) = 0
E = keRC
14 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, RC50, kon, koff , ke0, RC50, kon, koff , ηke0, ηRC50, ηkon, ηkoff ,
R˙C = kon(Rtot −RC)Ce − koffRC RC(0) = 0 Em, n Em, n ηEm, ηn
E = EmRCn
RCn50+RC
n
15 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, kon, koff , kin, ke0, kon, koff , kin, ηke0, ηkon, ηkoff , ηkin,
R˙C = kon(Rtot −RC)Ce − koffRC RC(0) = 0 kout, ke kout, ke ηkout, ηke
E˙ = kin(1 + keRC)− koutE E(0) = kout/kin
16 C˙e = ke0 ∗ (Cp − Ce) Cp/E Ce(0) = 0 ke0, Rtot, kon, koff , kin, ke0, kon, koff , kin, ηke0, ηkon, ηkoff , ηkin,
R˙C = kon(Rtot −RC)Ce − koffRC RC(0) = 0 kout, ke kout, ke ηkout, ηke
E˙ = kin − kout(1 + keRC)E E(0) = kout/kin
N: Model number. I/O: Inputs/outputs. ICs: Initial conditions. aRtot was fixed at 100. bAssuming a diagonal covariance matrix Ω with lognormal random effects.
Both fixed-effects and mixed-effects versions of each model were analysed
from a structural identifiability perspective, and the results are presented in Table
3.2. The results of the structural identifiability analysis showed that all of the fixed
effects versions of the models were in their original parameterisation structurally
unidentifiable. For all of the models, the source of the unidentifiability problem was
the parameters Rtot and either RC50 (Models 2, 6, 10, 14) or ke (remaining mod-
els) (see Table 3.2). The analysis showed that these parameters are unidentifiable
and therefore any numerical estimates of them are effectively meaningless from a
biological perspective. Furthermore, it was shown that even though Rtot and ke
or RC50 are unidentifiable, the product Rtotke and fraction Rtot/RC50 are globally
identifiable. The remaining parameters in the analysed models were all shown to
be globally identifiable. Therefore, three methods may be applied to ensure struc-
turally globally identifiable models: 1) A reparameterisation of the model could be
performed, e.g. defining a new parameter as Rtotke, representing the effect when
all targets are bound, and Rtot/RC50, representing the transducer ratio, to replace
the unidentifiable parameters. 2) Rtot or 3) ke and RC50 may be fixed to known or
assumed numerical values. However, the latter two affects the units and interpreta-
tion of the non-fixed parameter. For example, Rtot may be fixed at 100 %, resulting
in changed units for ke to units per percent bound receptor.
For the mixed effects versions of the models, it is discussed in [92] that if the
structural model is structurally globally identifiable, and if the statistical sub-model
is structurally globally identifiable, then it follows that the mixed-effects model is
also structurally globally identifiable. The statistical sub-model for the random ef-
fects considered in this paper takes the form of a structurally globally identifiable
lognormal distribution. Therefore, the mixed-effects versions of the models in Table
3.1 are structurally globally identifiable following the suggested reparameterisation
or by fixing of Rtot or ke and RC50.
3.2.2 Simulation study to investigate practical identifiability
Once the structural identifiability of the postulated model has been determined, pa-
rameter estimation can be performed. As with the structural identifiability example,
Model 13 (Table 3.1) was selected for the simulation study to investigate the influ-
ence of varying data quality on the practical identifiability of the parameters. This
model includes two different sources of delay, one from distribution to the effect site,
where the rate is controlled by the parameter ke0, and also through slow receptor
dynamics, where the off-rate is controlled by the parameter koff . The possibility
to distinguish the two different delays in practice under varying data quality was
investigated in a simulation study. Rtot was fixed to 1 following the results of the
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Table 3.2 Results of the structural identifiability analysis of the mixed-effects models 1-16 in Table 3.1. Structurally identifiable and unidentifiable param-
eters and a suggested reparameterisation are provided for the corresponding fixed effects models. Random effects were evaluated for the reparameterised
models Adapted from [2].
Model description Structural identifiability results
Fixed effects Random effectsa
N Distr. | Binding | Transd. SU parameters SI parameters & combinations SI parameters
1 Direct | SS | Linear Rtot, ke Rtotke,Kd ηke, ηKd
2 Direct | SS | Sigmoid Rtot, RC50 Rtot/RC50, ke,Kd, n ηRC50, ηke, ηKd, ηn
3 Direct | SS | Indirect Rtot, ke Rtotke, kin, kout,Kd ηkin, ηkout, ηke, ηKd
4 Direct | SS | Indirect Rtot, ke Rtotke, kin, kout,Kd ηkin, ηkout, ηke, ηKd
5 Direct | Dynamic | Linear Rtot, ke Rtotke, kon, koff ηRtot/RC50, ηkon, ηkoff , ηEm
6 Direct | Dynamic | Sigmoid Rtot, RC50 Rtot/RC50, kon, koff , Em, n ηRC50, ηkon, ηkoff , ηEm, ηn
7 Direct | Dynamic | Indirect Rtot, ke Rtotke, kon, koff , kin, kout ηkon, ηkoff , ηkin, ηkout, ηke
8 Direct | Dynamic | Indirect Rtot, ke Rtotke, kon, koff , kin, kout ηkon, ηkoff , ηkin, ηkout, ηke
9 Delay | SS | Linear Rtot, ke Rtotke, ke0,Kd ηke0, ηke, ηKd
10 Delay | SS | Sigmoid Rtot, RC50 Rtot/RC50, ke0, kon, koff , Em, n ηke0, ηRC50, ηEm, ηn, ηKd
11 Delay | SS | Indirect Rtot, ke Rtotke, ke0, kin, kout,Kd ηke0, ηkin, ηkout, ηke, ηKd
12 Delay | SS | Indirect Rtot, ke Rtotke, ke0, kin, kout,Kd ηke0, ηkin, ηkout, ηke, ηKd
13 Delay | Dynamic | Linear Rtot, ke Rtotke, ke0, kon, koff ηke0, ηkon, ηkoff , ηke
14 Delay | Dynamic | Sigmoid Rtot, RC50 Rtot/RC50, ke0, kon, koff , kin, Em, n ηke0, ηRC50, ηkon, ηkoff , ηEm, ηn
15 Delay | Dynamic | Indirect Rtot, ke Rtotke, ke0, kon, koff , kin, kout ηke0, ηkon, ηkoff , ηkin, ηkout, ηke
16 Delay | Dynamic | Indirect Rtot, ke Rtotke, ke0, kon, koff , kin, kout ηke0, ηkon, ηkoff , ηkin, ηkout, ηke
SU: Structurally unidentifiable; SI: Structurally identifiable. aRtot was fixed at 100 when analysing the mixed effects models.
structural identifiability analysis to ensure the structural identifiability of the model.
True parameter values were assigned to each model parameter: ke = 1, ke0 = 0.2,
koff = 0.02 and kon = 0.05 amounts per minute. All parameters were assumed to
vary between subjects following a log-normal distribution as this ensures positive
rates for all subjects, with standard deviation σ = 0.3 to represent differences in a
population. The model is summarised in Figure 3.4A.
The simulation study was performed in MATLAB 2013b (The MathWorks
[93]) and Monolix 4.3.2 (Lixoft [40]) as outlined in Figure 3.4 B. 1) PK data were
simulated without variability or noise, applying an intravenous bolus dose of 20
mg/kg to a hypothetical typical individual with volume of distribution 1 and rate
of elimination 0.2 mg/kg. 2) Model 13 with the selected ‘true’ parameter values
was used to simulate data sets of varying size and quality. Three factors were
changed that influence the information available in the data: i) different sampling
intervals ∆t = 1, 2, 5, 10, 15, 20, 25, 30 minutes. ii) different additive noise levels σ =
0.05, 0.15, 0.5 response units and iii) different numbers of subjects n = 100, 40, 12. 3)
Parameters were estimated using each simulated data set, with the following initial
guess selected for the optimisation algorithm: ke = 1, ke0 = 0.1, koff = 0.01 and
kon = 0.01 units per minute for the structural parameters and 0.3 units per minute
for the standard deviations. 4) The ratio between the final parameter estimates and
the true parameter values were calculated and compared for the typical parameters
to investigate the effects of varying sampling intervals, noise levels and number of
subjects on parameter accuracy.
In the simulation study, increasing noise, increasing sampling interval and
reducing the number of subjects all led to worse parameter estimation results (Fig-
ure 3.4). At the lowest noise level (column a), the model parameters were well
estimated up to a sampling interval of ∆t = 10, while increasing the sampling in-
terval above this level led to over- and underestimation of ke and kon respectively.
At the intermediate noise level (column b), similar results were obtained, although
problems occured at smaller sampling intervals. At the highest noise level (column
c), the parameter estimation was unsuccessful for all estimation runs except for 100
subjects and 1 min sampling interval. The simulation study shows a trend of de-
creasing accuracy to estimate the true parameters when the amount and quality of
the data decreases. Some of the model parameters vary more than others when the
data become worse in terms of noise levels, the number of measurements and the
number of subjects. For instance, koff was estimated reasonably well, except for
the very worst case 3c, while the estimates for ke and kon are poor in 1a. It can also
be seen that the uncertainty in the parameter estimates (standard errors) generally
widens with either increased noise, reduced sampling interval or reduced number of
number subjects. Interestingly, high precision (small standard errors) is in many
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optimisations acquired despite low accuracy in the parameter estimates.
3.2.3 Case study
A case study was conducted in order to exemplify the process of model development,
including structural identifiability analysis. Side effects of potential new drugs on
the heart must be evaluated by monitoring changes in the duration of specific inter-
vals monitored in the electrocardiogram (ECG), such as the QT interval (defined by
the Q and T peaks in the ECG) which corresponds to the duration of the ventric-
ular action potential. The main part of the QT interval constitutes the ventricular
repolarisation phase, corresponding to the JT interval (defined by the J point and T
peak in the ECG), and prolongations are strongly linked to inhibition of the cardiac
ion channel hERG [94]. In this example, model 10 (Table 3.1) was applied to link
inhibition of the hERG ion channel in vitro to prolongation of the JT interval follow-
ing treatment with the anti-arrhythmic compound and mixed ion channel blocker
AZD1305, a proprietary AstraZeneca compound. Model 10 was selected since an
identifiable version of this model has been used previously to fit this type of data
[9] and following evaluation of additional structures, for example model 2 (without
the effect compartment).
Methods. Clinical study and PK and QT interval data are described in [12]. JT
intervals were calculated by subtracting QRS from QT. In vitro data were acquired
from the original data collected by [95]. Methods for PKPD model development are
detailed in Chapter 5. Baseline variability of JT intervals was minimised applying
a circadian rhythm and RR correction model (Equation 5.5). The PK and PD were
modelled sequentially, and Model 10 (Table 3.1) was selected to describe the drug
effect. Kd was estimated prior to the PKPD modelling using the Imax model, where
the inhibition in % is calculated according to
I(C) = 100 ∗ C/(IC50 + C) (3.2)
where IC50 corresponds to the drug concentration resulting in 50 % inhibition, sub-
stituting Kd in Model 10. Parameter estimations were performed using the stochas-
tic approximation expectation maximisation (SAEM) algorithm as implemented in
Monolix 4.3.2 (Lixoft) [40].
Results: The estimated IC50 of hERG was 0.37 ± 0.04 µMwith between cell variabil-
ity of 0.19 ± 0.09 µM (Figure 3.5). PK modelling results are described in Chapter
5. Fitting all parameters of the operational model led to high uncertainty and cor-
relation between Rtot and RC50 (Table 3.3). Structural identifiability analysis of
this model showed that only the fraction Rtot/RC50 is identifiable (see Table 3.2)
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and the model was therefore reparameterised with τ = Rtot/RC50, resulting in a
structurally identifiable model. Estimation of the reduced model resulted in similar
parameter values for all of the identifiable parameters, similar goodness of fit values
and residuals and good precision in the population estimate of τ (Table 3.3). The
fits to the AZD1305 concentration and JT interval data can be seen in Figure 3.6.
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Figure 3.5 hERG inhibition data (markers) and model fit (lines) for AZD1305.
Table 3.3 Estimated parameter values for the original and re-parameterised Model 10
fitted to AZD1305 PK-hERG-JT interval data.
Unidentifiable model Identifiable model
Parameter Unit Estimate (SE) BSV % (SE) Estimate (SE) BSV % (SE)
Em ms 172 (23.9) 18.7 (9.09) 162 (18.9) 20.6 (7.67)
RC50 µM 0.753 (173) 13.3 (15300) - -
n 2.02 (0.24) 35.1 (7.5) 2.1 (0.219) 36.4 (7.69)
Rtot µM 1.1 (252) 13.2 (15400) - -
τ - - 1.55 (0.163) 15.2 (8.17)
IC50 µM 0.37 (fixed) 0.19 (fixed) 0.37 (fixed) 0.19 (fixed)
ke0 h−1 9.37 (2.96) 125 (24) 9.42 (2.91) 123 (23.4)
Residuals ms 6.64 (0.155) - 6.64 (0.155) -
-2LL 7662 7670
SE, standard error; BSV, between-subject variability; -2LL, -2 LogLikelihood. Adapted
from [2].
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Figure 3.6 PK and JT interval data (markers) and model predictions (lines) for humans
treated with placebo and 3 selected doses of AZD1305. A. Model predictions by the uniden-
tifiable JT model. B. Model predictions by the identifiable JT model. C. Individual PK
model parameters predicting the PK in each subject were used to drive the PD response.
Individual subjects are separated by colour. Figure from [2].
Discussion: Both the full and reparametererised versions of model 10 described the
data well. However, standard errors and correlations of Rtot and RC50 correctly
indicated identifiability issues with the former. The estimated parameters were
converted to the traditional Emax and EC50 parameters, which describe the maximal
effect and the drug concentration at half-maximum effect respectively. Emax and
EC50 were calculated according to
Emax =
Emτ
n
1 + τn (3.3)
EC50 =
IC50
(2 + τn)1/n − 1 (3.4)
and resulted in an estimated Emax of 117 ms and 116 ms and EC50 of 0.36 and
0.35 µM respectively for the full and reparameterised models. This highlights that
identifiable parts of a structurally unidentifiable model are still informative. The
estimated Emax is similar to that in previous hERG-QT modelling of dofetilide
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[9], while the estimated hERG block at 10 ms JT prolongation was slightly higher
(18% vs. 9%). This may be caused by AZD1305-induced calcium block [95], as the
calcium current depolarises the cardiac cells [47], counter-acting the repolarisation
by hERG. The structural identifiability analysis showed that two model parameters
could not be estimated. This led to model reduction. Performing this analysis
prior to parameter estimation ensures the theoretical possibility of estimating all
parameters in the model. Estimating the parameters of the unidentifiable model
could have been avoided, reducing the number of iterations in the optimisation. Also,
ensuring structural identifiability improves confidence in the biological interpretation
of the estimated parameter values.
3.3 Discussion
Unidentifiability issues can cause many different types of problems if not mitigated
when models are used to quantify, predict and understand the effects of potential
drugs. Most importantly, the biological/physiological interpretations of structurally
or practically unidentifiable parameters are not valid. This may lead to wrong con-
clusions, for example when unknowingly comparing unidentifiable parameters to rate
candidate drugs or for comparison with competitors. Also, any predictions based on
the profiles of unmeasured states of the system may be meaningless if the parameters
directly or indirectly related to those states are unidentifiable. For example, if the
effect of interest in a toxicity or efficacy study depends on the concentration in a
compartment for which the profile is linked to structurally unidentifiable parameters,
it may be impossible to separate the distribution to this compartment and the drug
effect. Unidentifiability issues may also cause technical problems, as the parameter
estimation step may take a very long time, or fail (crash), if a structurally uniden-
tifiable model is used (depending on what form of optimisation routine is used).
The investigated models (Table 3.1) have been used successfully and repeat-
edly in practice [96, 97], and the structural identifiability results confirm the general
assumption that these models are structurally identifiable. This provides confidence
in the theoretical soundness of using these models. For all of the investigated mod-
els, the total amount of receptor in the system was fixed (to e.g. 1 or 100%) in
order to achieve structural identifiability. This implies that some parameters for the
‘signal transduction’ are relative. For example, the units of a proportional signal
transduction are effect units per fraction bound/inhibited receptor if Rtot is fixed
to 1. This analysis shows that given sufficient data quality, it is, in theory, possible
to distinguish between different sources of delay from the data. Thus, it is possible
to differentiate delays that are compound-specific (e.g. distribution, drug-receptor
binding kinetics) from delays that are system-specific (e.g. turnover of receptors) to
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compare compounds and simulate untested systems.
3.4 Summary
Parameter identifiability should be investigated to ensure both structural and prac-
tical identifiability. Concerning structural identifiability, this chapter shows that
• Different initial estimates of the model parameters may lead to different esti-
mates of structurally unidentifiable parameters.
• Large standard errors may indicate that a parameter is structurally (or prac-
tically) unidentifiable but unidentifiable parameters may also appear
well-determined.
• Reparameterising the structurally unidentifiable model to become identifiable
leads to similar residuals (and likelihood) and improved parameter precision
of the new parameter(s).
• Identifiable parameters can still be well-determined when other parameters are
unidentifiable.
A structurally identifiable model is only a prerequisite for successful param-
eter estimation, and the model parameters may still be difficult to estimate using
experimental data. Some considerations for practical identifiability discussed in this
chapter were that
• A structurally identifiable model does not guarantee reliable parameter esti-
mates.
• Data must contain information over relevant time scales for the investigated
system.
• Noise levels, sampling density and the number of subjects (mixed-effects mod-
els) are all important in order to be able to estimate parameters with reason-
ably high precision.
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Chapter 4
Investigated compounds and
acquired data
4.1 Introduction
The work in this thesis is based on data acquired from previous in-house or out-
sourced AstraZeneca studies and collected from published studies. These data were
used for the quantitative and translational analyses in Chapters 5-7. The selection
of nonclinical assays to investigate was based on previous experience at AstraZeneca,
and the availability of in-house data. The primary assays that are conducted to as-
sess cardiac conduction liabilities at AstraZeneca were therefore investigated. These
include both in vitro and in vivo assays. In vitro screens of the Nav1.5 and Cav1.2
ion channels were included, and provide early information on the activity of the
compound towards the major channels involved in cardiac conduction. The primary
in vivo models used at AstraZeneca to assess CV safety and ECG effects are the
anaesthetised guinea pig and consious dog models. Data from these assays were col-
lected where available for all investigated compounds. Clinical data include in-house
Phase I and literature data.
4.2 Investigated compounds
A total of six compounds were investigated in this thesis, and the types of data col-
lected for each compound is summarised in Figure 4.1. Three compounds were
proprietary small molecules: AZD1305 [98], AZD8683 [99] and AZD9164 [100].
AZD1305 is an anti-arrhythmic compound previously in development for the treat-
ment of atrial fibrillations, where the development was discontinued due to safety
concerns regarding QTc prolongations and TdP risk [101]. AZD1305 is known to
have effects on multiple ion channels in vitro, including hERG, hNav1.5 and rCav1.2,
resulting in prolongations of QTc, QRS and PR observed in dogs and humans.
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AZD8683 and AZD9164 are anti-muscarinic compounds which selectively block the
human muscarinic acetylcholine receptor 3 (M3 receptor). These anti-muscarinics
are the result of a collaboration between AstraZeneca and Pulmagen Therapeu-
tics Limited (formerly Argenta Discovery Limited). AZD8683 and AZD9164 were
previously in development for the treatment of chronic obstructive pulmonary dis-
ease (COPD), but have been discontinued from development due to unfavourable
safety or efficacy (AZD8683) and transient drop in respiratory function in patients
(AZD9164). Nonclinical side effects of AZD8683 and AZD9164 indlude effects on
rCav1.2 and hCav1.2 in vitro resulting in PR prolongations observed in beagle dogs.
AZD1305 was manufactured by AstraZeneca, Mölndal, Sweden and AZD8683 and
AZD9164 by AstraZeneca, Charnwood, UK.
Figure 4.1 Summary of the collected nonclinical and clinical data. In vitro data were collected
for four compounds, guinea pig data for 2 compounds and dog and human data for all
compounds, although only four compounds caused quantifiable changes of QRS or PR in
humans (AZD1305, flecainide, quinidine and verapamil).
In addition, three anti-arrhythmic compounds were investigated (flecainide,
quinidine and verapamil). Quinidine and flecainide are class 1a and 1c anti-arrhythmics
which block hERG, hNav1.5 and to a lesser extent hCav1.2 and bind to rCav1.2 in
vitro. Both compounds cause QRS widening and QTc prolongation and flecainide
also causes PR prolongation. QT prolongation in beagle dogs induced by quinidine
has previously been quantified using PKPD modelling [102]. Verapamil is a class 4
anti-arrhythmic which blocks hCav1.2, hERG and hNav1.5 in vitro and causes PR
prolongation.
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4.3 Nonclinical data
This section presents the collected nonclinical data from in vitro and in vivo stud-
ies. These data were acquired from previous AstraZeneca studies including in vitro
Nav1.5 and Cav1.2 assays and in vivo guinea pig and dog assays. These are routine
assays at AstraZeneca, conducted at different stages of pre-clinical discovery and
development to assess and mitigate the cardiovascular safety of potential new drugs.
4.3.1 In vitro ion channel assays
In vitro ion channel assay data provide early information on the risk of cardiac
conduction liabilities.
4.3.1.1 Inhibition of hNav1.5
Compound interactions with the Nav1.5 channel had been assessed in cells trans-
fected with human Nav1.5 (hNav1.5) using conventional and automated electrophys-
iology (Table 4.1). IC50 values of the two assays show high correlation [103], and to
choose which data to use, the consistency of the assay setup between the evaluated
compounds was therefore investigated. The automated electrophysiology IonWorks
assay was evaluated consistently at physiological pacing rates for all compounds.
However, the conventional electrophysiology assay was performed at different (non-
physiological) pacing rates for AZD1305 compared to the remaining compounds.
Therefore, the effect parameters (IC50, γ) from the automated assay were chosen to
simulate in vitro Nav1.5 effects.
Table 4.1 Potency of the investigated compounds to inhibit human Nav1.5 in automated and
conventional functional electrophysiology assays. Data generated in-house at AstraZeneca,
Alderley Park, UK.
IonWorks HTa Conventional
Compound IC50 (µM) Pacing rate IC50 (µM) Pacing rate
AZD1305 34.6 3 Hz 6.4, 1.5b 0.2, 10 Hz
AZD8683 >33, >33, 23 3 Hz
AZD9164 >33 3 Hz
Flecainide 5.8 (5.7-5.84) 3 Hz 5.5 (4.3-7.0)a 3 Hz
Quinidine 8.7 (6.7-11.4) 3 Hz 10.4 (8.3-12.9)a 3 Hz
Verapamil 8.9 (7.0-11.3) 3 Hz 4.8 (3.8-6.1)a 3 Hz
hNav1.5, human Nav1.5 ion channel; IC50, concentration at half-maximum effect. a[103].
b[95].
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4.3.1.2 Binding to rCav1.2
Compound interactions with Cav1.2 were studied with automated electrophysiol-
ogy and radioligand binding to the diltiazem, verapamil and nifedipine sites (Table
4.2). Radioligand binding to the diltiazem site of rat Cav1.2 is the most predictive
of contractility in canine myocytes in vitro compared to radioligand binding at the
verapamil and nifedipine sites and conventional and automated functional hCav1.2
electrophysiology [54]. It is not known why the radioligand binding assay outper-
formes the functional assay, and as discussed in [54], the converse might be expected
to be true. For example, the radioligand assay was performed using rat brain Cav1.2
while the functional assay was performed using using human cardiac Cav1.2. Also, a
functional assay should theoretically detect the effects from binding to any binding
site, while the binding assay is directed at a specific site. All assays were initially
explored, however, the estimated parameter for the binding to the diltiazem site
(Ki) was chosen to simulate in vitro Cav1.2 effects.
Table 4.2 Potency of the investigated compounds to inhibit human Cav1.2 and to bind to three
rat Cav1.2 binding sites.
IonWorks HT Radioligand binding
Human Cav1.2 Rat Cav1.2
Verapamil
site
Nifedipine
site
Diltiazem site
Compound IC50 (µM) Ki (µM) Ki (µM) Ki (µM)
AZD1305 >100 39.9 Not active 4.5
AZD8683 1.1
AZD9164 5.8
Flecainide 18, >33 14.9 Not active 1.39
Quinidine >33, 57 5.64 Not active 8.41
Verapamil 2.9 (2.7-3.2) 0.0574 3.63 0.0441
IC50, concentration at half-maximum effect; Ki, dissociation constant. Electrophysiology data
were generated in-house at AstraZeneca, Alderley Park, UK and radioligand binding data out-
sourced to Cerep, France and these have been previously published [54].
4.3.2 In vivo guinea pig studies
The anaesthetised guinea pig model is routinely used at AstraZeneca as it provides
informative data of CV effects in a complete system [23]. Also, this model may be
conducted at the lead generation and optimisation stages, where this information
can be utilised for compound selection.
Exposure and telemetry data from anaesthetised guinea pig studies were
available for flecainide and verapamil only. Details of the experimental setup for
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the guinea pig studies are described in [23]. Exposure and CV biomarkers were in-
vestigated in sodium pentobarbitone anaesthetised male guinea pigs using a parallel
study design with four animals in each treatment and vehicle group. Baseline vari-
ability was minimised by controlled body temperature and respiratory rate. Lead II
ECGs were monitored continuously by needle electrodes during a 20 minute stabili-
sation period followed by an intravenous infusion of three 15-minute ascending doses
and a 30-minute washout period. CV measurements were extracted as mean values
over 1 minute and exposure collected at 10 time points each. All animal care and
experimental procedures had local ethics committee approval and conformed to the
UK Animals (Scientific Procedures) Act, 1986. Doses and study designs are sum-
marised in Table 4.3. Example data are provided in Figure 4.2. The three infusion
phases are clearly visible in the PK data, while some delays and nonlinearities may
be present in the QRS/PR data.
Table 4.3 Summary of the guinea pig studies. Details are found in [23].
Compound Flecainide Verapamil
Animals Anaesthetised guinea pigs Anaesthetised guinea pigs
Design Parallel Parallel
Dosing Multiple ascending dose Multiple ascending dose
n 4 vehicle + 4 treat 4 vehicle + 4 treat
Dose (mg kg−1) iv: 0, 0.3, 1, 3 iv: 0, 0.1, 0.3, 1
53
time (h)
fle
ca
in
id
e 
(uM
)
0.5 1
1
2
3
time (h)
QR
S 
(m
s)
0 0.5 1
20
25
30
35
40
time (h)
PR
 (m
s)
0 0.5 1
40
50
60
70
80
90
Figure 4.2 Exposure, QRS and PR data following intravenous infusion with three escalating
doses of flecainide (orange) and vehicle (black). Exposure, QRS and PR data in individual
guinea pigs are provided.
4.3.3 In vivo dog studies
A more in-depth analysis of the therapeutic dose range and safety of a compound is
required prior to human testing. At AstraZeneca, a conscious beagle dog model is
used to assess CV safety (primarily QTc, but also QRS, PR and haemodynamics).
4.3.3.1 Experimental animals and procedures
In vivo studies were carried out in-house at AstraZeneca sites in the UK or Swe-
den, or out-sourced to Huntingdon Life Sciences Ltd, UK (AZD9164 study). All
studies had local ethics committee approval and UK studies were carried out in
agreement with the UK Animals (Scientific Procedures) Act 1986. Study designs,
experimental procedures and doses are summarised in Table 4.4. Doses were selected
based on expected Cmax at multiples close to and above human therapeutic dose.
Human therapeutic routes of administration were used, and effects of AZD1305, fle-
cainide, quinidine and verapamil were therefore orally administered while AZD8683
and AZD9164 were administered through inhalation. Animals were housed individ-
ually in pens of at least 2 m2 during recording days and feeding and in groups of four
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or less in larger pens at other times. The pen temperature was kept within 20±5◦C.
10/14 hour light/dark cycles were kept in the AZD9164 PK study, and 12/12 hour
cycles in all other studies. Dry pellet was offered in the afternoon and consump-
tion recorded after two hours. Water was provided ad libitum and toys offered for
environmental enrichment. Example data are provided in Figure 4.3. Three esca-
lating doses were given, the first two by intravenous (iv) infusion and the third by
oral administration. Effects are visible in both QRS and PR intervals despite clear
between- and within-subject variability.
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Figure 4.3 Exposure, QRS and PR data following intravenous infusion with vehicle (black)
and 2.15 and 4.3 mg kg-1 AZD1305 (orange) followed by oral administration of vehicle
(black) and 8.7 mg kg-1 AZD1305 (orange). Exposure, QRS and PR data in individual
dogs are provided. Dots joined by a line represent data from the same animal.
4.3.3.2 Cardiovascular measurements
Cardiac effects were monitored using surgically implanted telemetry devices (DSI R©
PhysioTel) implanted as previously described [104]. Recordings took place through
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Table 4.4 Design of the nonclinical conscious dog studies.
Compound AZD1305 AZD8683 AZD9164 AZD9164 PK Flecainide Quinidine Verapamil
Design Cross-over Cross-over Cross-over Parallel Cross-over Cross-over
n 4 m 4 m 3 m, 3 f 4 m, 4 f 4 m 4 m
Age (months) 22-31 24-38 Appr. 12-24 9.0-16 19-20 19-25
Weight (kg) 11.2-15 13.9-17.5 10.4-17.1 11.3-17.7 11.2-12.0 14.5-18.3
Dose (mg kg-1) iv: 0, 2.15, 4.3;
oral: 0, 8.7
0, 0.02, 0.1, 0.25 0, 0.019, 0.092,
0.22
0, 0.02, 0.1, 0.48 0, 3, 10, 20 0, 10, 25, 50a 0, 1, 5, 15
Dose interval 2-5 days 3-4 days > 5 days Daily for 7 days 2-5 days 2-5 days 2-5 days
Time of dosing 09:00-09:45 11:00-13:00 Not reported 08:00-14:00 09:30 09:30 09:00
Route Oral (gavage), iv
inf (1 h)
Inh (∼10 min) Inh (2.5 min) Inh (4-6 min) Oral (tablets) Oral (gavage) Oral (gavage)
LLQ (nM) 0.2 0.1 0.05 0.1 25 15 2.2
PK sampling iv: pre-dose, 0.5,
1, 1.5, 2, 6, 24;
oral: pre-dose, 1,
2, 4, 6, 24 h
pre-dose, 0, 0.33,
0.67, 2, 4, 8, 24 h
a.c.d
pre-dose, a.c.d pre-dose, 0, 0.33,
0.67, 2, 4, 8, 24 h
a.c.d
pre-dose, 1, 2, 4,
24 h
pre-dose, 1, 2, 4,
24 h
pre-dose, 1, 2, 6
and 24 h
ECG sampling -1, -0.75, -0.5, -
0.25, 0.5:0.5:3, 4,
6, 8, 10, 12, 16, 20
h
-0.5b h, 5, 20, 40
min, 1:4, 6, 8, 12,
16, 20, 24 h
-70:5:-40, -15, -
10, -5, 1:10, 15,
30 min, 1, 2, 3, 5,
8, 12 h
Not collected -1, -0.75, -0.5, -
0.25, 0.5:0.5:3, 4,
6, 8, 10, 12, 16, 20
h
-1b, 0.5:0.5:3, 4,
6, 8, 10, 12, 16, 20
h
-1, -0.75, -0.5, -
0.25, 0.5:0.5:3, 4,
6, 8, 10, 12, 16, 20
h
ECG filtering Mean of 5 ECG
complexes
Mean of 20-60 s Mean of 1 min - Mean of 5 ECG
complexes
Mean of 5 ECG
complexes
Mean of 5 ECG
complexes
Inh, inhalation; iv inf, intravenous infusion.
receivers in telemetry pens and on telemetry tables for the inhalation studies for
at least 1h pre-dose to 20-24h post-dose. Inside the telemetry pens, animals were
allowed to move freely at all times except during dosing and blood sampling. ECG
intervals were acquired and analysed via “Po-Ne-Mah” V4.1 and/or EMKA “ECG
Auto” V2.4.0.30 (AZD9164) or the HEM data acquisition system (Notocord Inc.) us-
ing Dataquest Open ART software for the telemetry set up and calibration (remain-
ing studies). Lead II ECG (e.g. PR, RR, QRS and QT), body temperature, arterial
blood pressure and heart rate (HR) were recorded. PQ intervals were recorded in
the AZD8683 study. Automatically marked ECG intervals were manually inspected
and corrected at reported time points followed by averaging as indicated in Table
4.4. Intravenous infusion PK data from the AZD1305 study and PK-QRS data from
the flecainide/quinidine study have been published elsewhere [12, 22].
4.3.3.3 Bioanalysis
Drug concentrations were measured from 0.5-2 mL blood plasma acquired from
the jugular vein. The blood samples were mixed with anticoagulant, centrifuged
and blood plasma separated and frozen for storage. Drug concentrations were then
quantified with liquid chromatography and tandem mass spectroscopy (LC-MS/MS).
Due to sparse sampling in the AZD9164 study, a separate inhalation PK study with
similar doses was used to characterise drug disposition and elimination. For all other
compounds, PK and PD measurements were taken within the same study.
4.3.3.4 Excluded data
In the PK model development of the verapamil data, all PK data from the 15 mg
kg-1 dose in dog 2 were excluded. Clear dose-dependent effects in the PD data
suggested correct dosing, whilst PK data were approximately tenfold lower than
expected considering the exposure in dog 2 following the lower doses as well as
following all doses in dogs 1, 3 and 4. Simulated PK data for this dose were used in
the PD modelling.
4.4 Clinical data
As AZD8683 and AZD9164 did not cause QRS or PR prolongations in human vol-
unteers, these studies are not presented in this thesis.
4.4.1 Phase I AZD1305 study
A detailed protocol of the clinical phase I AZD1305 study is available in a previ-
ous publication of the PK and ECG (QTcF) data from this study [12]. Briefly,
29 healthy male volunteers participated in this randomised, double-blinded and
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placebo-controlled study. The study was performed in accordance with the ethi-
cal principles of the Declaration of Helsinki and are consistent with the Interna-
tional Conference on Harmonisation (ICH)/Good Clinical Practice. 12-lead stan-
dard ECGs were recorded in the supine position (Cardiovit AT-5 recorders, Schiller
AG, Baar, Switzerland) and data from Lead II were used in the analysis. Placebo
and six oral doses (10-500 mg) and two iv doses (10 and 70 mg) were administered
in a scaling dose study design where each subject received two separate doses of
placebo or AZD1305. Plasma samples were taken pre-dose and at 14 time points.
Lead II ECGs were monitored continuously and extracted at baseline and at 18
specific time points within 24 hours following dose administration. Data are shown
in Figures 4.4-4.6.
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Figure 4.4 Exposure data following intravenous infusion with 10 mg (0.3 mg kg-1 ) or 70 mg
(2.1 mg kg-1 ) or oral administration of 0.3-14.7 mg kg-1 (10-500 mg) AZD1305. Exposure
data in individual subjects are provided.
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Figure 4.5 QRS data following placebo (black) and intravenous infusion with 10 mg (0.3
mg kg-1 ) or 70 mg (2.1 mg kg-1 ) or oral administration of 0.3-14.7 mg kg-1 (10-500 mg)
AZD1305 (orange). QRS data in individual subjects are provided.
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Figure 4.6 PR data following placebo (black) and intravenous infusion with 10 mg (0.3
mg kg-1 ) or 70 mg (2.1 mg kg-1 ) or oral administration of 0.3-14.7 mg kg-1 (10-500 mg)
AZD1305 (orange). PR data in individual subjects are provided.
4.4.2 Literature survey of flecainide, quinidine and verapamil ef-
fects
Published studies reporting plasma drug concentrations and associated QRS and/or
PR measurements were identified for each compound in separate PUBMED searches.
These are described in Chapter 6.
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4.4.2.1 Methods for the literature survey
The literature survey was performed in PUBMED using the following search words:
• “drug name” AND (ECG OR electrophysiology OR electrophysiologic OR in-
terval) AND (QRS OR PR OR PQ OR P-R OR P-Q) AND (Humans[Mesh])
• quinidine AND ECG AND (healthy OR volunteer) AND (Humans[Mesh])
Inclusion criteria for the identified publications were the following:
• Study of more than 2 humans (not case studies).
• Plasma concentrations were measured and reported in textual format, tables
or figures.
• QRS and/or PR/PQ intervals were measured at sinus rhythm and reported
in textual format, tables or figures including change from baseline and/or pre-
and post-drug.
• The same type of PK and ECG data were reported. For example, both PK
and ECG were maximum values, both were mean values over the treatment
time or both were measured at similar time points.
Pairs of plasma concentrations and absolute QRS/PR change from baseline of the
same type (e.g. maximum values, mean values or measured at similar time points)
were collected or calculated using information published directly in the text, tables
and/or figures. Data provided only in figures were converted to numbers through
visual assessment or using webplotdigitizer (http://arohatgi.info/WebPlotDigitizer).
Average baseline QRS/PR in healthy volunteers were calculated and used to convert
the percentage change to absolute change where baselines were not provided. Drug
concentrations were converted to free concentrations in µM using in-house in vitro
plasma protein binding data and the molar mass of each compound. Additional
information was collected where available, and included the standard deviations of
the concentration and QRS/PR data, time since last dose, the number of subjects,
the dose administered, route of administration, dosing history and if the subjects
were healthy volunteers or patients.
4.4.2.2 Identified flecainide QRS/PR studies
A Pubmed search was performed on 2015-08-06 and generated a total of 143 pub-
lished studies of QRS and/or PR effects of flecainide in humans, of which 16 fulfilled
the postulated criteria (see Section 4.4.2.1). These are summarised in Table 4.5 and
in more detail in Appendix B, Table B.1 and the data are plotted in Figures 4.8 and
4.7.
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Table 4.5 Summary of the identified human flecainide studies.
Ref ECG Dose Subjects Dosing Data type
n Status History Route PK ECG n
[105] QRS 100-200 mg 24 HV Both oral Mean Cmax Mean Emax 8
[106] PR 200 mg 8 HV Acute oral Mean Cmax Max Emean 1
[107] QRS 2 mg/kg 10/12 Both Acute iv inf C(t)/Cmax E(t) 2
[108] QRS/PR 150 mg 10 HV Acute iv inf C(t) E(t) 1
[109] QRS/PR 2 mg/kg 6 HV Acute iv inf C(t) E(t) 1
[110] QRS/PR 100-200 mg 12 HV Chronic oral Mean C Mean E 2
[111] QRS 300 mg 27 Patients Acute oral Fitted Cmax Ereg 1
[112] QRS/PR 200-300 mg 13 Patients Both oral Mean Cmax Mean Emax 2
[113] QRS/PR 2 mg/kg 93 Patients Acute iv inf C(t) E(t) 1
[114] QRS/PR 2 mg/kg 10 Patients Acute iv inf C(t) E(t) 1
[115] QRS 1.5 mg/kg 11 Patients Acute iv inf C(t) E(t) 1
[116] QRS 2 mg/kg 47 Patients Acute iv inf C(t) E(t) 1
[117] QRS 100-300 mg 9 Patients Chronic oral Cmax Ereg 1
[118] QRS 200-400 mg 18 Patients Chronic oral Ctrough E(t) 1
[119] QRS/PR 200-600 mg 19 Patients Chronic oral C(t) E(t) 2
[120] QRS/PQ 400 mg 14 Patients Chronic oral C(t) E(t) 2
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Figure 4.7 PR prolongations in healthy volunteers (HV, circles) and patients (squares) in-
duced by flecainide. Data points represent associated plasma concentration-δPR pairs (1-2
per published study) with standard errors where available.
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Figure 4.8 QRS widening in healthy volunteers (HV, circles) and patients (squares) induced
by flecainide. Data points represent associated plasma concentration-δQRS pairs (1-8 per
published study) with standard errors where available.
4.4.2.3 Identified quinidine QRS studies
A Pubmed search was performed on 2015-08-06 and generated a total of 93 published
studies of QRS effects of quinidine in humans, of which 15 fulfilled the postulated
criteria (see Section 4.4.2.1). These are summarised in Table 4.6 and in more detail
in Appendix B, Table B.1 and the data are plotted in Figure 4.9.
Table 4.6 Summary of the identified human quinidine studies.
Ref ECG Dose Subjects Dosing Data type
n Status History Route PK ECG n
[121] QRS 3mg/kg 48 HV Acute oral Max Cmean Max Emean 2
[122] QRS 3.74mg/kg 10 HV Acute oral/iv inf Max Cmean E(t) 2
[123] QRS 100mg 9 HV Acute oral Max Cmean Max Emean 1
[124] QRS 10mg/kg 8 HV Acute iv inf Max Cmean E(t) 1
[125] QRS 800mg 8 HV Chronic oral Mean Cmax Max Emean 1
[126] QRS 400mg 6 HV Chronic oral Mean C MeanE 1
[127] QRS 4.4-9.1mg/kg 20 Patients Acute iv inf Mean Cmax E(t) 1
[128] QRS 9.1mg/kg 100 Patients Acute iv inf Mean C Mean E 1
[129] QRS 1000mg 9 Patients Chronic oral Ctrough E(≈ t) 1
[130] QRS 750-2250mg 22 Patients Chronic oral Max Cmean Ereg 2
[131] QRS 800-1600mg 20 Patients Chronic oral Ctrough E(t) 1
[132] QRS Not provided 18 Patients Chronic oral Ctrough E(t) 1
[133] QRS 180mg 10 Patients Chronic oral Ctrough Mean E 1
[134] QRS 972mg 10 Patients Chronic oral Ctrough Mean E 1
[135] QRS Not provided 10 Patients Chronic oral Ctrough E(t) 1
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Figure 4.9 QRS widening in healthy volunteers (circles) and patients (squares) induced
by quinidine. Data points represent associated plasma concentration-δQRS pairs (1-2 per
published study) with standard errors where available.
4.4.2.4 Identified verapamil PR studies
A Pubmed search was performed on 2015-08-06 and generated a total of 159 pub-
lished studies of PR effects of verapamil in humans, of which 20 fulfilled the pos-
tulated criteria (see Section 4.4.2.1). As iv administration of verapamil results in
higher potency to induce PR prolongations compared to oral administration [136],
only oral administration data were included in the analysis (16 studies). This is
primarily due to different first-pass metabolism and potency of the two verapamil
enantiomers [137, 138]. The more potent S-enantiomer is subject to higher first-pass
metabolism, and therefore the resulting fraction of S-enantiomer in plasma is lower
following oral administration compared to iv infusion. The selected studies are sum-
marised in Table 4.7 and in more detail in Appendix B, Table B.1 and the data are
plotted in Figure 4.10.
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Table 4.7 Summary of the identified human verapamil studies.
Ref ECG Dose Subjects Dosing Data type
n Status History Route PK ECG n
[139] PR 240mg 8 HV Acute oral Max Cmean Max Emean 1
[140] PR 120mg 6 HV Acute oral Max Cmean Max Emean 1
[141] PR 240mg 8 HV Acute oral Max Cmean Max Emean 1
[142] PR 80-240mg 16 HV Acute oral Max Cmean Max Emean 4
[106] PR 120mg 8 HV Acute oral Mean Cmax Max Emean 1
[143] PR 240mg 9 HV Acute oral Mean Cmax Mean Emax 2
[144] PR 40mg 6 HV Acute oral Max Cmean Max Emean 1
[145] PR 80mg 8 HV Acute oral Mean Cmax Mean Emax 1
[146] PR 80-160mg 20 HV Acute oral Max Cmean Max Emean 3
[147] PR 120mg 6 HV Acute oral Mean Cmax Max Emean 1
[148] PR 80mg 9/36 Both Acute oral Mean Cmax Mean Emax 3
[149] PR 240mg 8 HV Chronic oral C(t) E(t) 2
[150] PR 240mg 24 HV Chronic oral Max Cmean Max Emean 2
[151] PR 240mg 26 HV Chronic oral Mean Cmax Mean Emax 2
[152] PR 240-480mg 30 Patients Chronic oral Mean Cmax Mean Emax 8
[153] PR 480mg 11 Patients Chronic oral C(t) E(t) 1
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Figure 4.10 PR prolongations in healthy volunteers (circles) and patients (squares) induced
by verapamil. Data points represent associated plasma concentration-δPR pairs (1-8 per
published study) with standard errors where available.
4.5 Binding to plasma proteins
Free (unbound) plasma concentrations were calculated using in vitro estimates of
plasma protein binding for each compound in guinea pig, dog and human plasma
by a standard equilibrium dialysis method [154] for all compounds except flecainide,
where dog plasma protein binding (PPB) was acquired from [21] (Table 4.8).
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Table 4.8 Summary of the estimated % unbound drug in plasma for each drug in guinea pig, dog
and human plasma.
Compound AZD1305 Flecainide Quinidine Verapamil AZD8683 AZD9164
Guinea pig 57 19.7
Dog 50 36.9a 6.18 18.9 4.39 12.7
Human 63 62.1 12.2 20.7
a acquired from [21].
4.6 Summary
This chapter presents the nonclinical and clinical data used for the quantitative
and translational analyses in Chapters 5, 6 and 7. In chapter 5, the pre-clinical
guinea pig and dog data as well as the clinical phase I AZD1305 data are used to
develop PKPD models describing QRS and PR intervals at baseline and following
drug administration. Following this, chapter 6 presents exposure-effect modelling to
quantify the clinical effects on QRS and PR intervals by flecainide, quinidine and
verapamil in humans. Finally, the resulting PKPD and exposure-effect models are
used together with the in vitro data in Chapter 7 to investigate the pre-clinical to
clinical translation to predict QRS and PR effects in humans.
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Chapter 5
Population PKPD modelling of
QRS/PR data in guinea pigs,
dogs and humans
5.1 Introduction
As subtle CV effects may cause concern in long term patient use, safety studies
aim to detect small changes in often highly variable data. Ethical, practical and
economical considerations all underscore the importance of proper workflows and
experimental designs that enable maximal information retrieval. PKPD modelling
of drug-induced prolongations of QT intervals in animals and humans has been
shown to improve both pre-clinical and clinical CV risk assessment, with multiple
published examples (reviewed in [155]).
While PKPD modelling of drug-induced QT effects in animals and humans
can inform and improve CV risk assessment (reviewed in [155]), examples of pub-
lished PKPD models describing pharmacological QRS and PR effects are limited
[1]. Important factors for predicting baseline QT in humans have been identified,
including heart rate, circadian rhythm, sex and age [10]. Incorporating such factors
into a model reduces unexplained residual variability and can improve the precision
in estimating and predicting drug effects. However, the effects of these factors on
QRS and PR intervals are largely unknown. A few PKPD models have been devel-
oped to describe drug-induced effects on QRS and PR intervals, including examples
in dogs [57, 156, 157] and humans [111, 117, 122]. However, models to describe
baseline variability of QRS and PR intervals had not been investigated previously.
Therefore, baseline models were adapted from a published QT modelling approach
[13, 63], including circadian variations and correction to simultaneous RR intervals,
and evaluated to assess their performance in describing the baseline variability of
QRS and PR intervals.
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This chapter contains descriptions of novel PKPD models developed to de-
scribe baseline and drug-induced effects for a selection of compounds on QRS and
PR intervals in guinea pigs, dogs and humans (Sections 5.3-5.9). QRS and PR effects
in guinea pigs were evaluated for flecainide (section 5.7.2) and verapamil (section
5.9.2), in dogs for AZD1305 (section 5.4.2), AZD8683 (section 5.5.2), AZD9164 (sec-
tion 5.6.2), flecainide (section 5.7.3), quinidine (section 5.8.2) and verapamil (section
5.9.3) and in humans for AZD1305 (section 5.4.3). The results of the PKPD mod-
elling analyses performed in this chapter were used to define appropriate models for
describing QRS and PR intervals in guinea pigs, dogs and humans. PKPD mod-
elling has been shown to considerably improve the power to detect and quantify
small effects on QTc in simulated pre-clinical studies [18], and established methods
for PKPD modelling of QRS and PR intervals can thus improve cardiac safety as-
sessment with clear impact for compound selection, progression and development
decisions.
Methods for modelling QRS and PR intervals were developed by Bergenholm
et al. [3], where the effects of four antiarrhythmics (AZD1305, flecainide, quinidine
and verapamil) and side effects of two anti-muscarinics (AZD8683 and AZD9164)
were investigated using dog telemetry data. PKPD models for QRS and PR ef-
fects by flecainide and verapamil in guinea pigs and by AZD1305 in humans were
developed using these methods by Bergenholm et al. [? ].
5.2 PKPD modelling methods
Population PKPD models were developed and evaluated with Monolix 4.3.2, Lixoft,
France and MATLAB Release 2013b, The MathWorks, Inc., US. Parameters were
estimated using the SAEM algorithm described in Section 2.2.2.1, as implemented
in Monolix [44]. Default settings were used for the SAEM algorithm, and standard
errors and likelihoods were estimated using linearisation. The mixed effects models
were developed using a sequential process, separating the PK and PD parameter
estimation steps. Model selection was primarily based on performance statistics
using the AIC (Equation 2.15, [46]). The AIC values were used to calculate relative
likelihoods of the models according to
p = exp((AICmin −AIC)/2) (5.1)
where the relative likelihood p of a model compared to a reference model with lower
AIC (AICmin) can be estimated [158]. To reduce the risk of over-fitting, a simpler
model was selected if it was at least 5 % as likely as the model with the lowest AIC.
In addition, precision of parameter estimates, residual plots and visual inspection
of the fits to data were considered. When the precision of fixed or random effects
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was low (standard errors above 100 %), the random effect for this parameter was
removed and the reduced model tested.
5.2.1 Modelling of QRS and PR intervals at baseline
Investigations of different baseline models were conducted to ensure a proper descrip-
tion of QRS and PR interval baselines while modelling the drug effects. Whereas
baseline subtraction leads to increased variance in the data, simultaneous fitting of
baseline and drug effect parameters can accommodate known sources of variabil-
ity using “raw” data. Baseline QRS and PR intervals were investigated by fitting
vehicle data separately and full data sets to ensure that relevant baseline model
structures were used. For dogs, vehicle models were fitted separately both evalu-
ating each study separately and using a merged data set of vehicle data from all
studies. Estimated baseline parameters from fitting the vehicle models were used as
initial estimates for modelling the full data sets. The performance of two submodels
describing baseline variability of QRS and PR intervals was evaluated, namely and
individual RR correction model and a single phase cosine model. These submodels
were chosen as they have been successfully used to minimise the baseline variabilty
of QT intervals [13, 159], and may therefore also be suitable for other ECG intervals.
The two submodels were evaluated alone and in combination, resulting in 4 different
baseline models: the constant baseline model (Equation 5.2), the circadian rhythm
model (Equation 5.3), the RR correction model (Equation 5.4) and the combined
model (Equation 5.5), described by
ECG = ECG0 (5.2)
ECG = ECG0
(
1 +A cos
(
2pi (t− φ)24
))
(5.3)
ECG = ECG0
(
RR
RRref
)α
(5.4)
ECG = ECG0
((
RR
RRref
)α
+A cos
(
2pi (t− φ)24
))
(5.5)
where ECG is the duration of the ECG interval (e.g. QRS/PR), ECG0 is the point
baseline, RRref is the reference RR (or HR), α the exponent of the RR correction
function, RR the observed duration between two consecutive R peaks measured
simultaneously to QRS/PR and A and φ the amplitude and phase shift of the cir-
cadian rhythm. The reference RR was varied between the species, and was 250 ms
(240bpm) in guinea pigs, 750 ms (80 bpm) in dogs and 1000 ms (60 bpm) in humans
[59]. The phase shift φ gives identical predictions in 24 h cycles, but was assumed to
converge to a local minimum close to the initial condition. Circadian rhythms were
not evaluated in guinea pigs due to the short experimental time (2h). The effect
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of restraining animals to the inhalation table was also evaluated for AZD8683 and
AZD9164 treatment in dogs, as visual assessment of the data suggested that such
effects may be present. This was modelled according to
ECG = ECGbaseline + krestraint ∗REST (5.6)
where krestraint descibes a constant effect of being restrained to the inhalation table.
Normal distributions for the between subject variabilities (BSVs) of ECG0, φ and
krestraint and log-normal distributions for α and A were assumed for PR intervals
while also a normal distribution of α was tested for the QRS intervals.
5.2.2 PK modelling
1-3 compartmental PK models were developed to infer drug concentrations at the
full ECG sampling periods. An example two-compartment model is provided in
Section 2.2.1.1. Zero-order absorption models and nonlinear bioavailability models
were applied where required to fit the data. Data below the limit of quantification
(BLQ, 0-33 % excluding pre-dose measurements) for each assay were left-censored
with the BLQ value as an upper limit and used in the parameter estimation as
implemented in Monolix [160]. A log-normal distribution of the BSVs was assumed
for all PK parameters. Residual errors for the PK models were assumed to be mixed
additive and proportional (Equation 2.14). The proportional part of the residual
error models were estimated from the data or fixed to 10 or 15 %, both in the
range of the known analytical variability. Non-linear features and/or inter-occasion
variability were applied where required to reach an acceptable fit to individual data.
5.2.3 PKPD modelling
Individually estimated PK parameters were fixed and used as regression variables to
drive the response in the PKPD modelling. Predicted plasma concentrations were
converted to unbound concentrations through the inclusion of in vitro estimated
free fractions (1-PPB) as regression variables in the PKPD modelling step. Unbound
concentration vs. ECG data were plotted to identify time delays and/or appropriate
drug effect model structures. Time delays were modelled with an effect compartment
(Equation 2.5) [33], assuming a (distributional) delay between plasma concentration
Cc and concentration at a hypothetical “effect site” Ce.
PQ intervals were used for AZD8683 treatment in dogs and AZD1305 treat-
ment in humans as PR intervals were not recorded. PQ intervals are slightly shorter
as the QR part (up-rise in the QRS complex) is only included in the PR interval, but
both intervals are used to investigate the effects on atrial and AV node conduction.
Proportional, power and Emax models (Equations 2.2-2.4) were evaluated to describe
the drug effects. Normal distributions of the BSVs were assumed for the slope, a and
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Emax and log-normal distributions for EC50 and the exponents. Additive residual
errors were assumed for the PD effects (Equation 2.14, b=0).
5.3 Modelling baseline QRS and PR interval variability
in dogs
Vehicle data were investigated to identify appropriate baseline models and provide
initial parameter estimates in the drug effect modelling step. Four baseline models
(Equations 5.2-5.5) were fitted to each vehicle data set separately and to a pooled
data set with all vehicle data. Full BSV models were assumed. The percentage
likelihood of each baseline model was calculated using Equation 5.1.
5.3.1 Modelling baseline QRS variability of dog data
Assuming a constant baseline (Equation 5.2) with normally distributed BSV resulted
in a residual variability of 2.1 ms for the pooled data set, which was reduced to 1.9 ms
for the combined model (Equation 5.5). This suggests that little residual variability
is explained by the RR correction and circadian rhythm models. The percentage
likelihood of each of the four baseline models is summarised in Table 5.1. These
likelihoods suggest that RR correction slightly improves the goodness of fit to QRS
data in dogs, although constant models perform almost as well with likelihoods of
at least 5% compared to the RR correction model for all data sets but one. The
circadian rhythm model slightly improved the goodness of fit to QRS intervals in
the merged data set, but also here the model with only RR correction was around
5% as likely, suggesting that including circadian rhythms may lead to overfitting.
Parameter estimates for the best models were similar between the different data sets
(Table 5.2).
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Table 5.1 Relative likelihood compared to the model with the lowest AIC
(Equation 5.1) of the different QRS baseline models (Equations 5.2-5.5)
evaluated using vehicle data sets from each study separately and a pooled
data set.
Study Constant
Circadian
rhythm
RR
correction
Both
1 22 0 100 5
2 22 8 100 100
4 0 0 100 0
5 100 3 14 1
6 14 1 100 61
All 0 0 5 100
Likelihoods given in %. Vehicle data from telemetry studies investigating
AZD1305 (Study=1), AZD8683 (Study=2), flecainide (Study=4), quini-
dine (Study=5), verapamil (Study=6). Most simple baseline model with
likelihood of at least 5% is indicated by bold font for each data set.
Table 5.2 Parameter estimates for the most simple vehicle QRS models with at least 5%
relative likelihood compared to the model with the lowest AIC value.
QRS0 (ms) α Res. (ms)
Study Value (SE) BSV % (SE) Value (SE) BSV % (SE) Value (SE)
1 46 (1) 5.5 (2.0) - - 1.2 (0.1)
2 44 (1) 6.1 (2.2) - - 1.6 (0.2)
4 53 (1) 5.0 (1.8) 0.012 (0.023) 220 (160) 2.1 (0.2)
5 52 (2) 7.9 (2.8) - - 1.3 (0.1)
6 44 (1) 6.0 (2.2) - - 2.6 (0.2)
All 47 (1) 9.9 (1.8) 0.038 (0.011) 62 (30) 2.0 (0.1)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal distri-
butions. Vehicle data from telemetry studies investigating AZD1305 (Study=1), AZD8683
(Study=2), flecainide (Study=4), quinidine (Study=5), verapamil (Study=6).
5.3.2 Modelling baseline PR variability of dog data
Assuming a constant baseline (Equation 5.2) with normally distributed BSV resulted
in a residual variability of 7.3 ms for the pooled data set, which was reduced to 5.4 ms
for the combined model (Equation 5.5). This suggests that some residual variability
is explained by the RR correction and/or circadian rhythm models. The percentage
likelihood of each of the four baseline models are summarised in Table 5.3. These
likelihoods suggest that the goodness of fits are improved by including primarily RR
correction, but also circadian rhythms to describe PR intervals in dogs. Parameter
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estimates for the best models were similar between the different data sets (Table
5.4).
Table 5.3 Relative likelihood compared to the model with the lowest AIC
(Equation 5.1) of the different PR baseline models (Equations 5.2-5.5)
evaluated using vehicle data sets from each study separately and a pooled
data set.
Study Constant
Circadian
rhythm
RR
correction
Both
1 0 0 100 37
2 0 0 100 61
3 0 0 0 100
4 0 1 0 100
5 0 100 0 37
6 0 0 100 2
All 0 0 0 100
Likelihoods given in %. Vehicle data from telemetry studies investi-
gating AZD1305 (Study=1), AZD8683 (Study=2), AZD9164 (Study=3),
flecainide (Study=4), quinidine (Study=5), verapamil (Study=6). Most
simple baseline model with likelihood of at least 5% is indicated by bold
font for each data set.
Table 5.4 Parameter estimates for the most simple vehicle PR models with at least 5%
relative likelihood compared to the model with the lowest AIC value.
PR0 (ms) A (%) α Res. (ms)
Study Value BSV % Value BSV % Value BSV % Value
1 100 (4) 8.4 (3.0) - - 0.14 (0.02) 19 (18) 5.5 (0.6)
2a 110 (4) 6.3 (2.4) - - 0.24 (0.04) 5.6 (46) 6.9 (0.7)
3 91 (3) 8.3 (2.4) 2.8 (0.7) 43 (25) 0.12 (0.02) 25 (18) 3.1 (0.2)
4 95 (3) 6.0 (2.2) 6.0 (1.2) 29 (18) 0.08 (0.05) 110 (53) 3.8 (0.4)
5 94 (3) 6.6 (2.4) 4.9 (1.3) 44 (23) - - 3.5 (0.4)
6 110 (6) 10 (3.7) - - 0.15 (0.03) 7 (77) 5.9 (0.5)
All 103 (3) 9.9 (1.8) 1.9 (0.6) 93 (26) 0.16 (0.02) 33 (11) 5.4 (0.2)
Data are given as estimated value (SE). BSV is the coefficient of variation, approximated by
CV% = SD*100 for log-normal distributions. Vehicle data from telemetry studies investigat-
ing AZD1305 (Study=1), AZD8683 (Study=2), AZD9164 (Study=3), flecainide (Study=4),
quinidine (Study=5), verapamil (Study=6). aPQ intervals.
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5.4 Modelling of AZD1305 data
5.4.1 Acquired data
Effects of AZD1305 were available in dogs from an in-house telemetry study and in
humans from an in-house Phase I clinical study, as described in Chapter 4. Maximum
QRS widenings induced by AZD1305 were 4 ms in dogs and 12 ms in humans, and
maximum PR prolongations were 23 ms in dogs and 14 ms in humans (Table 5.5).
Similar drug exposures were acquired in dogs and humans, both for total and free
drug.
Table 5.5 Summary of the acquired AZD1305 data.
Species Dog Human
n 4 29
Dose iv: vehicle, 2.15, 4.3; oral:
vehicle, 8.7 mg kg−1
iv: placebo, 10, 70; oral:
placebo, 10, 30, 90, 180,
360, 430, 500 mg
Cmax (µM) 3.2 ±0.8 3.4
QRS0 (ms) 46±3 96.0±6.0
QRSmax (ms) 50±5 11.5±12.4 (∆, n=2)
PR0 (ms) 108±13 164±19
PRmax (ms) 131±15 14.4±12.0 (∆, n=2)
Free drug (%) 50 63
Data presented as mean±SD. iv, intravenous; QRS0, QRS at baseline; PR0,
PR at baseline; QRSmax, maximal QRS; PRmax, maximal PR. ∆, QRS or
PR change from baseline for highest dose group.
5.4.2 PKPD modelling in dogs
5.4.2.1 PK modelling
One and two compartment PK models were evaluated following visual inspection of
the log-normalised data, and a 2 compartment model selected as this better described
the data. Proportional bioavailability for the oral dose and linear elimination were
assumed following visual inspection of dose-normalised plasma concentrations. The
final PK model well described plasma concentrations following iv and oral AZD1305
treatment (Figure 5.1). BSVs for the rate of elimination and distribution from the
peripheral to the central compartment could not be identified (SE >100%), most
likely due to the small number of dogs, and these rates were therefore assumed to
be the same for all dogs. Estimated parameters are summarised in Table 5.6 and
goodness of fit plots are shown in Figure 5.2.
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Figure 5.1 Unbound plasma concentration data (markers) and model fits (lines) for dogs
treated with AZD1305. Individual dogs are separated by colour and marker type.
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Figure 5.2 Observed data vs. individual model fits of AZD1305 concentrations in linear
(left) and log (right) scale with different colour/marker type for each dog.
Table 5.6 Parameter estimates for the dog AZD1305 PK model.
Parameter Estimate (SE) BSV % (SE)
ka (µmol h-1) 1.33 (0.21) 24.8 (11)
F 0.796 (0.023) 3.0 (2.4)
V (L kg-1) 1.78 (0.18) 20.3 (7.4)
k12 (h-1) 2.04 (0.05) -
k21 (h-1) 1.99 (0.28) 27.4 (9.7)
k (h-1) 0.466 (0.009) -
Additive residuals (µM) 0.00074 (0.00019)
Proportional residuals 0.132 (0.013)
BSV is the coefficient of variation, approximated by CV% = ω*100 for log-normal dis-
tributions.
5.4.2.2 PK-QRS drug effect modelling
A proportional direct effect model (Equation 2.4) well characterised the AZD1305-
induced QRS prolongations (Figure 5.3). Summary statistics for a selection of tested
models are provided in Table 5.7. Estimated parameters are summarised in Table
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5.8 and goodness of fit plots are shown in Figure 5.4. When evaluating the full data
set, similar results were obtained for describing baseline variability compared to the
vehicle data set (Section 5.3), where the RR correction model (Equation 5.4), but
not the circadian rhythm model (Equation 5.3), slightly improved the goodness of
fit to the data. This was mainly driven by a small correlation between QRS and RR
in one dog.
Table 5.7 Summary of a selection of the tested dog AZD1305 QRS models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 1.38 1225 0.0111
Proportional, RR corr 1.34 1218 0.368 Selected model
Proportional, RR corr,
circ rhythm
1.32 1220 0.135 No improvement
Proportional, RR corr,
effect comp
1.32 1216 1 No improvement
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Figure 5.3 Top: QRS interval duration data (markers) and model fits (lines) for dogs treated
with AZD1305. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Table 5.8 Parameter estimates for the dog AZD1305 QRS model.
Estimate (SE) BSV % (SE)
QRS0 (ms) 46.0 (1.4) 5.9 (2.1)
α 0.014 (0.008) 79.8 (51.0)
slopeu (ms µM-1) 1.93 (0.67) 66.2 (25.2)
Additive residuals (ms) 1.34 (0.0524)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions.
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Figure 5.4 Population (left) and individual (right) model fits vs. observed QRS intervals
with different colour/marker type for each animal.
5.4.2.3 PK-PR drug effect modelling
A proportional direct effect model (Equation 2.4) well characterised the AZD1305-
induced PR prolongations (Figure 5.5). Summary statistics for a selection of tested
models are provided in Table 5.9. Estimated parameters are summarised in Table
5.10 and goodness of fit plots are shown in Figure 5.6. When evaluating the full
data set, similar results were obtained for describing baseline variability compared
to the vehicle data set (Section 5.3), where the RR correction model (Equation 5.4)
considerably improved the goodness of fit to the data, and the circadian rhythm
model (Equation 5.3) slightly improved the goodness of fit to the data.
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Table 5.9 Summary of a selection of the tested dog AZD1305 PR models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 7.35 2354 1.6E-28
Proportional, RR corr 6.05 2233 0.0302 Improved fit
Proportional, RR corr,
circadian rhythm
5.87 2228 0.368
Improved fit, high
uncertainty BSV(A)
Proportional, RR corr,
circ rhythm, no BSV on
A
5.86 2226 1 Selected model
Proportional, RR corr,
circ rhythm, no BSV on
A, effect comp
5.86 2229 0.223 No improvement
Table 5.10 Parameter estimates for the dog AZD1305 PR model.
Estimate (SE) BSV % (SE)
PR0 (ms) 102 (4) 7.95 (2.85)
A (%) 2.45 (0.58) -
φ (h) 4.25 (1.65) 67.4 (31.3)
α 0.165 (0.023) 22.4 (11.9)
slopeu (ms µM-1) 13.8 (1.8) 22.5 (10.0)
Additive residuals (ms) 5.86 (0.23)
BSV is presented as the coefficient of variation, approximated by CV% = SD*100 for
log-normal distributions.
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Figure 5.5 Top: PR interval duration data (markers) and model fits (lines) for dogs treated
with AZD1305. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
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Figure 5.6 Population (left) and individual (right) model fits vs. observed PR intervals with
different colour/marker type for each animal.
5.4.3 PKPD modelling in humans
5.4.3.1 PK modelling
Two and three compartment PK models were evaluated following visual inspection of
log-normalised plasma concentrations, and a three compartment model was selected
as this showed improved goodness of fit to the data. A lag time was included to
account for a short delay between administration of the oral dose and the initial
increase in plasma concentrations. The oral bioavailability was observed to increase
with dose and modelled according to the operational equation
F = FmaxDOSE
ED50 +DOSE
(5.7)
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where F is the bioavailability, Fmax the maximal bioavailability, ED50 the dose
at half-maximum bioavailability and DOSE is the administered (oral) dose in µmol.
Model fits to the data are shown in Figure 5.7. Estimated parameters for the selected
PK model are summarised in Table 5.11 and goodness of fit plots are shown in Figure
5.8.
Table 5.11 Parameter estimates for the human AZD1305 PK model.
Parameter Estimate (SE) BSV % (SE)
ka (µmol h-1) 1.02 (0.11) 39.7 (7.5)
Fmax 0.523 (0.064) 31.4 (7.9)
ED50 (µmol) 1.46 (0.47) 73 (22)
Tlag (h) 0.172 (0.012) 31.0 (5.1)
V (L kg-1) 0.712 (0.071) 20.4 (5.9)
k12 (h-1) 4.03 (0.74) -
k21 (h-1) 1.28 (0.12) 14.4 (6.1)
k13 (h-1) 0.0893 (0.012) 17.8 (12)
k31 (h-1) 0.0472 (0.013) -
k (h-1) 0.967 (0.11) 10.1 (4.5)
Additive residuals (µM) 0.0012 (0.0002)
Proportional residuals 0.147 (0.008)
BSV is presented as coefficient of variation, approximated by CV% = SD*100 for log-
normal distributions.
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Figure 5.8 Observed data vs. individual model fits of AZD1305 concentration in linear (left)
and log (right) scale with a different colour for each subject. Initial horizontal points in the
loglog plot are data below the limit of quantification.
5.4.3.2 QRS baseline modelling
Baseline QRS intervals in humans were best described by the combined circadian
rhythm/RR correction baseline model (Equation 5.5, AIC -247 for the full data set)
and additional inter-occasion variability (IOV) of the point baseline value (AIC -
735 for the full data set). Both the estimated correction factor (α) of the QRS-RR
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relationship and the amplitute of the circadian rhythm were small. However, baseline
parameter values were similar when fitting placebo data separately and the full data
set (Tables 5.12 and 5.14). As some individuals showed negative correlations between
QRS and RR intervals (Figure 5.9), a normally distributed BSV of α was evaluated
and improved the goodness of fit. One placebo-treated subject showed consistently
lower QRS intervals compared to the remaining subjects, and this difference was
not due to shorter RR intervals (Figure 5.9). As this subject had consistently lower
QRS intervals at both occasions, it was included in the analysis.
Table 5.12 Parameter estimates for the human baseline QRS model.
Estimate (SE) BSV % (SE)
QRS0 (ms) 93.9 (2.23) 7.5 (1.68)
α 0.0463 (0.0276) 159 (47.3)
A (%) 1.45 (0.22) 22.9 (21.4)
φ (h) -7.12 (0.751) -28.3 (-8.48)
Additive residual (ms) 1.36 (0.0522) -
BSV and IOV are presented as the coefficient of variation, approximated by CV% =
SD*100 for log-normal distributions.
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Figure 5.9 QRS duration vs. RR duration for subjects treated with placebo show small but
clear individual-specific correlations.
5.4.3.3 PK-QRS drug effect modelling
Proportional and power models (Equations 2.3-2.4) were tested following visual in-
spection of simulated PK data plotted against QRS intervals. Summary statistics for
a selection of tested models are provided in Table 5.13. The power model improved
the goodness of fit slightly (AIC -36) with estimated parameters a = 10.1±0.8, b
= 0.87±0.08, suggesting an exponentially declining positive drug effect. However, b
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was not largely different from 1 and residual unexplained variability was very similar
between both models. Also, BSV for both a and b allowed large variability in the
drug effect profiles of each subject, potentially leading to overfitting of the data.
Therefore, the more simple proportional model was selected. Also, accounting for
a short delay using the effect compartment (Equation 2.5) improved the goodness
of fit value (∆AIC = -35). The estimated proportional drug effect was 11.4 ±0.8
ms µM-1 unbound AZD1305. The fit to individual data is shown in Figure 5.10,
final parameter estimates are summarised in Table 5.14 and goodness of fit plots are
shown in Figure 5.11.
Table 5.13 Summary of a selection of the tested human AZD1305 QRS models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 1.06 3666 4.66E-15
Proportional, effect
comp
1.02 3621 2.75E-05 Selected model
Power, effect comp 0.999 3600 1
Improved fit, high
freedom with BSV(a)
and BSV(b)
Power, effect comp, no
BSV(b)
1.01 3616 0.000335
No improvement from
proportional when no
BSV(b)
All models included IOV on the point baseline and the RR correction and circadian
rhythm models to describe the baseline.
Table 5.14 Parameter estimates for the selected human AZD1305 QRS model.
Estimate (SE) BSV % (SE) IOV % (SE)
QRS0 (ms) 96 (1.08) 5.8 (0.838) 2.17 (0.33)
α 0.0553 (0.00937) 70 (11.8)
A (%) 1.46 (0.129) 33.1 (8.65)
φ (h) -6.46 (0.318) 22.9 (1.94)
slopeu (ms µM-1) 11.4 (0.84) 26.1 (1.39)
ke0 (h-1) 43.1 (27.1) 203 (13.7)
Additive residual (ms) 1.02 (0.0241)
BSV and IOV are presented as the coefficient of variation, approximated by CV% = SD*100
for log-normal distributions.
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Figure 5.11 Population (left) and individual (right) model fits vs. observed QRS intervals
with different colour for each subject.
5.4.3.4 PQ baseline modelling
PQ intervals in humans were best described by the combined circadian rhythm/RR
correction baseline model (Equation 5.5, ∆AIC = -511). Both the estimated correc-
tion factor (α) of the PQ-RR relationship and the amplitute of the circadian rhythm
were similar when fitting placebo data separately and the full data set (Tables 5.15
and 5.17). Goodness of fit was improved using a normal rather than a lognormal dis-
tribution of the α parameter across individuals as some individuals showed negative
PQ-RR correlations (Figure 5.12).
Table 5.15 Parameter estimates for the human baseline PQ model.
Estimate (SE) BSV % (SE)
PQ0 (ms) 170 (5.94) 11 (2.48)
α 0.191 (0.0761) 119 (29.5)
A (%) 2.83 (0.528) 50.7 (15.1)
φ (h) -3.2 (0.905) -80.8 (-21.8)
Additive residual (ms) 3.57 (0.137) -
BSV and IOV are presented as the coefficient of variation, approximated by CV% =
SD*100 for log-normal distributions.
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Figure 5.12 PQ duration vs. RR durations for subjects treated with placebo show clear
individual-specific correlations.
5.4.3.5 PK-PQ drug effect modelling
Proportional and power models (Equations 2.3-2.4) were tested following visual in-
spection of simulated PK plotted against PQ intervals. Summary statistics for a
selection of tested models are provided in Table 5.16. The power model improved
the goodness of fit slightly (∆AIC = -31) with estimated parameters a = 18 ±3 and
b = 1.2 ±0.2, suggesting a small exponential increase in the drug effect. However, b
was not largely different from 1 and residual unexplained variability was very similar
between the proportional and the power model. Also, BSV for both a and b allowed
large variability in the drug effect profiles of each subject, potentially leading to
overfitting of the data. Therefore, the more simple proportional model was selected.
Also, accounting for a short delay using the effect compartment (Equation 2.5) im-
proved the goodness of fit value (∆AIC = -22). BSV could not be fitted to the rate
of distribution to the effect compartment (SE of BSV > 100%) and the BSV of this
parameter was therefore removed. The estimated proportional drug effect was 17.0
±2.6 ms µM-1 unbound AZD1305. The fits to individual data are shown in Figure
5.13, final parameter estimates are summarised in Table 5.17 and goodness of fit
plots are shown in Figure 5.14.
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Table 5.16 Summary of a selection of the tested human AZD1305 PQ models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 3.74 6432 1.69E-10
Proportional, effect comp 3.7 6410 0.0000101
Improved fit, high
uncertainty BSV(ke0)
Proportional, effect comp,
no BSV(ke0)
3.7 6406 0.0000749 Selected model
Power, effect comp 3.6 6387 1
Improved fit, high
freedom with BSV(a) and
BSV(b)
Power, effect comp, no
BSV(b)
3.69 6405 0.000123
No improvement from
proportional when no
BSV(b)
All models included IOV on the point baseline and the RR correction and circadian rhythm
models to describe the baseline.
Table 5.17 Parameter estimates for the selected human AZD1305 PQ model.
Estimate (SE) BSV % (SE) IOV % (SE)
PQ0 (ms) 160 (3.57) 11.7 (1.61) 4.53 (0.70)
A (%) 2.77 (0.303) 47.4 (2.62) -
φ (h) -3.55 (0.491) 64.9 (2.78) -
α 0.123 (0.0338) 134 (5.92) -
slopeu (ms µM-1) 17 (2.57) 51.7 (4.07) -
ke0 (h-1) 10.5 (2.4) 34.4 (46.4) -
Additive residuals (ms) 3.72 (0.09)
BSV and IOV are presented as the coefficient of variation, approximated by CV% = SD*100
for log-normal distributions.
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Figure 5.14 Population (left) and individual (right) model fits vs. observed PQ intervals
with different colour for each subject.
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5.5 Modelling of AZD8683 data
5.5.1 Acquired data
Effects of AZD8683 were available in dogs from an in-house telemetry study and
in human volunteers, and the compound was administered by inhalation. Neither
PR nor QRS intervals were prolonged in humans, where maximum plasma concen-
trations of 1.00 nM AZD8683 (geometric mean, 85 CV%) were achieved. Only dog
data were therefore modelled. Maximum PQ interval prolongations in dogs were 40
ms and maximum QRS interval widenings were 3 ms (Table 5.18). Significant QRS
prolongations were observed at a single time point 2 hours after Cmax, but reported
as an unlikely effect of the compound. Important side effects included AV block.
Table 5.18 Summary of the acquired AZD8683 data.
Species Dog
n 4
Dose Inhalation: 0, 0.02, 0.1, 0.25 mg kg-1
Cmax (µM) 0.048±0.02
QRS0 (ms) 44±3
QRSmax (ms) 47±4
PQ0 (ms) 116±6
PQmax (ms) 156±19
Free drug (%) 4.39
Data presented as mean±SD. QRS0, QRS at baseline; PR0, PR at base-
line; QRSmax, maximal QRS; PRmax, maximal PR.
5.5.2 PKPD modelling in dogs
5.5.2.1 PK modelling
Two and three compartment PK models were evaluated following visual inspection of
log-normalised plasma concentrations, and a three compartment model was selected
as this showed improved goodness of fit to the data. A lag time was included to
account for a short delay between inhalation of the dose and the initial increase of
plasma concentrations. The bioavailability was observed to decrease with dose and
modelled according to
F = 1− DOSE
ED50 +DOSE
(5.8)
where F is the relative bioavailability, ED50 the dose-dependent bioavailability and
DOSE is the administered (inhaled) dose in nmol. It was assumed that F → 0 as
DOSE →∞. As F describes the relative bioavailability, the volume of distribution
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of this model represents the true volume of distribution divided by the maximum
bioavailability. Absorption to the central compartment was very fast and could be
approximated as instantaneous without loss of goodness of fit. The proportional
part of the estimated residuals was large (>45 %) with a high degree of shrinkage
for the random variables resulting in bad fits to the individual data, especially at
high concentrations. A fixed proportional error of 15 % improved the fit to high
concentration data and improved the estimation of individual parameters. BSV
for the volume of distribution, distribution to the third compartment and rate of
elimination were reduced without loss of the goodness of fit to the data. The fits to
data are shown in Figure 5.15. Estimated parameters for the selected PK model are
summarised in Table 5.19 and goodness of fit plots are shown in Figure 5.16.
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Figure 5.15 Unbound plasma concentration data (markers) and model fits (lines) for dogs
treated with AZD9164.
Table 5.19 Parameter estimates for the dog AZD8683 PK model.
Parameter Estimate (SE) BSV % (SE)
ED50 (µmol) 1280 (710) 79.6 (36)
V (L kg-1) 2.45 (0.8) -
k12 (h-1) 17.1 (11) 70.4 (28)
k21 (h-1) 3.59 (1.1) 55.6 (24)
k13 (h-1) 1.16 (0.002) -
k31 (h-1) 0.064 (0.095) -
k (h-1) 2.36 (0.89) -
Additive residuals (µM) 0.695 (0.091)
Proportional residuals 0.15 (fixed)
BSV is presented as the coefficient of variation, approximated by CV% = SD*100 for
log-normal distributions.
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Figure 5.16 Observed data vs. individual model fits of AZD8683 concentration in linear (left)
and log (right) scale with different colour/marker type for each subject. Initial horizontal
points in the loglog plot are data below the limit of quantification.
5.5.2.2 PK-PQ drug effect modelling
The Emax model (Equation 2.2) with an effect compartment (Equation 2.5) best
described PQ prolongations caused as a side effect by AZD8683. Summary statistics
for a selection of tested models are provided in Table 5.20. BSV on the maximum
effect did not improve the goodness of fit and was therefore removed. Although
the SE of the exponent of the Emax model was large, this parameter was required
to fit the data. The high SE was due to large variability of this value between the
individual dogs. The fits to data are shown in Figure 5.17, final parameter estimates
are summarised in Table 5.21 and goodness of fit plots are shown in Figure 5.18.
Inclusion of both a circadian rhythm and RR correction (Equation 5.5) improved
the goodness of fit to the full PQ data set and were therefore included, although
circadian rhythm did not improve the goodness of fit to the vehicle data set (Section
5.3).
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Table 5.20 Summary of a selection of the tested human AZD8683 PQ models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 13.3 1755 2.89E-63
Proportional, effect comp 10.5 1669 1.37E-44 Improved fit
Proportional, effect comp,
RR corr, circ rhythm
8.37 1594 2.64E-28
Improved fit, high
uncertainty BSV(A)
Proportional, effect comp,
RR corr, circ rhythm, no
BSV(A)
8.35 1591 1.19E-27
Emax, effect comp, RR
corr, circ rhythm, no
BSV(A)
5.78 1467 1
Improved fit, high
uncertainty BSV(Emax)
Emax, effect comp, RR
corr, circ rhythm, no
BSV(A) or BSV(Emax)
5.84 1468 0.607 Selected model
Table 5.21 Parameter estimates for the dog AZD8683 PQ model.
Estimate (SE) BSV % (SE)
PQ0 (ms) 109 (3) 4.53 (1.66)
A (%) 3.07 (0.61) -
φ (h) 3.30 (2.44) 139 (56)
α 0.194 (0.027) 21.6 (12.3)
Emax (ms) 61.0 (3.0) -
EC50 (nM) 0.306 (0.042) 25.7 (10.0)
n 6.52 (3.63) 98.7 (41.3)
ke0 (h-1) 0.632 (0.162) 48.0 (19.0)
Additive residuals (ms) 5.84 (0.30)
BSV is presented as the coefficient of variation, approximated by CV% = SD*100 for
log-normal distributions.
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Figure 5.17 Top: PQ interval duration data (markers) and model fits (lines) for dogs treated
with AZD8683. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Figure 5.18 Population (left) and individual (right) model fits vs. observed PR intervals
with different colour/marker type for each subject.
5.6 Modelling of AZD9164 data
5.6.1 Acquired data
Effects of AZD9164 were available in dogs from an in-house telemetry study and
in human volunteers, and the compound was administered by inhalation. Neither
PR nor QRS intervals were prolonged in humans, where maximum plasma concen-
trations of 13.2 nM AZD9164 (geometric mean, 75 CV%) were achieved. Only dog
data were therefore modelled. Maximum PR interval prolongations in dogs were
approximately 30 ms (Table 5.22) while no effects were observed on QRS intervals.
Important side effects included AV block.
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Table 5.22 Summary of the acquired AZD9164 data.
Species Dog
n 6
Dose Inhalation: 0, 0.019, 0.092, 0.220 mg kg-1
Cmax (µM) 0.21±0.04
QRS0 (ms) 47±5
QRSmax (ms) No effect.
PR0 (ms) 95±10
PRmax (ms) 124±30
Free drug (%) 12.7
Data presented as mean±SD. iv, intravenous; QRS0, QRS at baseline;
PR0, PR at baseline; QRSmax, maximal QRS; PRmax, maximal PR. ∆
QRS/PR change is provided for humans as change is from the highest
dose group while baseline is from all groups.
5.6.2 PKPD modelling in dogs
5.6.2.1 PK modelling
AZD9164 exposure was only measured immediately pre- and post-dosing in the
dog telemetry data set, limiting the possibility of developing a PK model using
these data only as the distribution to peripheral compartments and elimination of
AZD9164 are not captured in the data. Therefore, a dog tolerability inhalation study
with similar study design (beagle dogs, similar inhalation duration and dose levels)
was used to identify a population model of the PK profile of AZD9164. Between-
subject variability in the distribution and elimination of AZD9164 was relatively
small, as shown by Cmax-normalised exposures of AZD9164 which all were within a
ten-fold range (Figure 5.19). This suggests that typical parameters describing the
distribution and elimination of AZD9164 can be used to predict exposure in the
telemetry study, where only the exposures immediately following administration are
known.
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Figure 5.19 Normalised plasma concentration data over Cmax plotted against time for the
tolerability dog study of AZD9164. Data were available for 2 dogs receiving low (grey solid
line), medium (dashed line) and high dose (black solid line). As the last 2 and 1 time points
respectively are at the limit of quantification for the lowest dose, these points are likely to
be closer to the medium and high dose than they appear in the plot.
Two and three compartment PK models were evaluated following visual in-
spection of log-normalised plasma concentrations, and a three compartment model
was selected as this showed improved goodness of fit to the data. Absorption to
the central compartment was very fast and could be assumed to be instantaneous.
The proportional part of the estimated residual error was large (>30 %) resulting
in poor fits to the maximal concentration data points. A fixed proportional error
of 15 % improved the fits to the high concentration data. BSV was removed for all
parameters except V (/F ) without loss of goodness of fit to the data.
For modelling exposure in the telemetry study, the distribution and elimi-
nation parameters were fixed to the values estimated in the tolerability study. To
maximise the information capture from the single measured post-administration data
point, a random inter-occasion variability was included for the volume of distribu-
tion. The fits to data are shown in Figure 5.20. Estimated parameters for the tol-
erability study PK model and the telemetry study PK model with re-parameterised
volume of distribution are summarised in Table 5.23 and goodness of fit plots are
shown in Figure 5.21.
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Figure 5.20 Unbound plasma concentration data (markers) and model fits (lines) for dogs
treated with AZD9164.
Table 5.23 Parameter estimates for the dog AZD9164 PK models, with disposition
parameter estimates generated using the PK data from a tolerability study and final
volumes of distribution estimated from the PK data for the telemetry study.
Tolerability study Telemetry study
Parameter Estimate (SE) BSV % (SE) Estimate (SE) IOV % (SE)
V (L kg-1) 2.25 (0.44) 40.7 (13) 2.3 (0.23) 40.3 (7.7)
k12 (h-1) 3.64 (0.75) - 3.64 (fixed) -
k21 (h-1) 0.704 (0.16) - 0.704 (fixed) -
k13 (h-1) 2.68 (0.88) - 2.68 (fixed) -
k31 (h-1) 0.135 (0.043) - 0.135 (fixed) -
k (h-1) 5.3 (0.42) - 5.3 (fixed) -
Add. res. (µM) 0.127 (0.033) 0.024 (0.016)
Prop. res. 0.15 (fixed) 0.15 (fixed)
BSV and IOV are presented as the coefficient of variation, approximated by CV% =
SD*100 for log-normal distributions.
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Figure 5.21 Observed data vs. individual model fits of AZD9164 concentration in linear (left)
and log (right) scale with different colour/marker type for each subject. Initial horizontal
points in the loglog plot are data below the limit of quantification.
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5.6.2.2 PK-PR drug effect modelling
The Emax model (Equation 2.2) with an effect compartment (Equation 2.5) best
described PR prolongations caused as a side effect by AZD9164. Summary statistics
for a selection of tested models are provided in Table 5.24. BSV on the maximum
effect did not improve goodness of fit and was therefore removed. Although the
SE of the exponent of the Emax model was large, this parameter was required to
fit the data. The high SE was due to large variability of this value between the
individual dogs. The fits to data are shown in Figure 5.22, final parameter estimates
are summarised in Table 5.25 and goodness of fit plots are shown in Figure 5.23.
Similar results were obtained for modelling baseline variability between the full data
set and the vehicle only data set, where inclusion of both the circadian rhythm and
RR correction models improved the goodness of fits (Equation 5.5).
Table 5.24 Summary of a selection of the tested human AZD9164 PR models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional, effect comp 5.19 4674 1.6E-66 Improved fit
Proportional, effect comp,
RR corr, circ rhythm
4.85 4600 1.88E-50 Improved fit
Emax, effect comp, RR
corr, circ rhythm
4.16 4433 3.44E-14
Improved fit, high
uncertainty BSV(A) and
BSV(Emax)
Emax, effect comp, RR
corr, circ rhythm, no
BSV(A) or BSV(Emax)
3.98 4371 1 Selected model
Table 5.25 Parameter estimates for the dog AZD9164 PR model.
Estimate (SE) BSV % (SE)
PR0 (ms) 92.4 (3.3) 8.59 (2.50)
A (%) 2.76 (0.39) -
φ (h) 1.39 (3.47) 605 (179)
α 0.0688 (0.0196) 59.7 (22.9)
Emax (ms) 52.2 (1.4) -
EC50 (nM) 3.39 (1.37) 87.5 (29.8)
n 7.81 (3.07) 84.5 (29.3)
ke0 (h-1) 1.74 (1.03) 136 (43)
Additive residuals (ms) 3.98 (0.11)
BSV and IOV are presented as the coefficient of variation, approximated by CV% =
SD*100 for log-normal distributions.
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Figure 5.22 Top: PR interval duration data (markers) and model fits (lines) for dogs treated
with AZD9164. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Figure 5.23 Population (left) and individual (right) model fits vs. observed PR intervals
with different colour/marker type for each subject.
5.7 Modelling of flecainide data
5.7.1 Acquired data
Maximum QRS interval widenings were 6, 9 and 31 ms in guinea pigs, dogs and
humans respectively and maximum PR interval prolongations were 9, 25 and 56 ms
(Table 5.26). Similar exposures were acquired in guinea pigs and humans, while ex-
posures in dogs were approximately doubled. However, as the free fraction estimated
in vitro was smaller in dogs compared to guinea pigs and humans, the exposure of
free drug may be more similar.
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Table 5.26 Summary of the acquired flecainide data.
Species Guinea pig Dog Human
Source of data In-house: Single
study
In-house: Single
study
Literature: 16
published studies
n 4 veh + 4 treat 4 Many
Dose iv: 0, 0.3, 1, 3 mg
kg-1
oral: 0, 3, 10, 20
mg kg-1
iv: 1.5-2 mg kg-1,
150 mg. oral:
100-600 mg
Cmax (µM) 2.70±0.52 4.5±2.2 2.6
QRS0 (ms) 24±2 55±5 92.5
QRSmax (ms) 30±4 64±11 31 (∆)
PR0 (ms) 55±12 97±7 160
PRmax (ms) 64±12 118±11 56 (∆)
Free drug (%) 57 36.9a 62.1
Data presented as mean±SD. iv, intravenous; QRS0, QRS at baseline; PR0, PR at
baseline; QRSmax, maximal QRS; PRmax, maximal PR; ∆, QRS or PR change from
baseline. a[21]
5.7.2 PKPD modelling in guinea pigs
5.7.2.1 PK modelling
Compartmental models with 1 and 2 compartments were tested following visual
inspection of the log-normalised PK data and a 2 compartment model was selected to
describe plasma concentrations following flecainide infusion (Figure 5.24). Estimated
parameters for the selected PK model are summarised in Table 5.27 and goodness
of fit plots are shown in Figure 5.25.
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Figure 5.24 Unbound plasma concentration data (markers) and model fits (lines) for guinea
pigs treated with three 15 min ascending doses of flecainide (circle) or with vehicle (black
cross). Individual guinea pigs treated with flecainide are separated by colour.
98
O
bs
er
ve
d 
PK
Individual PK prediction
0 1 2 3
0
1
2
3
Individual PK prediction
1
1
Figure 5.25 Observed data vs. individual model fits of flecainide concentration in linear
(left) and log (right) scale with different colour for each animal.
Table 5.27 Parameter estimates for the guinea pig flecainide PK model.
Parameter Estimate (SE) BSV % (SE)
V (L kg-1) 0.259 (0.111) -
k12 (h-1) 38.2 (19.4) 21.3 (9.79)
k21 (h-1) 2.7 (0.582) -
k (h-1) 14.2 (6.62) -
Additive residuals (µM) 0.0848 (0.0196)
Proportional residuals 0.1 (fixed)
BSV is the coefficient of variation, approximated by CV% = ω*100 for log-normal dis-
tributions.
5.7.2.2 PK-QRS drug effect modelling
Visual inspection of the PK and PD data indicated delays between plasma concen-
tration and QRS prolongations (see Figure 5.26). This was confirmed by the PKPD
modelling, as the effect compartment model (Equation 2.5) improved the goodness
of fit to QRS intervals following infusions of flecainide. Summary statistics for a
selection of tested models are provided in Table 5.28. The power model (Equation
2.3) best described the flecainide-induced QRS prolongations. The fits to data are
shown in Figure 5.26. Estimated parameters for the selected model are summarised
in Table 5.29 and goodness of fit plots are shown in Figure 5.27. The PKPD model
was developed using the full data set including animals receiving vehicle and animals
receiving flecainide. No correlations were observed between QRS and HR, and the
RR correction model (Equation 5.4) did not improve the goodness of fit. Circadian
rhythms were not evaluated due to the short experimental time (2h).
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Table 5.28 Summary of a selection of the tested guinea pig flecainide QRS models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 2.14 627.4 1.34E-54
Proportional, effect comp 0.952 431.7 4.18E-12 Improvement
Proportional, effect comp,
HR corr
0.953 435.9 5.12E-13 No improvement
Power, effect comp 0.775 383.7 0.111
Improvement, high
uncertainty BSV(a)
Power, effect comp, no
BSV(a)
0.776 379.3 1 Selected model
Table 5.29 Parameter estimates for the guinea pig flecainide QRS model.
Estimate (SE) BSV % (SE)
QRS0 (ms) 21.7 (0.893) 11.6 (2.92)
a 16.9 (1.66) -
b 2.46 (0.365) 23.4 (9.15)
ke0 (h-1) 1.6 (0.111) -
Additive residuals (ms) 0.776 (0.0495) -
BSV is the coefficient of variation, approximated by CV% = ω*100 for log-normal
distributions.
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Figure 5.26 Left: Individual PK model parameters predicting the PK in each guinea pig were
used to drive the PD response. Right: QRS interval duration data (markers) and model
fits (lines) for guinea pigs treated with three 15 min ascending doses of flecainide (circle) or
with vehicle (black cross). Individual guinea pigs treated with flecainide are separated by
colour.
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Figure 5.27 Population (left) and individual (right) model fits vs. observed QRS intervals
with different colour for each animal.
5.7.2.3 PK-PR drug effect modelling
Visual inspection of the PK and PD data indicated delays between plasma concen-
tration and PR prolongations (see Figure 5.28). This was confirmed by the PKPD
modelling, as the effect compartment model (Equation 2.5) improved the goodness
of fit to PR intervals following infusions of flecainide. Summary statistics for a se-
lection of tested models are provided in Table 5.28. A power model (Equation 2.3)
best described the flecainide-induced PR prolongations. The fits to data are shown
in Figure 5.28. Estimated parameters of the selected model are summarised in Table
5.31 and goodness of fit plots are shown in Figure 5.29. The HR correction model
(Equation 5.4) did improve the goodness of fit to PR interval data. The exponent
of the PR-HR correction was assumed the same for all animals. Circadian rhythms
were not evaluated due to the short experimental time (2h).
Table 5.30 Summary of a selection of the tested guinea pig flecainide PR models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 2.43 691.8 3.1E-12
Proportional, effect comp 2.14 664.4 0.00000276 Improvement
Proportional, effect comp,
HR corr, no BSV(α)
1.94 641.7 0.235
Improvement, high
uncertainty BSV(ke0)
Proportional, effect comp,
HR corr, no BSV(α) or
BSV(ke0)
1.95 639.8 0.607 Selected model
Power, effect comp, HR
corr, no BSV(α)
1.87 638.8 1 No improvement
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Table 5.31 Parameter estimates for the guinea pig flecainide PR model.
Estimate (SE) BSV % (SE)
PR0 (ms) 57 (4.39) 21.8 (5.45)
α 0.31 (0.0575) -
slopeu (ms µM-1) 4.14 (1.84) 82 (31.4)
ke0 (h-1) 11.9 (3.62) -
Additive residuals (ms) 1.95 (0.124)
BSV is the coefficient of variation, approximated by CV% = ω*100 for log-normal
distributions.
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Figure 5.28 Left: Individual PK model parameters predicting the PK in each guinea pig
were used to drive the PD response. Right: PR interval duration data (markers) and model
fits (lines) for guinea pigs treated with three 15 min ascending doses of flecainide (circle) or
with vehicle (black cross). Individual guinea pigs treated with flecainide are separated by
colour.
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Figure 5.29 Population (left) and individual (right) model fits vs. observed PR intervals
with different colour for each animal.
5.7.3 PKPD modelling in dogs
5.7.3.1 PK modelling
A one compartment model was fitted to the plasma concentrations following oral
treatment with flecainide following visual inspection of the log-normalised data (Fig-
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ure 5.30). A zero order absorption model improved the goodness of fit to the data
compared to first order absorption, and was therefore selected. The proportional
part of the estimated residual error was large (>40 %) with a high degree of shrink-
age for the random variables resulting in a poor fit to individual data, especially
at high concentrations. A fixed proportional error of 15 % improved the fit to the
high concentration data and improved the estimation of individual parameters. BSV
effects on the rate of elimination from the central compartment (ke) could not be
identified (SE >100%) and the same elimination rate was therefore assumed for all
dogs. Estimated parameters of the selected PK model are summarised in Table 5.32
and goodness of fit plots are shown in Figure 5.31.P
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Figure 5.30 Unbound plasma concentration data (markers) and model fits (lines) for dogs
treated with flecainide.
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Figure 5.31 Observed data vs. individual model fits of flecainide concentration in linear
(left) and log (right) scale with different colour/marker type for each animal. One animal
shows highly variable PK data at low concentrations causing large errors (green squares).
Initial horizontal points in the right plot are below the limit of quantification.
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Table 5.32 Parameter estimates for the dog flecainide PK model.
Parameter Estimate (SE) BSV % (SE)
ka (µmol h-1) 1.81a (0.42) 37.9 (16)
V (L kg-1) 8.1 (1.6) 21.4 (10)
k (h-1) 0.356 (0.091) -
Additive residuals (µM) 0.257 (0.061)
Proportional residuals 0.15 (fixed)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions. aZero-order absorption.
5.7.3.2 PK-QRS drug effect modelling
A proportional direct effect model (Equation 2.4) well characterised the flecainide-
induced QRS prolongations (Figure 5.32). Summary statistics for a selection of
tested models are provided in Table 5.33. The direct effect model was selected
despite slightly improved goodness of fit for the effect comparmtment model. As the
data showed high variability and the PR data did not support the effect compartment
model, it was concluded that any potential delay could not be estimated confidently.
Estimated parameters for the selected model are summarised in Table 5.34 and
goodness of fit plots are shown in Figure 5.33. While inclusion of RR correction
(Equation 5.4) improved the goodness of fit to the vehicle only data, the constant
model (Equation 5.2) equally well described the full flecainide data set and was
therefore selected.
Table 5.33 Summary of a selection of the tested dog flecainide QRS models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 2.65 1414 0.00248 Selected model
Proportional, RR corr 2.65 1418 0.000335 No improvement
Proportional, RR corr,
circ
2.61 1420 0.000123 No improvement
Proportional, effect comp 2.58 1402 1 Improvement
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Table 5.34 Parameter estimates for the dog flecainide QRS model.
Estimate (SE) BSV % (SE)
QRS0 (ms) 53.6 (1.5) 5.68 (2.03)
slopeu (ms µM-1) 5.38 (0.95) 30.8 (14.3)
Additive residuals (ms) 2.65 (0.11)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions.
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Figure 5.32 Top: QRS interval duration data (markers) and model fits (lines) for dogs treated
with flecainide. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Figure 5.33 Population (left) and individual (right) model fits vs. observed QRS intervals
with different colour/marker type for each animal.
5.7.3.3 PK-PR drug effect modelling
A proportional direct effect model (Equation 2.4) well characterised the flecainide-
induced PR prolongations (Figure 5.34). Summary statistics for a selection of tested
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models are provided in Table 5.35. Estimated parameters for the selected PR model
are summarised in Table 5.36 and goodness of fit plots are shown in Figure 5.35.
Inclusion of the circadian rhythm model (Equation 5.3), but not the RR correction
model (Equation 5.4), improved the goodness of fits to the full flecainide data set,
while both improved the goodness of fits to the vehicle data.
Table 5.35 Summary of a selection of the tested dog flecainide PR models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 6.42 1915 3.58E-29
Proportional, RR corr 6.27 1910 4.36E-28
Proportional, circ rhythm 4.93 1787 0.223
Improvement, high
uncertainty BSV(φ)
Proportional, circ
rhythm, no BSV(φ)
4.97 1785 0.607 Selected model
Proportional, RR corr,
circ rhythm, no BSV(φ)
4.87 1784 1 No improvement
Proportional, circ
rhythm, effect comp, no
BSV(φ)
4.92 1790 0.0498 No improvement
Table 5.36 Parameter estimates for the dog flecainide PR model.
Estimate (SE) BSV % (SE)
PR0 (ms) 95.8 (2.3) 4.76 (1.72)
A (%) 4.60 (1.39) 55.6 (22.8)
φ (h) 0.035 (0.369) -
slopeu (ms µM-1) 11.0 (1.2) 13.3 (10.9)
Additive residuals (ms) 4.97 (0.21)
BSV is presented as the coefficient of variation, approximated by CV% = SD*100 for
log-normal distributions.
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Figure 5.34 Top: PR interval duration data (markers) and model fits (lines) for dogs treated
with flecainide. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Figure 5.35 Population (left) and individual (right) model fits vs. observed PR intervals
with different colour/marker type for each animal.
5.8 Modelling of quinidine data
5.8.1 Acquired data
Maximum QRS interval widenings were 5 and 18 ms in dogs and humans respectively
(Table 5.37). PR was increased only at a single time point 2.5 h after dosing in the
single dog dosed with 50 mg kg-1 quinidine. Treatment of 50 mg kg-1 quinidine was
stopped in the remaining dogs due to adverse effects in the single 50 mg kg-1 dosed
dog. Total exposures were doubled in dogs compared to humans, while exposures of
unbound quinidine were similar due to differences in free fractions.
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Table 5.37 Summary of the acquired quinidine data.
Species Dog Human
Source of data In-house: Single study Literature: 15 published studies
n 4 Many
Dose oral: vehicle, 10, 25, 50a mg kg-1
iv: 3.7-10 mg kg-1. oral: 3 mg
kg-1, 100-2250 mg
Cmax (µM) 24±12 (60) 12.3
QRS0 (ms) 54±3 (52) 92.5
QRSmax (ms) 59±5 (61) 18 (∆)
PR0 (ms) 102±10 (95) 160
PRmax (ms) n.e. (120) -
Free drug (%) 6.18 12.2
Data presented as mean±SD. iv, intravenous; QRS0, QRS at baseline; PR0, PR at baseline;
QRSmax, maximal QRS; PRmax, maximal PR; ∆, QRS or PR change from baseline. an=1
for 50 mg dose.
5.8.2 PKPD modelling in dogs
5.8.2.1 PK modelling
A one compartment model was fitted to the quinidine exposure data following visual
inspection of the log-normalised data (Figure 5.36). The bioavailability was observed
to decrease with dose and this decrease was modelled according to Equation 5.8.
BSV for the rate of absorption and the rate of elimination were removed as these
parameters were not identifiable (SE >100%). Estimated parameters for the selected
PK model are summarised in Table 5.38 and goodness of fit plots are shown in Figure
5.37.Q
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Figure 5.36 Unbound plasma concentration data (markers) and model fits (lines) for dogs
treated with quinidine.
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Figure 5.37 Observed data vs. individual model fits of quinidine concentration in linear
(left) and log (right) scale with different colour/marker type for each animal. One animal
shows highly variable PK data at low concentrations causing large errors (green squares).
Initial horizontal points in th eright plot are below the limit of quantification.
Table 5.38 Parameter estimates for the dog quinidine PK model.
Parameter Estimate (SE) BSV % (SE)
ka (µmol h-1) 1.79 (0.48) -
ED50 (µmol) 124 (65) 66.1 (47)
V (L kg-1) 1.82 (0.43) 36.6 (17)
k (h-1) 0.137 (0.009) -
Additive residuals (µM) 0.282 (0.12)
Proportional residuals 0.207 (0.038)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions.
5.8.2.2 PK-QRS drug effect modelling
A proportional direct effect model (Equation 2.4) well characterised the quinidine-
induced QRS prolongations (Figure 5.38). Summary statistics for a selection of
tested models are provided in Table 5.39. Estimated parameters for the selected QRS
model are summarised in Table 5.40 and goodness of fit plots are shown in Figure
5.39. A constant baseline model (Equation 5.2) equally well described baseline QRS
variability compared to the RR correction and circadian rhythm models (Equations
5.4 and 5.3) when fitting both the vehicle only and the full data sets.
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Table 5.39 Summary of a selection of the tested dog quinidine QRS models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 2.19 830.8 0.301
High uncertainty on
BSV(slope)
Proportional, no
BSV(slope)
2.19 828.4 1 Selected model
Proportional, circ 2.12 831.1 0.259 No improvement
Proportional, RR corr 2.17 831.8 0.183 No improvement
Proportional, RR corr,
circ
2.1 832.7 0.116 No improvement
Proportional, effect comp 2.19 834.2 0.055 Improvement
Table 5.40 Parameter estimates for the dog quinidine QRS model.
Estimate (SE) BSV % (SE)
QRS0 (ms) 53.3 (1.7) 6.25 (2.23)
slopeu (ms µM-1) 3.00 (0.25) -
Additive residuals (ms) 2.19 (0.12)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions.
QR
S 
(m
s)
50
60
Fr
ee
 q
ui
ni
di
ne
 (u
M)
time (h)
0 mg kg−1
0 6 12 18 24
0
0.5
1
1.5
2
2.5
3
3.5
time (h)
10 mg kg−1
0 6 12 18 24
time (h)
25 mg kg−1
0 6 12 18 24
time (h)
50 mg kg−1
0 6 12 18 24
Figure 5.38 Top: QRS interval duration data (markers) and model fits (lines) for dogs treated
with quinidine. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Figure 5.39 Population (left) and individual (right) model fits vs. observed QRS intervals
with different colour/marker type for each dog.
5.9 Modelling of verapamil data
5.9.1 Acquired data
Maximum PR interval prolongations induced by verapamil were 16, 55 and 53 ms
in guinea pigs, dogs and humans respectively (Table 5.41). No effect of verapamil
was observed on QRS intervals. Exposures were doubled in guinea pigs and humans
compared to dogs for both total and free drug.
Table 5.41 Summary of the acquired verapamil data.
Species Guinea pig Dog Human
n 4 veh + 4 treat 4 16 studies
Dose iv: vehicle, 0.1, 0.3,
1 mg kg-1
oral: vehicle, 1, 5,
15 mg kg-1
oral: 80-480 mg
Cmax (µM) 1.97±0.26 0.78±0.26 1.7
QRS0 (ms) 22±1 44±2 92.5
QRSmax (ms) 25±2a (NS) n.e. -
PR0 (ms) 61±6 114±22 160
PRmax (ms) 77±5a 169±45 53 (∆)
Free drug (%) 19.7 18.9 20.7
Data presented as mean±SD. iv, intravenous; QRS0, QRS at baseline; PR0, PR at
baseline; QRSmax, maximal QRS; PRmax, maximal PR; ∆, QRS or PR change from
baseline. an=2 due to the death of 2 animals from compound-related effects.
5.9.2 PKPD modelling in guinea pigs
5.9.2.1 PK modelling
Compartmental models with 1 and 2 compartments were tested following visual in-
spection of the log-normalised PK data and a 2 compartment model was selected
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to describe plasma concentrations following verapamil infusion (Figure 5.40). Es-
timated parameters for the selected PK model are summarised in Table 5.42 and
goodness of fit plots are shown in Figure 5.41.
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Figure 5.40 Unbound plasma concentration data (markers) and model fits (lines) for guinea
pigs treated with three 15 min ascending doses of verapamil (circle) or with vehicle (black
cross). Individual guinea pigs treated with verapamil are separated by colour.
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Figure 5.41 Observed data vs. individual model fits of flecainide concentration in linear
(left) and log (right) scale with different colour/marker type for each animal.
Table 5.42 Parameter estimates for the guinea pig verapamil PK model.
Parameter Estimate (SE) BSV % (SE)
V (L kg-1) 0.362 (0.0415) -
k12 (h-1) 1.94 (1.94) 145 (57)
k21 (h-1) 1.07 (0.553) -
k (h-1) 2.71 (0.523) -
Additive residuals (µM) 0.0679 (0.0203)
Proportional residuals 0.127 (0.0465)
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions.
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5.9.2.2 PK-PR drug effect modelling
Visual inspection of the PK and PD data indicated delays between verapamil plasma
concentration and PR prolongations (see Figure 5.42). This was confirmed by the
PKPD modelling, as the effect compartment model (Equation 2.5) improved the
goodness of fit to PR intervals following infusions of verapamil. Summary statis-
tics for a selection of tested models are provided in Table 5.43. Verapamil-induced
PR prolongations were well described by a proportional model (Equation 2.4). Es-
timated parameters of the selected PR model are summarised in Table 5.44 and
goodness of fit plots are shown in Figure 5.43. The fits to data are shown in Figure
5.42. Inclusion of the HR correction model (Equation 5.4) did not improve the fit
to PR intervals in either the vehicle only or full data set. Circadian rhythms were
not evaluated due to the short experimental time (2h).
Table 5.43 Summary of a selection of the tested guinea pig verapamil PR models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional 3.96 800.8 3.32E-19
Proportional, effect comp 2.7 717.8 0.35
Improvement, high
uncertainty BSV(ke0)
Proportional, effect comp,
no BSV(ke0)
2.7 715.7 1 Selected model
Proportional, effect comp,
HR corr, no BSV(α)
2.7 719.7 0.135 No improvement
Power, effect comp, HR
corr, no BSV(α)
2.66 721.3 0.0608 No improvement
Table 5.44 Parameter estimates for the guinea pig verapamil PR model.
Estimate (SE) BSV % (SE)
PR0 (ms) 61.6 (1.64) 7.42 (1.91)
slopeu (ms µM-1) 161 (69.7) -
ke0 (h-1) 1.07 (0.801) 86.8 (32.7)
Additive residuals (ms) 2.7 (0.171) -
BSV is the coefficient of variation, approximated by CV% = SD*100 for log-normal
distributions.
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Figure 5.42 Left: Individual PK model parameters predicting the exposure in each guinea
pig were used to drive the PD response. Right: PR interval duration data (markers) and
model fits (lines) for guinea pigs treated with three 15 min ascending doses of verapamil
(circles) or with vehicle (black cross). Individual guinea pigs treated with flecainide are
separated by colour.
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Figure 5.43 Population (left) and individual (right) model fits vs. observed PR intervals
with different colour for each guinea pig.
5.9.3 PKPD modelling in dogs
5.9.3.1 PK modelling
One and two compartment models were evaluated following visual inspection of the
log-normalised data and a two compartment model was selected to describe exposure
following oral administration of verapamil. Exposure in one dog following 15 mg kg-1
verapamil was around tenfold lower than expected considering exposure following
the other two doses in this dog and exposure following the 15 mg kg-1 dose in the
other dogs. High similarity between all other data and clear effects in the PD data
for this dose indicate that these data may be erroneous. The PK data for 15 mg
kg-1 in dog 2 were therefore excluded. The PK prediction was used in the PKPD
modelling step as normal. The bioavailability was observed to increase with dose.
This increase was modelled according to Equation 5.7. ED50 could not be identified
from the data as saturation was not reached, and was therefore fixed. 2 different
values above the maximal tested dose were tested, namely 50 and 100 µmol. Both
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resulted in accurate capture of the increased bioavailability and similar goodness of
fits to the data. An ED50 of 100 µmol was selected based on a slightly improved
performance. Furthermore, the absorption phase was not captured in the data. Fast
absorption compared to elimination was assumed, and the first order rate parameter
was estimated according to
kabs =
lnC1 − lnC0
t1 − t0 (5.9)
where t0 is time of dosing and t1 the first measured time point for the highest dose.
Absorption was fixed at this value ( 4 h-1). BSVs for the rate of distribution from
the peripheral to the central compartment and the rate of elimination could not
be fitted and were therefore removed. The fits to data are shown in Figure 5.44.
Estimated parameters for the selected PK model are summarised in Table 5.32 and
goodness of fit plots are shown in Figure 5.45.P
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Figure 5.44 Unbound plasma concentration data (markers) and model fits (lines) for dogs
treated with verapamil.
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Figure 5.45 Observed data vs. individual model fits of verapamil concentration in linear
(left) and log (right) scale with different colour/marker type for each animal. One animal
shows highly variable PK data at low concentrations causing large errors (green squares).
Initial horizontal points in the right plot are below the limit of quantification.
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Table 5.45 Parameter estimates for the dog verapamil PK model.
Parameter Estimate (SE) BSV % (SE)
ka (µmol h-1) 4 (fixed) -
V (L kg-1) 100 (fixed) -
k12 (h-1) 0.283 (0.033) 20.5 (9.8)
k21 (h-1) 0.352 (0.035) -
k (h-1) 0.443 (0.029) -
Additive residuals (µM) 0.00035 (0.00012)
Proportional residuals 0.22 (0.038)
BSV is coefficient of variation, approximated by CV% = SD*100 for log-normal distri-
butions. aZero-order absorption.
5.9.3.2 PK-PR drug effect modelling
The Emax direct effect model (Equation 2.2) well characterised the verapamil-induced
PR prolongations. Summary statistics for a selection of tested models are provided
in Table 5.46. The maximum effect Emax was assumed to be the same for all dogs.
The shape factor n was fixed to 1 as this was required for successful parameter
estimation. Estimated parameters for the selected model are summarised in Table
5.47 and goodness of fit plots are shown in Figure 5.47. The fits to data are shown
in Figure 5.46. Inclusion of the RR correction model (Equation 5.4) but not the
circadian rhythm model (Equation 5.3) improved the goodness of fits to the vehicle
only and the full data sets.
Table 5.46 Summary of a selection of the tested dog verapamil PR models.
Model Residuals AIC
Relative
likelihood
Comment
Proportional, RR corr 7.55 1924 1.04E-15
Emax, RR corr - - -
Parameter estimation
failure
Emax, RR corr, no
BSV(n)
6.55 1862 0.0302 Improvement
Emax, RR corr, no
BSV(n) or BSV(Emax)
6.83 1870 0.000553 Small drop in AIC
Emax, RR corr, effect
comp, no BSV(n)
6.56 1855 1
Small improvement, fast
ke0
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Table 5.47 Parameter estimates for the dog verapamil PR model.
Estimate (SE) BSV % (SE)
PR0 (ms) 111 (6.13) 11 (3.91)
α 0.132 (0.0148) -
Emax (ms) 105 (9.23) -
EC50 (nM) 0.196 (0.0881) 83.6 (30.6)
n 1 (fixed) -
Additive residuals (ms) 6.84 (0.298)
BSV is presented as the coefficient of variation, approximated by CV% = SD*100 for
log-normal distributions.
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Figure 5.46 Top: PR interval duration data (markers) and model fits (lines) for dogs treated
with verapamil. Bottom: Individual PK model parameters predicting the PK in each dog
were used to drive the PD response. Individual dogs are separated by colour and marker
type.
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Figure 5.47 Population (left) and individual (right) model fits vs. observed PR intervals
with different colour/marker type for each animal.
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5.10 Discussion
This investigation presents a quantitative assessment of QRS and PR intervals in
guinea pigs, dogs and humans during baseline conditions and following treatment
with different compounds with CV effects.
5.10.1 Modelling drug effects on QRS interval durations
Drug-induced QRS widenings were successfully described using PKPD models with
linear pharmacological effects for AZD1305, flecainide and quinidine in dogs and
for AZD1305 in humans (Table 5.48). However, QRS widenings in guinea pigs fol-
lowing flecainide treatment were nonlinear, and better explained by a power model
(Equation 2.3). Measured QRS widenings observed in dogs in the present study
were lower than most Emax values estimated in a previous PK-QRS study of five
compounds (9-16 vs. 8-57 %) [57]. Also in guinea pigs and humans, relatively small
QRS widenings were seen (6 and 11 ms at the highest dose, respectively). In dogs,
flecainide was most potent in terms of prolongation of QRS, followed by quinidine
and AZD1305 (Figure 5.48). This is consistent with the results from hNav1.5 in
vitro findings where flecainide, quinidine, verapamil and AZD1305 were active. De-
spite similar in vitro potency, verapamil did not prolong QRS in vivo. This is most
likely explained by the comparatively low free drug concentrations reached in the in
vivo study. In the current study, unbound flecainide induced QRS widening with 10
% µM-1 (Table 5.34). This is consistent with previous PK-QRS modelling in beagle
dogs where the estimated effect was 9.1-15.9 % µM-1 unbound flecainide (above a
threshold of 0.19 µM) at 100-200 bpm [157]. In another study, higher QRS effects of
42 % µM-1 unbound drug were observed after intravenous dosing [21]. Similar differ-
ences between oral and intravenous administration were noted for quinidine. In the
current study, unbound quinidine induced QRS widening by 5.6 % µM-1 while higher
effects of 12-35 % µM-1 were previously observed following intravenous administra-
tion [161, 162, 163]. However, in these studies dogs were anaesthetised or paced,
which may have contributed to the observed differences as flecainide and quinidine
induce rate-dependent Na+-block [164, 165] causing enhanced QRS widening at in-
creased heart-rates in dogs [157, 166] and in humans [167, 168]. In the current
study adequate fits to data were accomplished without the inclusion of heart-rate
dependent effects.
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Table 5.48 Summary of the selected QRS drug effect models.
AZD1305 Flecainide Quinidine
Human Linear - -
Effect comp - -
Dog Linear Linear Linear
Direct Direct Direct
Guinea pig - Power -
- Effect comp -
Models refer to: Linear, Equation 2.4; Power, Equation 2.3; Emax, Equation 2.2;
Direct, no delay; Link, Equation 2.5.
Figure 5.48 Model-predicted median and 95% confidence interval for the percent QRS in-
terval prolongation in a typical beagle dog treated with AZD1305, flecainide or quindine.
5.10.2 Modelling drug effects on PR interval durations
Drug-induced prolongations of the PR intervals were successfully described using
PKPD models with linear pharmacological effects for flecainide in guinea pigs, for
AZD1305 and flecainide in dogs and for AZD1305 in humans (Table 5.49). However,
a power model was required to fit PR prolongations in guinea pigs following vera-
pamil treatment and Emax models could be fitted to PR prolongations induced by
AZD8683, AZD9164 and verapamil in dogs. AZD1305 and flecainide induced pro-
longations of QRS as well as PR intervals in all tested species. AZD8683, AZD9164
and verapamil were the most potent in terms of prolongation of PR intervals in
dogs (Figure 5.49), and also the most active in the hCav1.2 electrophysiology assay.
However, hCav1.2 inhibition by AZD1305 and flecainide was not clearly identified
in the functional assay, despite PR prolongation in vivo. On the contrary, all four
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antiarrhythmic compounds bound to the verapamil and diltiazem binding sites of
rat Cav1.2 in the radioligand binding assay. These results indicate that rat Cav1.2
radioligand assays may be more sensitive to potential PR prolongation in vivo com-
pared to the automated functional hCav1.2 electrophysiology assay. Similarly, radi-
oligand rat Cav1.2 assays have previously shown superior performance compared to
functional hCav1.2 assays to predict drug-induced changes in contractility in canine
myocytes [54]. Published studies of PR effects following flecainide or AZD1305 dos-
ing in dog for comparison with the results from the current study were not identified.
PR prolongations induced by the anti-arrhythmic compounds were proportional at
low exposures and best captured with linear models when average maximal effects
were around 20 %. Emax models better described compounds with average effects
above 30 %. This is consistent with observations from the PKPD modelling of QRS
effects. In a previous study, PR prolongations in mongrel dogs correlated to the
logarithm of plasma verapamil concentrations following intravenous administration
[169].
Table 5.49 Summary of the selected PR drug effect models.
AZD1305 AZD8683 AZD9164 Flecainide Verapamil
Human Linear No effect No effect - -
Effect comp - - -
Dog Linear Emax Emax Linear Emax
Direct Effect comp Effect comp Direct Direct
Guinea pig - - - Linear Power
- - - Effect comp -
Models refer to: Linear, Equation 2.4; Power, Equation 2.3; Emax, Equation 2.2; Direct, no
delay; Effect compartment, Equation 2.5.
The electrophysiological side effects of the two anti-muscarinic compounds
(AZD8683 and AZD9164) on the PR interval were different from the anti-arrhythmic
compounds and best characterised with sigmoid Emax models and marked delays
compared to plasma concentrations. This may reflect mechanistic differences in ion
channel interactions or possibly result from the differences in the pharmacokinet-
ics as AZD8693 and AZD9164 are inhaled drugs. AZD8683 appears to be tenfold
more potent to prolong PR compared to AZD9164, while the estimated Emax values
were similar (61.0 and 52.2 ms, respectively). PR effects above this level were mea-
sured following verapamil treatment suggesting that verapamil can induce larger PR
prolongation than the two anti-muscarinic compounds. Although the Emax model
better characterised verapamil-induced PR prolongations in dogs compared to lin-
ear or power models, the saturation level is not well captured by the data and the
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estimated EC50 and Emax values are therefore correlated.
Figure 5.49 Model-predicted median and 95% confidence interval for the percent QRS
(left) and PR (right) interval prolongation in a typical beagle dog treated with AZD1305,
AZD8683, AZD9154, flecainide, quindine or verapamil.
5.10.3 Modelling variability of QRS and PR baselines
Baseline modelling results from the different species suggest that different baseline
models may be appropriate in guinea pigs, dogs and humans as well as between
QRS and PR intervals (Table 5.50). In guinea pigs, RR correction may sometimes
improve fit to PR, but not to QRS data. These results are however limited by the
small study sizes and few studies investigated. In dogs, analysis of both the full
data sets and vehicle data only suggested that RR correction and to a lower extent
circadian rhythm improved the goodness of fits to PR intervals, while RR correction
marginally improved the goodness of fit to QRS data. The RR correction exponent
(α) of the combined vehicle data was four times smaller for QRS compared to PR
(0.04 vs. 0.16, log-normal BSV, Tables 5.2 and 5.4). Results in humans were similar,
where α was 0.05 for QRS and 0.19 for PR (placebo data set; normal BSV). These
results are consistent with previous results in humans, where PR intervals increase
with RR in most individuals while QRS-RR relationships are close to zero and can
be positive or negative [61]. Normal distribution of α in dogs was tested to allow
positive and negative QRS-RR relationships and resulted in similar goodness of fits
as the log-normal distribution. Linear correlations of PR and QRS intervals to RR
intervals show large variability between humans [61]. This may explain the large
inter-study variability observed for the typical α-values of the PR-RR correction
(0-0.2, Table 5.4). Similarly, the amplitude of the circadian rhythms showed large
inter-study variability, ranging from none to six percent of the point baseline (Table
5.4). Circadian variations were not included in previous PK-QRS/PR models in
dogs [57, 156, 157].
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Table 5.50 Summary of the suggested baseline models to de-
scribe QRS and PR interval data in guinea pigs, dogs and
humans.
QRS PR
Human Combined Combined
Dog Constant or RR
correction
RR correction or
Combined
Guinea pig Constant
Constant or RR
correction
Models refer to: Constant, Equation 5.2; RR correction,
Equation 5.4; Combined, Equation 5.5.
Importantly, the choice of baseline model had an impact on the estimated
parameter values of the drug-induced effects on PR and on the predicted drug ef-
fects. Neglecting to account for correlations with RR intervals led to predictions of
smaller drug effects for four of the five compounds (AZD1305, AZD8683, flecainide
and verapamil, Figure 5.50). Circadian rhythms had less impact on predicted drug
effects on PR intervals. It should however be noted that the differences in predicted
drug effects are within the confidence intervals for the selected models for all com-
pounds. Similarly, inclusion of circadian rhythms was observed to have low impact
on estimated sotalol effect during PK-QTc modelling [18]).
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Figure 5.50 Predicted drug-induced PR prolongations by AZD1305, AZD8683, AZD9164,
flecainide and verapamil assuming different baseline structures (constant, RR correction
and/or circadian rhythm).
5.10.4 Time delays
Time delays were observed mainly during rapidly changing plasma kinetics (e.g.
inhalation or iv infusion). Disequilibrium between plasma and effect site concentra-
tions may therefore cause the observed delay, especially where the half-lives were
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short (<30 min). Effect compartments have been utilised frequently to characterise
time delays in PK-QTc models [1]. Direct PR effects were reported following intra-
venous infusion of verapamil to conscious dogs [169]) while published PK-PR/QRS
models used both direct [57, 157] and effect compartment models [156]. Account-
ing for time delays resulted in considerable improvement in fitting the cardiac side
effects on conduction slowing by the anti-muscarinic compounds (AZD8683 and
AZD9164), with half-lives around 1 h, and QRS and PR effects in guinea pigs fol-
lowing iv infusion of flecainide and verapamil, with half-lives of less than 30 min.
Effect compartment models also slightly improved the goodness of fit to QRS and
PR prolongations in humans induced by AZD1305, although the impacts on the
estimated drug effect parameters were small. Direct-effect models were selected to
describe QRS and PR prolongations of all anti-arrhythmic compounds in dogs, al-
though inclusion of effect compartments improved the goodness of the fits slightly
to QRS, but not to PR prolongation induced by flecainide and AZD1305. Due to
the large variability in the data it was concluded that this potential delay could not
be estimated confidently. Investigating PK and PD data of higher resolution may
improve the ability to distinguish between these two models.
5.10.5 Limitations
In the present study, QRS and PR intervals in six safety pharmacology studies were
investigated where in-house data were available in guinea pigs, dogs and humans.
Three compounds showed drug-induced QRS widenings and five caused PR pro-
longations. Although our current analysis demonstrates that PKPD modelling can
accurately describe drug-induced QRS and PR prolongations in these species, quan-
tifications of more compounds are needed to improve the methodology for assessing
these effects in the nonclinical and clinical settings.
Most nonclinical studies in dogs that were investigated here consisted of only
four animals in a cross-over study. These are typical sizes of safety pharmacology
studies, but the small number of animals may reduce the accuracy of the estimated
parameters. The power of PKPD analyses to detect QTc prolongations has been
investigated using simulated data [18]. With four animals and three doses, QTc
prolongations above 7 ms (2.8 %) were detected with reasonable power. However,
this may differ for QRS and PR intervals as the power to detect drug effects depends
on the variability in the data. Also, the knowledge of safe clinical margins for
conduction slowing is limited, as well as the translation from pre-clinical to clinical
effects. Therefore, it is difficult to assess the potential risks to humans based on the
present results.
In this work we used PQ or PR intervals as recorded in the original report.
However, for compounds that prolong QRS complex duration, the PQ interval may
more accurately reflect atrial conduction as delays in the initial phase of ventricular
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conduction (QR interval in the ECG) will prolong the PR interval. However, the
relatively short prolongations of the QRS intervals (3-9 ms) compared to PR intervals
(21-55 ms) indicate that any such influence on the results obtained in this study
would be small.
Sequential PKPD analysis is commonly applied, as was also the case for
this study. As exposure data are often limited for nonclinical studies, simultaneous
analysis of PK and PD may be beneficial allowing PD data to provide information
on the PK profile. Also, using PK information from separate studies with similar
design can provide additional information on the PK profiles where PK data are
sparse, as was done in this work for modelling AZD9164 exposure in dogs.
5.11 Summary
QRS and PR intervals have been quantified during baseline and drug-induced con-
ditions in anaesthetised guinea pigs, conscious dogs and humans using PKPD mod-
elling. This investigation provides a starting point for modelling QRS and PR in-
tervals in animals and humans. The selected drug effect models will be used in
Chapter 7 to investigate the translation between species, together with models de-
scribing human effects of flecainide, quinidine and verapamil described in Chapter
6.
In addition to the benefit of translational analyses, the models evaluated
in this chapter may be used to improve the possibility to identify and quantify
QRS and PR effects in nonclinical and clinical studies. These results show that
all four anti-arrhythmic compounds display direct QRS and PR effects when orally
administered. QRS and PR effects were typically proportional at low exposures
(up to around 20 % prolongation). On the other hand, side effects on QRS and PR
intervals during rapidly changing plasma concentrations, such as following inhalation
or iv infusion, were typically delayed compared to plasma concentrations, requiring
effect compartment models. Also, in these studies, the QRS and PR effects appeared
to be nonlinear, requiring power or sigmoid Emax models to characterise the drug
effects. Mechanistic explanations for this different behaviour could be of interest for
further studies.
The results of these analyses can also be used to suggest models to be used
to minimise baseline variability of QRS and PR. Correction to simultaneous RR
intervals may improve model performance for predicting PR, but generally not QRS
intervals in guinea pigs and dogs and may also have an impact on the estimated
drug parameters for PR effects. In humans, RR correction improved goodness of fit
to both QRS and PR intervals. Also, PR intervals follow circadian rhythms which
may be captured with a cosine function, although the impacts on estimated drug
effects were negligible in dogs.
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PKPD models of QRS and PR intervals provide quantitative information on
the pharmacological effects and can support compound selection and risk/benefit
assessments through-out drug discovery and development. However, to confidently
translate identified pre-clinical conduction liabilities to clinical risk, studies address-
ing clinical safety margins and translation from nonclinical to clinical effects are
needed.
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Chapter 6
Exposure-effect modelling of
human QRS/PR using
literature data
6.1 Introduction
To investigate the translation from nonclinical to clinical QRS and PR effects of
flecainide, quinidine and verapamil, it was required to quantify the effect of these
compounds in humans. These anti-arrhythmic drugs have been used over decades,
and many studies of clinical effects on monitored ECGs have been published [105,
108, 122, 141]. This was utilised by performing a literature survey to find studies
where both plasma concentrations and QRS/PR effects were provided (as described
in Chapter 4). For the PKPD modelling of in-house data, exposure data as well as
QRS and PR intervals measured over time were available from each animal/subject
in the study. Such detailed data were not available for the published studies. Many
published studies only provide single observations such as maximum exposure and
QRS/PR effects. Therefore, it was decided to take a different approach when mod-
elling the literature data. Pairs of exposure/effect data were collected and merged
into one data set per compound and investigated interval. The QRS/PR effects of
the drugs were then quantified using simple exposure-effect models. This allowed the
merging of data from many studies. Thus, factors such as correction to RR intervals
or circadian rhythms were not taken into account in this regression analysis. Also,
individual data were not available, and the regression models were developed using
average study data. The results of the modelling analyses performed in this chapter
are used to investigate the in vivo to clinical translations of QRS and PR effects in
Chapter 7. The literature study and exposure-effect modelling analyses have been
published in Bergenholm et al. [? ].
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6.2 Summary of the available data
Effects of flecainide, quinidine and verapamil had been collected in a literature sur-
vey, and are summarised in Table 6.1. Detailed information of the publications are
described in Chapter 4. Not all studies provided the baseline QRS or PR values.
Modelling of absolute values (e.g. pre-dose and post-dose QRS and PR) would have
required reductions in the data due to the missing baseline information. Instead, the
change from baseline was investigated and modelled in this work. Average QRS and
PR baselines were calculated using the baseline data of all healthy volunteers. These
calculated baselines (92.5 ms for QRS and 160 ms for PR) were used to convert any
percentage data where baseline information were missing to absolute change in ms.
Table 6.1 Summary of the acquired literature data. For details and references see Tables
4.5-4.7.
Compound Flecainide Quinidine Verapamil
No. studies 16 15 16
Dose
iv: 1.5-2 mg kg-1,
150 mg. oral:
100-600 mg
iv: 3.7-10 mg kg-1.
oral: 3 mg kg-1,
100-2250 mg
oral: 80-480 mg
Cmax (µM) 2.6 12.3 1.7
QRS0 (ms) 92.5 92.5 -
∆QRSmax (ms) 31 18 -
PR0 (ms) 160 - 160
∆PRmax (ms) 56 - 53
Free drug (%) 62.1 12.2 20.7
Data presented as mean±SD. iv, intravenous; QRS0, QRS at baseline; PR0, PR at
baseline; ∆QRS, QRS change from baseline; ∆PR, PR change from baseline.
6.3 Exposure-effect modelling methods
The concentration-effect pairs collected in the literature studies were visually strati-
fied in groups following the health status of the subjects (healthy volunteers/patients),
administration route (oral/iv) and the dosing history (acute; single or first dose,
chronic; following repeated dosing) to detect differences in potency between the
groups.
Absolute changes in the ECG intervals were regressed over measured free
concentrations in MATLAB R2013b using the built-in nonlinear model fit function
fitnlm.m. Two drug effect models were tested, namely the proportional and the Emax
drug effect models (Equations 2.2 and 2.4). As the ECG data were normalised to
change from pre-dose value, no intercepts were included in the regression analysis.
Including intercepts would have required reductions of the data sets, as data were
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sometimes provided only as a change from the pre-dose value. A combined additive
and proportional error model was applied (Equation 2.14). Model selection was
performed considering the goodness of fit value (-2LL), visual fit to the data, residual
plots, adjusted R-sqared (R2) values and precision of and correlation between the
parameter estimates.
6.4 QRS and PR effects of flecainide in humans
6.4.1 Visual inspection of the identified QRS data
QRS prolongations following flecainide treatment appear approximately propor-
tional at lower concentrations and may saturate around 1.5 µM free flecainide (Fig-
ure 6.1). Higher and/or more frequent doses of flecainide were administered in the
patient studies compared to the studies with healthy volunteers, and plasma concen-
trations were also higher in patients. Despite clear differences in the concentration-
effect relationship between studies, no clear reason for the varying drug effects was
identified.
The influence of the data point at 12 ms/1.5µM unbound flecainide [120]
was investigated further during the modelling step as both QRS and PR interval
prolongations were small compared to the remaining studies. No explanation for
the comparatively small prolongations could be identified. In addition, QRS effects
by flecainide in patients with Brugada syndrome were excluded based on increased
QRS prolongation in this group compared to controls [107], as indicated in Figure
6.1.
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Figure 6.1 QRS widening in healthy volunteers (HV, circles) and patients (squares) induced
by flecainide. Data points represent associated plasma concentration-δQRS pairs (1-8 per
published study) with standard errors where available. The data point marked by a black
cross was excluded prior to modelling as these Brugada syndrome patients were shown to
have increased QRS prolongation compared to healthy patients [107].
Only one study was conducted at acute oral dosing in healthy volunteers sim-
ilar to the dog telemetry studies [105]. No evidence was found of general differences
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between healthy volunteers and patients. Visual stratification of single/repeated
dosing data (acute/chronic) and iv infusion/oral administration data indicated a
potentially lowered effect following chronic administration compared to acute dos-
ing (Figure 6.2). Such lowered effects from chronic dosing may arise from tolerance
development. Although no clear evidence of altered exposure-effect relationships
following repeated dosing were found in the literature, the possibility of such effects
was investigated in the regression analysis.
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Figure 6.2 QRS widening by flecainide stratified by dosing history (left) and route of ad-
ministration (right).
6.4.2 Quantification of QRS effects by flecainide in humans
Summary statistics for a selection of tested models are provided in Table 6.2. The
sigmoid Emax model (Equation 2.2) was selected to describe QRS widenings by fle-
cainide (Figure 6.3). The proportional model (Equation 2.4) over-predicted prolon-
gations at higher concentrations. Also, R2, goodness of fit value (-2LL) and residual
plots were improved when applying the Emax models, and residual plots were further
improved for the sigmoid Emax model. The outlier at 12 ms QRS widening/1.5 µM
free flecainide was excluded from the QRS data set as this improved residual plots
and visual fit to the remaining data. Exclusion of the outlier resulted in approxi-
mately 20% increase in the estimated Emax and EC50 values, while the ratio was
unchanged. Including a covariate for history of dosing on the EC50 did not improve
R2 or the goodness of fit value and led to high uncertainty in all parameters. Esti-
mated parameters for the selected model are summarised in Table 6.3 and residual
plots are shown in Figure 6.4. High correlations were found between the estimated
Emax and EC50.
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Table 6.2 Summary of a selection of the tested human flecainide QRS models.
Model R2 -2LL Comment
Proportional 0.439 150
Over-predicting at high
concentrations
Emax 0.545 144
Improved visual fit to
data and residual plots
Emax, exclude outlier 0.656 133
Improved visual fit to
data and residual plots,
selected model
Emax, covariate on dosing
history
0.547 143 No improvement
RMSE, root mean squared error; -2LL, -2 loglikelihood.
Table 6.3 Estimated parameter values for QRS
widenings by flecainide.
Parameter Value (SE)
Emax (ms) 33.7a (10.8)
EC50 (µM) 0.573a (0.256)
n 1.65 (0.61)
aCorrelation Emax:EC50 = 0.977.
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Figure 6.3 Model predictions (solid line) and observed QRS widenings in healthy volunteers
(HV, circles) and patients (squares) induced by flecainide. Data points represent associated
plasma concentration-δQRS pairs (1-8 per published study) with standard errors where
available. Shaded areas represent the 95% confidence intervals (CI) and prediction intervals
(PI). Excluded outlier is marked by a black cross.
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Figure 6.4 Residual plots for the selected model for QRS widenings induced by unbound
flecainide.
6.4.3 Visual inspection of the identified PR data
PR prolongations show a clear concentration-dependent increase with possible satu-
ration at higher flecainide concentrations (Figure 6.5). Higher flecainide concentra-
tions were reached in the patient studies where higher and/or more frequent doses
were generally used. The data point at 10 ms/1.5µM free flecainide [120] originates
from the same study as the excluded QRS data point. This outlier was investigated
further during the regression analysis as it appeared to be an outlier, potentially
reducing the goodness of fit to the remaining data. Also, as this is the only obser-
vation of PQ effect rather than PR interval changes, which may contribute to the
smaller effect as this excludes any potential prolongation of the QR part of the PR
interval.
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Figure 6.5 PR prolongations in healthy volunteers (circles) and patients (squares) induced
by flecainide. Data points represent associated plasma concentration-δPR pairs (1-2 per
published study) with standard errors where available.
Only one study was conducted at acute oral dosing in healthy volunteers sim-
ilar to the dog telemetry studies [106]. No evidence was found of general differences
between healthy volunteers and patients. Visual stratification of single/repeated
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dosing data (acute/chronic) and iv infusion/oral administration data did not indi-
cate any differences in the concentration-effect relationships (Figure 6.6).
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Figure 6.6 PR prolongations by flecainide stratified by dosing history (left) and route of
administration (right).
6.4.4 Quantification of PR effects by flecainide in humans
Summary statistics for a selection of tested models are provided in Table 6.4. The
sigmoid Emax model (Equation 2.2) was selected to describe PR widenings by fle-
cainide (Figure 6.7). This model could capture the small saturation seen in the
data, and the sigmoid model showed improved parameter precision. The outlier at
10 ms/1.5µM free flecainide [120] was excluded as this improved the residual plots
and R2, while the ratio of Emax : EC50 remained unchanged. Estimated parameters
for the selected model are summarised in Table 6.5 and residual plots are shown in
Figure 6.8. High correlations were found between the estimated Emax and EC50. A
slight deviation of the normal probability plot for the residuals was observed (Fig-
ure 6.8) and deemed acceptable as this plot was improved compared to the rejected
models, and the devation may be a result of the low number of data points.
Table 6.4 Summary of a selection of the tested human flecainide PR models.
Model R2 -2LL Comment
Proportional 0.439 150
Over-predicting at high
concentrations
Emax 0.545 144
Improved visual fit to
data and residual plots
Emax, exclude outlier 0.656 133
Improved visual fit to
data and residual plots,
selected model
Emax, covariate on dosing
history
0.547 143 No improvement
RMSE, root mean squared error; -2LL, -2 loglikelihood.
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Table 6.5 Estimated parameter values for PR
widenings by unbound flecainide.
Parameter Value (SE)
Emax (ms) 68.9a (27.2)
EC50 (µM) 0.77a (0.43)
n 1.57 (0.51)
aCorrelation Emax:EC50 = 0.979.
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Figure 6.7 Model predictions (solid line) and observed PR prolongations in healthy volun-
teers (HV, circles) and patients (squares) and induced by flecainide. Data points represent
associated plasma concentration-δPR pairs (1-2 per published study) with standard errors
where available. Shaded areas represent the 95% confidence intervals (CI) and prediction
intervals (PI). Excluded outlier is marked by a black cross.
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Figure 6.8 Residual plots for the selected model for PR widenings induced by flecainide.
6.5 QRS effects of quinidine in humans
6.5.1 Visual inspection of the identified QRS data
QRS widenings show a clear concentration-dependent increase with large variability
at higher concentrations (Figure 6.9). The high number of studies with concentra-
tions around 1.3-1.5 µM unbound quinidine appear to be a result of variable dosing
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to reach clinically relevant concentrations in patient studies. Higher doses of quini-
dine were in general administered in the patient studies compared to the studies
with healthy volunteers, and plasma concentrations were also higher in patients.
Despite clear differences in the concentration-effect relationship between studies, no
clear reason for the varying drug effects was identified. One data point of QRS
shortening by quinidine was excluded (indicated in Figure 6.9) as the average QRS
did not return to baseline despite concentrations below 0.1 µM [121].
Visual stratification of QRS prolongations following acute and chronic dos-
ing and administration through the oral and iv route did not indicate any clear
differences (not shown).
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Figure 6.9 QRS widening in healthy volunteers (circles) and patients (squares) induced
by quinidine. Data points represent associated plasma concentration-δQRS pairs (1-2 per
published study) with standard errors where available. The data point marked by a black
cross was excluded prior to modelling as the average QRS did not return to baseline despite
concentrations below 0.1 µM [121].
Only three studies were conducted at acute oral dosing in healthy volunteers
similar to the dog telemetry studies. No evidence was found of general differences
between healthy volunteers and patients.Visual stratification of single/repeated dos-
ing data (acute/chronic) and iv infusion/oral administration data did not indicate
any differences in the concentration-effect relationships (Figure 6.10).
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Figure 6.10 QRS widening by quinidine stratified by dosing history (left) and route of ad-
ministration (right).
6.5.2 Quantification of QRS effects by quinidine in humans
Summary statistics for a selection of tested models are provided in Table 6.6. The
proportional model (Equation 2.4) was selected to describe QRS widenings by quini-
dine (Figure 6.11) even though the Emax model (Equation 2.2) resulted in improved
goodness of fit and R2 value. The proportional model was selected as the sigmoid
model resulted in unrealistic parameter values (Emax=11 ms and n =4.4) and fix-
ing n to 1 resulted in the EC50 being practically unidentifiable (SE>100%). Also,
although patient data are highly variable, the slope of the concentration-effect rela-
tionship was unchanged when a proportional model was fitted only to healthy vol-
unteer data. Estimated slope of the concentration-effect relationship was 9.57±1.14
ms µM-1 free quinidine. Residual plots are shown in Figure 6.12.
Table 6.6 Summary of a selection of the tested human quinidine QRS models.
Model R2 -2LL Comment
Proportional 0.614 92.1 Selected model
Emax 0.651 88.6
Unrealistic estimate of
Emax
Emax, n fixed to 1 0.633 90.5
High uncertainty Emax
and EC50
RMSE, root mean squared error; -2LL, -2 loglikelihood.
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Figure 6.11 Model predictions (solid line) and observed QRS prolongations in healthy volun-
teers (HV, circles) and patients (squares) and induced by quinisine. Data points represent
associated plasma concentration-δQRS pairs (1-2 per published study) with standard errors
where available. Shaded areas represent the 95% confidence intervals (CI) and prediction
intervals (PI).
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Figure 6.12 Residual plots for the selected model for QRS widenings induced by quinidine.
6.6 PR effects of verapamil in humans
6.6.1 Visual inspection of the identified PR data
PR prolongations show a clear concentration-dependent increase and saturation at
higher verapamil concentrations (Figure 6.13). Higher verapamil concentrations
were typically reached in the patient studies compared to the healthy voluteers. The
eight patient data points clustered around 50 ms PR prolongation are from the same
study, where two patient groups were treated with immediate and sustained release
verapamil in two doses (240/480 mg/day) under fed and fasted conditions. The
change from baseline in ms showed no dose-dependency (all between 45 and 53 ms).
This suggests saturated PR prolongation at these concentrations. Two observations
of PR effects conducted in patients with Crohn’s syndrome were excluded as this
group was found to have a reduced effect on PR compared to controls in the original
study [148]. These data are indicated in Figure 6.13.
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Figure 6.13 PR prolongations in healthy volunteers (circles) and patients (squares) induced
by verapamil. Data points represent associated plasma concentration-δPR pairs (1-8 per
published study) with standard errors where available. The data points marked by black
crosses were excluded prior to modelling as verapamil induce less PR prolongation in patients
with Crohn’s syndrome compared to controls [148].
Of the identified studies, 11 were conducted at acute oral dosing in healthy
volunteers (summarised in Table 4.7) similar to the dog telemetry studies. No ev-
idence was found of general differences between healthy volunteers and patients.
Visual stratification of the data suggests possible lower effects following chronic dos-
ing compared to acute dosing, sustained and immediate release tablets appear to
result in similar concentration-effect relationships (Figure 6.14).
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Figure 6.14 PR prolongations by verapamil stratified by dosing history (left) and route of
administration (right).
6.6.2 Quantification of PR effects by verapamil in humans
Summary statistics for a selection of tested models are provided in Table 6.7. The
Emax model (Equation 2.2) with a covariate effect of chronic dosing on EC50 was
selected to describe PR widenings by verapamil (Figure 6.15. This covariate effect
on EC50 was implemented according to
EC50 = EC50,acute + βEC50,chronic (6.1)
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where βEC50,chronic allows different EC50s during acute and chronic dosing. This
covariate model was selected as visual stratification of the data indicates possible
differences between acute and chronic dosing in the effects at lower concentrations,
with no evidence of differences in Emax. Inclusion of the covariate improved the
residual plots, goodness of fit values and R2 and reduced the correlations. R2 and
goodness of fit value were clearly improved when applying the Emax model compared
to the proportional model (Equation 2.4) as effects at high concentrations were
overpredicted by the proportional model. Fixing n to 1 resulted in improved model
performance, indicated by smaller correlations between the parameters and similar
likelihood. Estimated parameters for the selected model are summarised in Table 6.8
and residual plots are shown in Figure 6.16. Fitting only the healthy volunteer data
to the Emax model resulted in approximately 10 % smaller Emax and 15 % smaller
EC50. As the highest concentrations reached in the healthy volunteer data set were
smaller, this may be a result of missing data at fully saturated concentration levels.
Table 6.7 Summary of a selection of the tested human verapamil PR models.
Model R2 -2LL Comment
Proportional -0.831 286 Bad fit to data.
Emax 0.379 246
Improved fit, high
uncertainty EC50 and
correlations
Emax, n fixed to 1 0.394 246
Reduced uncertainty and
correlations
Emax, covariate on dosing
history
0.425 243
Similar Emax and EC50.
Selected model
RMSE, root mean squared error; -2LL, -2 loglikelihood.
Table 6.8 Estimated parameter values for PR widen-
ings by unbound verapamil.
Parameter Value (SE)
Emax (ms) 53.7a (7.2)
EC50,acute (µM) 0.0371a (0.0144)
βEC50,chronic (µM) 0.0243 (0.0187)
aCorrelation Emax:EC50 = 0.878.
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Figure 6.15 Model predictions (solid line) and observed PR prolongations in healthy volun-
teers (HV, circles) and patients (squares) and induced by verapamil. Data points represent
associated plasma concentration-δPR pairs (1-8 per published study) with standard errors
where available. Shaded areas represent the 95% confidence intervals (CI) and prediction
intervals (PI).
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Figure 6.16 Residual plots for the selected model for PR widenings induced by verapamil.
6.7 Discussion
In this chapter, regression models were developed to describe drug-induced prolon-
gations of QRS and PR intervals by flecainide, quinidine and verapamil in humans.
Proportional and Emax models (Equations 2.4 and 2.2) were evaluated to describe
absolute (ms) changes in QRS and PR durations using data collected in literature
searches performed in Pubmed.
6.7.1 Modelling drug effects on QRS interval durations
Flecainide and quinidine induced QRS widenings in humans, with maximum widen-
ings of 31 ms by flecainide and 18 ms by quinidine (Table 6.1). The Emax model
(Equation 2.2) was selected to describe the flecainide data, albeit with a high corre-
lation between Emax and EC50. The estimated maximum effect was 34±11 ms. On
the other hand, the smaller effects induced by quinidine did not allow estimation of
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the Emax model, and the proportional model (Equation 2.4) equally well described
the data.
QRS widenings induced by flecainide in patients with atrial fibrillations were
previously found to be 44.3 ± 18.5 ms L mg -1 total flecainide [111], which equals
30.6 ms µM-1 free flecainide. Visual inspection of the final QRS model suggests
that this is roughly in agreement with the predicted relationship. A smaller effect
of flecainide on QRS durations was found when regressing average individual con-
centrations and QRS effects over 24 h in healthy volunteers [105]. In this study,
average prolongations of 26-32 ms L mg -1were estimated at steady-state dosing of
100 and 200 mg flecainide, which corresponds to approximately 18-22 ms µM-1 free
flecainide.
QRS widenings induced by quinidine were previously analysed in a PKPD
analysis, where quinidine was found to induce QRS widenings by 3.6 ms L mg-1 total
quinidine following iv administration and 3.8 ms L mg-1 total quinidine following
oral administration [122]. This equals approximately 1.2 ms µM-1 (or 10 ms µM-1
unbound quinidine) and is in clear agreement with the results of the current work,
where the slope was 9.6 ms µM-1 unbound quinidine. Also, a delay was identified
between plasma concentrations and QRS widening [122]. The delay was found to be
short, with a half-life of around 5 min. This short half-life supports the assumption
of negligible delays for the purpose of this modelling work.
6.7.2 Modelling drug effects on PR interval durations
Flecainide and verapamil induced PR prolongations in humans, with maximum pro-
longations of 56 ms by flecainide and 53 ms by verapamil (Table 6.1). Emax models
could be estimated to both data sets, albeit with high correlation between Emax and
EC50 for flecainide, and the maximum effects were estimated to be 69 ± 27 ms for
the flecainide model and 56± 7 for the verapamil model (Tables 6.5 and 6.8).
Previously published models for flecainide-induced PR prolongations were
not identified.
PR prolongations by orally administered verapamil were previously found to
have a maximal effect of 38±13.4% (61 ms assuming a baseline of 160 ms) in healthy
volunteers [137], which is in agreement with the results of the current analysis. Also,
the estimated EC50 was found to be 123 µg L-1 total verapamil, which corresponds
to 0.055 µM free verapamil. This is comparable to the estimated EC50 of the current
study, which was 0.041 µM free verapamil (Table 6.8).
6.7.3 Limitations
These models were developed using limited data from a large number of studies
rather than detailed exposure and QRS/PR data over time from a single study. Us-
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ing data from different studies conducted over decades increases variability in the
data due to the development of new and improved methods for data collection during
this time. Variability and uncertainty in the data would occur from differences in, for
example, frequency of sampling, number of subjects and data handling. Also, several
different data types were allowed, such as pairs of maximum concentrations/effects
in a study or concentrations and effects measured at the same time points, which
assumes that the impact of potential delays is negligible. The developed QRS and
PR models would potentially have had less limitations by published high quality
data of observed PK and QRS/PR measured simultaneously. Sharing of detailed
data between pharmaceutical companies can thus be valuable for many different fu-
ture analyses, providing new insights potentially improving drug development across
companies.
6.8 Summary
QRS widenings induced by flecainide and quinidine and PR prolongations induced
by flecainide and verapamil have been quantified in humans using exposure-effect
modelling. This investigation was primarily conducted to quantify the drug effects
in humans in order to evaluate the translation between nonclinical effects quantified
in Chapter 5 and clinical effects. The translational analyses are described in Chapter
7.
Literature data from 15-16 publications for each drug were identified in an
extensive survey and extracted for analysis. Detailed PKPD data were typically
not available in the published material, and data sets were therefore constructed
by merging pairs of concentration-effect data into one data set for each drug and
endpoint. QRS widenings were best described by an Emax model for flecainide
and a proportional model for quinidine, for which the widenings were smaller, and
both models were in good agreement with previous publications. PR prolongations
by flecainide and verapamil were both best described by Emax models, and while
no published model for flecainide was identified, the verapamil model was in good
agreement with previous publications.
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Chapter 7
Translation from nonclinical
effects to QRS/PR effects in
humans
7.1 Introduction
Identifying effects on cardiac conduction slowing in nonclinical studies is vital for
the progression of safe compounds into first clinical trials. Numerous investigations
provide insights into the prediction of risk of prolongation of the heart-rate corrected
QT (QTc) interval [9, 11, 12, 13]. However, much less is known of the nonclinical
to clinical translation of conduction liabilities manifested as QRS and PR prolonga-
tions. In previous chapters, QRS and PR effects of a number of compounds were
quantified in guinea pigs, dogs and humans. In this chapter, the developed QRS and
PR drug effect models were used to investigate the nonclinical to clinical translation
of QRS and PR effects for the anti-arrhythmic compounds AZD1305, flecainide,
quinidine and verapamil.
Translations were investigated applying an empirical (top-down) transla-
tional approach, as has been successfully done for QTc [12] and used to identify
nonclinical effects corresponding to 10% (appr. 10 ms) QRS widening or 10% (appr.
16 ms) PR prolongation in humans. Thresholds of 10% effect in humans were se-
lected as such effects were deemed clinically relevant and quantifiable in clinical
studies, in the absence of generally accepted thresholds for concern [15].
Furthermore, the in vitro to clinical translation between ion channel activity
and QRS and PR interval prolongations in humans were investigated applying two
different approaches. Firstly, an empirical approach was applied similar to that for
the in vivo to clinical translation. Secondly, mechanism-based translation using an
operational model [35] was investigated to identify the system parameters linking
ion channel effects to clinical QRS and PR prolongations induced by AZD1305.
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7.2 Methods
7.2.1 Empirical in vitro/in vivo to clinical translation
Empirical translational relationships between nonclinical and clinical effects were
investigated for the anti-arrhythmic compounds AZD1305, flecainide, quinidine and
verapamil, following the approach visualised in Figure 7.1.
Top-down translation to compare effects at matched drug concentrations
or or
VS
or
or
𝑐 𝑐
PD PD Plot translation
Figure 7.1 Top-down translation to empirically assess effects at matched drug concentrations
were performed for AZD1305, flecainide, quinidine and verapamil. Resulting translational
relationships may be used to identify approximate estimates of nonclinical effects that cor-
respond to a clinical safety margin.
Firstly, drug effects were simulated in each species using the drug effect pa-
rameters estimated in the PKPD and exposure-effect modelling and ion channel
effects were simulated using the collected in vitro parameters. The drug effects were
simulated using the estimated models of the effect of drug in the plasma compart-
ment (direct effect models) or the effect compartment (distributional delay models).
Also, drug effects were simulated as the predicted change from baseline, thus ignor-
ing all baseline variability or uncertainty. Change from baseline was simulated as
this was the nature of the literature models for the effects of flecainide, quinidine and
verapamil in humans. Three different drug effect models had been tested, including
the proportional, power and Emax drug effect models (Equations 2.2-2.4). The final
drug effect model for each drug and species was used to simulate the effects at 100
evenly spaced, matched concentrations within the supported concentration ranges.
Translations were investigated at matching total and unbound concentrations, where
the unbound concentration relates to the total concentration according to
Cu = fu · Ct (7.1)
where Cu is the unbound (free) concentration in plasma, fu the free fraction (1-
PPB) and Ct the total concentration in plasma. This relationship was used to
convert the estimated drug effect parameters of the proportional, power and Emax
models between unbound and total effects according to
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slopeu · Cu = slopeu · fu · Ct = slopet · Ct ⇒ slopet = slopeu · fu (7.2)
au · Cbuu = au · (fuCt)bu = au · Cbut f buu = at · Cbtt ⇒
at = au · f bu
bt = bu
(7.3)
Emax,uC
nu
u
ECnu50,u + Cnuu
= Emax,u(fuCt)
nu
ECnu50,u + (fuCt)nu
=
Emax,uC
nu
t(
EC50,u
fu
)nu + Cnut =
Emax,tC
nt
t
ECnt50,t + Cntt
⇒
Emax,t = Emax,u
EC50,t =
EC50,u
fu
nt = nu
(7.4)
where slope, a and b and Emax, EC50 and n are parameters of the proportional,
power and Emax models respectively, and the subscripts u and t represent parame-
ters related to unbound and total plasma concentrations respectively. In addition,
translations were investigated both in terms of millisecond and percentage change
from baseline by scaling the simulated response. Uncertainty and variability in the
estimated drug effects were estimated and visualised by 95% confidence and predic-
tion intervals.
For the population PKPD models, confidence and prediction intervals for
the drug effects were generated using Monte Carlo methods. Confidence intervals
were constructed from the covariance matrices of the typical parameters for the PD
drug effects and prediction intervals from the estimated typical parameters, between-
subject variabilities and residual variabilities. 10000 randomly sampled parameter
sets were simulated and sorted at each concentration, and the 2.5th and 97.5th
percentiles were extracted. Non-physiological parameter values (e.g., EC50 below 0)
were excluded. Confidence and prediction intervals for the regression models based
on literature data were produced using the built-in Matlab function predict.
Lastly, the predicted in vitro, guinea pig and dog effects were plotted against
the predicted human effect at matched concentrations to visualise the translations
for each compound, as shown in Figure 7.1. Nonclinical effects corresponding to a
10% change in humans were extracted.
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7.2.2 Semi-mechanistic in vitro to clinical translation
7.2.2.1 Development of an operational model to link in vitro and clinical
AZD1305 data
In vitro and clinical AZD1305 data were combined to estimate the signal transduc-
tions from effects at the ion channel level to clinical QRS or PR prolongations using
the operational model of agonism (Equation 2.10) [35] as visualised in Figure 7.2.
Middle-out translation to separate compound- and system-related effects
𝑐 𝑐
System 
parameters
Estimate translation
Figure 7.2 Middle-out approach combining compound potency in vitro with clinical data
to estimate the signal transduction was performed for AZD1305. The estimated signal
transduction parameters define the system and may potentially be used to predict the effects
of different compounds with similar mechanisms of action.
The operational model is built by combining two functions, one linking the
percentage bound/inhibited ion channel to the QRS/PR effect according to
∆ECG = Em[RC]
n
ECn50 + [RC]n
(7.5)
where EC50 the QRS/PR prolongation at 50% bound/inhibited ion channel, Em
the maximal QRS or PR prolongations possible in the system and RC the percent
bound ion channel. RC is then substituted by the second function, which links the
concentration of drug to the percentage bound/inhibited ion channel according to
RC = RtotCu
Kd + Cu
(7.6)
where Cu is the predicted unbound drug concentration, Kd the concentration at
50% bound or inhibited receptor and Rtot the total amount of ion channels, e.g.
100%. Combining these two equations yields the operational model (Equation 2.10).
However, for the hNav1.5 data, a sigmoid model better fitted the data. This model
is given by
RC = RtotC
γ
u
Kγd + C
γ
u
(7.7)
where γ the Hill factor of the drug-ion channel interaction. Substituting this equa-
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tion in the operational model gives
∆ECG = EmRC
n
ECn50 +RCn
=
Em
(
RtotC
γ
u
Kγ
d
+Cγu
)n
ECn50 +
(
RtotC
γ
u
Kγ
d
+Cγu
)n = Em(RtotCγu)n(Kγd + Cγu)nECn50 + (RtotCγu)n ,
(7.8)
so, if τ = Rtot/EC50, then
∆ECG = Em(τC
γ
u)n
(Kγd + C
γ
u)n + (τCγu)n
(7.9)
where τ is the transducer ratio, which is the ratio of the maximum inhibited/bound
ion channels to the inhibited/bound ion channels corresponding to the half-maximum
response. Importantly, the reparameterisation of τ = Rtot/EC50 is required for this
model to be structurally identifiable (Table 3.2). BSVs were assumed to be normally
distributed for Em to allow positive and negative effects and lognormally distributed
for τ and n. As the goal was to quantify the relationship between observed in vitro
and clinical effects, Kd and γ were fixed to the in vitro estimates describing hNav1.5
inhibition (QRS widening operational model) or rCav1.2 binding at the diltiazem
site (PR prolongation operational model).
To estimate the parameters of the operational model using AZD1305 data,
the human PK model that was developed in Chapter 5 was used to simulate indi-
vidual AZD1305 exposures. In addition, the operational model was combined with
the combined RR correction and circadian rhythm model (Equation 5.5 which was
used to describe QRS and PR variability in humans at baseline in Chapter 5. In
addition, an effect compartment model (Equation 2.5 was applied to account for the
short delay between exposure and QRS and PR effect, where the distribution rate
ke0 was assumed to be log-normally distributed.
7.2.2.2 Predicting effects of flecainide, quinidine and verapamil using
the system models
The operational models estimated with AZD1305 data may be used to predict the
effects of other compounds acting by the same mechanism, as the model separates
compound-specific parameters (Kd and γ) from system-specific parameters (Em, τ
and n). To predict the effects of new compounds, the system-specific parameters
were fixed to the estimates from the AZD1305 modelling, while the compound-
specific parameters were changed to their respective in vitro-estimated values. By
simulating these models, the effects of flecainide, quinidine and verapamil in humans
were simulated and the predictions compared to the collected data from the literature
study in Chapter 6. This can be viewed as a form of validation of the system-specific
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parameters, as this evaluates the performance of the system model to predict new
data on which it was not trained.
95% confidence intervals for the typical effects were constructed from the
covariance matrices of the typical parameters for the PD drug effects, and 95% pre-
diction intervals from the estimated typical parameters, between-subject variabilities
and residual variabilities. 10000 randomly sampled parameter sets were simulated
and sorted at 100 concentrations between 0 and the observed Cmax, and the 2.5th
and 97.5th percentiles were extracted.
7.2.2.3 Quantifying the translational relationship using the system mod-
els
The system parameters were used to predict QRS and PR prolongations at 0-
100% inhibition/binding by simulating only the link between ion channel effect and
QRS/PR effect according to
∆ECG = EmRC
n
(100/τ)n +RCn (7.10)
at evenly distributed inhibition levels up to 100%. 95% confidence intervals for the
typical effects were constructed from the covariance matrices of the typical parame-
ters for the PD drug effects, and 95% prediction intervals from the estimated typical
parameters, between-subject variabilities and residual variabilities. 10000 randomly
sampled parameter sets were simulated and sorted at 100 concentrations between 0
and the observed Cmax, and the 2.5th and 97.5th percentiles were extracted. The
translational relationships were used to identify nonclinical effects corresponding to
10% QRS/PR prolonations in humans.
7.3 Translation to QRS widenings in humans
7.3.1 Comparison of baseline parameters between species
Models to minimise baseline variability are investigated in guinea pigs, dogs and
humans in Chapter 5. In these investigations, data were pooled for each species
separately, using vehicle data from two guinea pig studies and five dog studies and
placebo data from one human study. A selection of baseline models were fitted to
these data, namely the constant baseline model, a model incorporating correction to
simulaneous RR intervals, a circadian rhythm model comprising of a single cosine
function, and a combination of the two later models (Equations 5.2-5.5). Estimates
for the parameters of the selected final baseline models are summarised in Table
7.1. For each species, an optimal baseline model was selected based on its relative
likelihood and its complexity, where the most simple model with at least 5% relative
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likelihood compared to the model with the lowest AIC value was selected (Equation
5.1).
Table 7.1 Comparison of the extracted baseline parameters of QRS intervals in guinea pigs,
dogs and humans.
Human Dog Guinea pig
Estimate Estimate % of
human
Estimate % of
dog/human
QRS0 (ms) 94 47 50 22 47/23
A (ms) 4.8 - - NA
α 0.046 0.038 83 - -
Residual error (ms) 1.4 2 143 0.32 23/16
Parameter estimates from the “best” models when evaluating pooled data from two vehicle
guinea pig studies, pooled data from five vehicle dog studies and placebo human data from
one phase I study. The BSV of α was assumed to be lognormal in dogs and normal in humans
as some humans had negative QRS-RR correlations. Assuming normally distributed α in
dogs led to a similar estimate of 0.44.
Typical QRS interval point baselines were 94 ms in humans, 47 ms in dogs
(50 % of human duration) and 22 ms in guinea pigs (23% of human duration).
Correction to RR intervals improved goodness of fit slightly to QRS intervals in
humans and dogs with estimated correction coefficient (α) values around 0.04-0.05,
but were negligible when describing QRS intervals in guinea pigs. Including circadian
rhythms improved the goodness of fit to human data only, with an amplitude of 1.4
ms, but did not improve the goodness of fit to QRS intervals in dogs and were not
evaluated in guinea pigs as the experimental time was short compared to the period
of the investigated circadian rhythm function (2 vs. 24 hours). These results suggest
that simpler models are sufficient when fitting animal data compared to human data.
This may be a result of different physiologies, i.e. that the circadian rhythms and
correlations to RR are larger in humans, but may also be a result of less noise in the
human data, allowing more detail when estimating the baselines. In fact, residual
variability was larger in dogs (≈4%) compared to guinea pigs and humans (≈1.5%),
most likely because dogs were allowed to move freely during the experiment, while
humans were resting and the guinea pigs were anaesthetised.
7.3.2 Empirical translation of in vivo effects
Drug effect parameters were extracted from the final PKPD models in guinea pigs,
dogs and humans (Chapter 5) and directly applied from the human exposure-effect
models (Chapter 6), are summarised in Table 7.2. QRS effects of AZD1305 and
quinidine were well described by proportional models in dogs and humans, as were
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QRS effects by flecainide in dogs, while the effects in guinea pigs were better de-
scribed by a power model and in humans by an Emax model (Equations in Table
7.2). Also, in humans, a short delay was identified between AZD1305 plasma con-
centrations and QRS widening. The collected drug effect parameters summarised
in Table 7.2 were used to simulate the model-predicted drug effects in each species
(Figure 7.3).
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Figure 7.3 QRS prolongations in guinea pigs (top row), dogs (middle row) and humans
(bottom row) induced by AZD1305 (left column), flecainide (middle row) and quinidine
(right row). Data points represent individual healthy animal/human volunteer change from
model-predicted QRS baseline against simulated concentrations in the plasma (dog) or effect
compartment (guinea pig, AZD1305 human) (dots), or associated average exposure-∆QRS
pairs with standard errors where available in healthy volunteers (circles) and in patients
(squares). The shaded areas represent the 95% confidence intervals (darker area) and pre-
diction intervals (lighter area). Brown colours represent excluded data (human flecainide).
Simulated QRS widenings in humans were plotted against the corresponding
effects at matched exposures in guinea pigs and dogs to visualise the translational
relationships for each compound (Figure 7.4). 10% QRS widening in humans corre-
sponded to 4.6% (CI range: 2.1-9.9) in guinea pig and 2.3-3.3% (CI range: 0.8-4.5)
in dog at matched total concentrations. The confidence intervals for all three com-
pounds overlapped for the dog to human translation, while only one compound
was available for the guinea pig to human translation. QRS interval baselines were
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Table 7.2 Summary of the selected QRS drug effect models for the antiarrhythmic compounds.
AZD1305 Flecainide Quinidine
Estimate (SE) BSV % (SE) Estimate (SE) BSV % (SE) Estimate (SE) BSV % (SE)
HUMAN ∆QRS = slope ∗ Ce,u ∆QRS = EmaxCnu/(ECn50 + Cnu ) ∆QRS = slope ∗ Cu
QRS0 (ms) 96 (1.08) 5.8 (0.838)
slope (ms µM-1) 11.4 (0.84) 26.1 (1.39) - 9.57 (1.14)
Emax (ms) - - 33.7a (10.8) -
EC50 (µM) - - 0.573a (0.256) -
n - - 1.65 (0.61) -
ke0 (h-1) 43.1 (27.1) 203 (13.7) - -
DOG ∆QRS = slope ∗ Cu ∆QRS = slope ∗ Cu ∆QRS = slope ∗ Cu
QRS0 (ms) 46.0 (1.4) 5.9 (2.1) 53.6 (1.5) 5.68 (2.03) 53.3 (1.7) 6.25 (2.23)
slope (ms µM-1) 1.93 (0.67) 66.2 (25.2) 5.38 (0.95) 30.8 (14.3) 3.00 (0.25) -
GUINEA PIG ∆QRS = a ∗ Cbe,u
QRS0 (ms) 21.7 (0.893) 11.6 (2.92)
slope (ms µM-1) - -
a 16.9 (1.66) -
b 2.46 (0.365) 23.4 (9.15)
ke0 (h-1) 1.6 (0.111) -
All estimates are mean±SE. QRS0, baseline; slope, proportional unbound drug effect; Emax, maximal effect; EC50, unbound concentration at 50%
effect; n, Hill factor; a and b, parameters of the power model; ke0, rate of distribution to the effect compartment. BSV is presented as the coefficient
of variation, approximated by CV% = SD*100 for log-normal distributions. aCorrelation Emax : EC50 was 0.977.
shorter in guinea pigs and dogs by approximately three quarters and half, respec-
tively. Comparisons of absolute differences therefore further increased the transla-
tional gap. Fractions of PPB were similar between the investigated species, and
similar results were therefore acquired while applying unbound and total concentra-
tions. All in vivo to clinical translations are shown assuming the same PPB in each
species.
7.3.3 Empirical translation of in vitro effects
Drug effects were simulated using the final human drug effect models and plotted
against the in vitro effects at matched exposures to visualise the translational re-
lationships for each compound (Figure 7.5). Nonclinical effects corresponding to
10% QRS widening in humans were extracted. QRS widening of 10% occurred at
unbound concentrations corresponding to 3-7% hNav1.5 inhibition in vitro. This
indicates that conduction liabilities may occur well below the IC50 of a compound,
where Hill factors have a large impact. Hill factors were 0.75-1.2 for the investi-
gated compounds. However, assuming Hill factors of 1 resulted in considerably less
consistent translational relationships (2-10% hNav1.5 inhibition compared to 3-7%
when Hill factors were included). Confidence intervals for AZD1305 and quinidine
were overlapping, while the relationship for flecainide was steeper. Contrary to the
in vivo to clinical translations, accounting for the free fractions of drug in plasma
was vital for consistent in vitro to human translational relationships between the
compounds.
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IN VITRO
3-7%
AZD1305
Flecainide
Quinidine
95% CI
95% PI
Figure 7.5 Top-down translation to QRS widenings in humans from hNav1.5 inhibition in
vitro, by AZD1305 (solid lines), flecainide (dashed lines) and quinidine (dashed-dotted lines).
7.3.4 Semi-mechanistic translation of in vitro effects
The operational model (Equation 7.9) well described AZD1305-induced QRS widen-
ings. However, as maximum QRS widenings were not reached in these data, the
model was practically unidentifiable when estimating both the parameter describing
the maximum QRS widening possible in the system (Em) and the transducer ratio
(τ), which control the strength of the transduction from ion channel inhibition to
QRS widening. This identifiability issue led to high correlation between Em and τ (-
0.97) and was solved by fixing Em. Different values of Em were investigated (20-100
ms). Similar goodness of fit values and residual variabilities were achieved for Em
values between 40 and 100 ms, while the goodness of fit was worse at Em=20 ms.
To investigate the influence of the chosen Em on the behaviour of the fitted model,
simulations were conducted for optimised models with fixed Em values between 40
and 100 ms (Figure 7.6). This showed that regardless of Em being 40 or 100 ms,
these models result in highly similar model predictions up to 20 ms (after which
predictions diverge, with larger effects for increasing Em values due to saturation at
different effect levels). However, widenings above 20 ms are unlikely to occur in a
safety setting (by a drug not intended to cause QRS widening), while effects in the
range of 5-10 ms are likely to cause concern.
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Figure 7.6 Predicted AZD1305-QRS prolongation relationship (left) and hNav1.5 inhibition-
QRS widening relationship for operational models with Em fixed at 40, 60, 80 and 100 ms
(followed by estimation of the remaining parameters) show that QRS widenings up to 20
ms are predicted similarly despite the fact that Em is varied.
An Em of 40 ms QRS widening was selected based on the simulation re-
sults and the highest QRS widenings reached in the clinical literature data sets (31
ms). The estimated model well captured the observed drug-induced QRS widenings
(Figures 7.8 and 7.7). The final estimate for τ was high (8.0 ± 0.4), suggesting an
efficient signal transduction with high signal amplification (Table 7.3). The selected
value of Em influences the estimated value of τ . Baseline and effect compartment
parameters were similar to the estimates for the PKPD models (Chapter 5).
Table 7.3 Parameter estimates for the human AZD1305 operational model describ-
ing baseline and drug-induced effects on QRS interval durations.
Estimate (SE) BSV % (SE) IOV % (SE)
QRS0 (ms) 95.9 (1.08) 5.78 (0.832) 2.10 (0.32)
α 0.0468 (0.0077) 1340 (150) -
A (%) 1.55 (0.157) 42.2 (5.79) -
φ (h) -6.51 (0.311) 22.5 (1.37) -
Em (ms) 40 (fixed) - -
τ 8.00 (0.39) 8.74 (3.12) -
n 1.54 (0.10) 21.1 (2.4) -
ke0 (h-1) 37.4 (23.7) 210 (10) -
Additive residual (ms) 1.00 (0.02) - -
BSV and IOV are presented as the coefficient of variation, approximated by CV%
= ω*100 for log-normal distributions.
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Figure 7.8 Baseline-subtracted QRS data and simulated QRS widening for the operational
model.
7.3.4.1 Simulating the in vitro to clinical relationship
The translational relationship between inhibited hNav1.5 and QRS widening in hu-
mans was simulated and 95% confidence and prediction intervals generated (Figure
7.9). These results predict that only 5-7% inhibition of hNav1.5 is required to induce
10% QRS widening.
hNav1.5 inh (%)
δQ
RS
 (%
)
 
 
0 5 10 15
0
10
20
30
Model CI
Model PI
Median
Figure 7.9 Model predicted translation between hNav1.5 inhibition in vitro and QRS widen-
ing in humans, highlighting the confidence interval for inhibited ion channel at 10% QRS
widening.
7.3.4.2 Predicting effects of flecainide and quinidine using the estimated
system parameters
The system parameters were combined with in vitro potency parameters for fle-
cainide and quinidine and used to predict the QRS widening of these compounds
in the measured range of unbound concentrations (Figure 7.10). QRS widenings
induced by quinidine were well predicted while flecainide effects were slightly under-
predicted.
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7.4 Translation to PR prolongations in humans
7.4.1 Comparison of baseline parameters between species
Models to minimise baseline variability are investigated in guinea pigs, dogs and
humans in Chapter 5. In these investigations, data were pooled for each species
separately, using vehicle data from two guinea pig studies and five dog studies and
placebo data from one human study. A selection of baseline models were fitted to
these data, namely the constant baseline model, a model incorporating correction to
simulaneous RR intervals, a circadian rhythm model comprising of a single cosine
function, and a combination of the two later models (Equations 5.2-5.5). Estimates
for the parameters of the selected final baseline models are summarised in Table
7.4. For each species, an optimal baseline model was selected based on its relative
likelihood and its complexity, where the most simple model with at least 5% relative
likelihood compared to the model with the lowest AIC value was selected (Equation
5.1).
Table 7.4 Comparison of the extracted baseline parameters of PR intervals in guinea pigs,
dogs and humans.
Human Dog Guinea pig
Estimate Estimate % of
human
Estimate % of
dog/human
PR0 (ms) 170a 103 61 62.4 61/37
A (ms) 4.8 1.9 136 NA
α 0.19 0.16 84 0.582 306
Residual error (ms) 3.6 5.4 235 1.45 63
Parameter estimates from the “best” models when evaluating merged vehicle guinea pig
(2 studies) and dog data (5 studies) respectively, and the placebo human data from the
AZD1305 study. The BSV of α was assumed to be lognormal in dogs and normal in
humans as some humans had negative PR-RR correlations. Assuming normally distributed
α in dogs led to a similar estimate of 0.17. aPQ intervals.
Typical PR interval point baselines were 170 ms in humans, 103 ms in dogs
(61% of human duration) and 62 ms in guinea pigs (37% of human duration). Cor-
rection to RR intervals improved the goodness of fit to PR intervals in all three
species with estimated correction coefficient (α) values of 0.19, 0.16 and 0.58 in hu-
mans, dogs and guinea pigs respectively. Despite the very high α value when fitting
vehicle guinea pig PR intervals, RR correction only improved estimation of RR in-
tervals in guinea pigs in one of the two full data sets including also drug treatment
data (Sections 5.7.2 and 5.9.2). Including circadian rhythms improved goodness of
fit to PR intervals in humans and dogs, with amplitudes of 5 and 2 ms (3 and 2% of
the estimated point baselines respectively), and were not evaluated in guinea pigs.
158
As for QRS intervals, residual variability was larger in dogs (≈5%) compared to
guinea pigs and humans (≈2%).
7.4.2 Empirical translation of in vivo effects
Drug effect parameters were extracted from the final PKPD models in guinea pigs,
dogs and humans (Chapter 5) and directly applied using the human exposure-effect
models (Chapter 6) and are summarised in Table 7.5. PR effects of AZD1305 were
well described by proportional models in dogs and humans, as were flecainide and
verapamil effects in guinea pigs, while verapamil effects in dogs and humans and
flecainide effects in humans were better described by Emax models (Equations in
Table 7.5). Also, in guinea pigs and for AZD1305 treatment in humans, short delays
were identified between plasma drug concentrations and PR prolongations. The
collected drug effect parameters summarised in Table 7.5 were used to simulate the
model-predicted drug effects in each species (Figure 7.11).
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Table 7.5 Summary of the selected PR drug effect models for the antiarrhythmic compounds.
AZD1305 Flecainide Verapamil
Estimate BSV % Estimate BSV % Estimate BSV %
Human ∆PR = slopeCe,u ∆PR = EmaxCnu/(ECn50 + Cnu ) ∆PR = EmaxCu/(EC50 + Cu)
PR0 (ms) 160 (4) 12 (2)
slope (ms/µM) 17.0 (2.6) 52 (4) - -
Emax (ms) - - 68.9a (27.2) 55.9 (6.8)
EC50 (µM) - - 0.77a (0.43) 0.041 (0.014)
n - - 1.57 (0.51) 1 (fixed)
ke0 (h-1) 10.5 (2.4) - - -
Dog ∆PR = slopeCu ∆PR = slopeCu ∆PR = EmaxCu/(EC50 + Cu)
PR0 (ms) 102 (4) 8.0 (2.9) 95.8 (2.3) 4.8 (1.7) 111 (6) 11 (4)
slope (ms/µM) 13.8 (1.8) 23 (10) 11.0 (1.2) 13 (11) - -
Emax (ms) - - - - 105 (9) -
EC50 (µM) - - - - 0.196 (0.088) 84 (31)
Guinea pig ∆PR = slopeCe,u ∆PR = slopeCe,u
PR0 (ms) 57 (4.39) 22 (5) 61.6 (1.6) 7.4 (1.9)
slope (ms/µM) 4.14 (1.84) 82 (31) 161 (70) -
ke0 (h-1) 11.9 (3.6) - 1.07 (0.80) 87 (33)
All estimates are mean±SE. PR0, baseline; slope, proportional unbound drug effect; Emax, maximal effect; EC50, unbound concentration at 50%
effect; n, Hill factor; a and b, parameters of the power model; ke0, rate of distribution to the effect compartment. BSV is presented as the coefficient
of variation, approximated by CV% = SD*100 for log-normal distributions. aCorrelation Emax : EC50 was 0.979.
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Figure 7.11 PR prolongations in guinea pigs (top row), dogs (middle row) and humans
(bottom row) induced by AZD1305 (left column), flecainide (middle row) and verapamil
(right row). Data points represent individual healthy animal/human volunteer change from
model-predicted PR baseline against simulated concentrations in the plasma (dog) or ef-
fect compartment (guinea pig, AZD1305 human) (dots), or associated average exposure-PR
pairs with standard errors where available in healthy volunteers (circles) and in patients
(squares). The shaded areas represent the 95 % confidence intervals (darker area) and
prediction intervals (lighter area). Brown colours represent repeated dosing data (human
verapamil).
Simulated PR prolongations in humans were plotted against effects at matched
exposures in guinea pigs and dogs to visualise the translational relationships for each
compound (Figure 7.12). 10 % PR prolongation in humans corresponded to a 2.3-4.3
% change in guinea pigs (CI range: 0.3-7.6) and 2.4-10 % change in dogs (CI range:
1.9-28) at matched total concentrations. The confidence intervals for flecainide and
verapamil overlapped in guinea pigs while the confidence intervals for AZD1305
and verapamil overlapped in dogs. The translational relationship for flecainide was
steeper in dogs compared to AZD1305 and verapamil. Typical PR interval point
baselines were 170 ms in humans, 103 ms in dogs (61 % of human) and 62 ms in
guinea pigs (37 % of human), and absolute differences between effects in guinea pigs,
dogs and humans were thus larger than relative differences. The in vitro-estimated
plasma protein bindings (PPBs) were similar between the species, and the trans-
lational relationships are therefore shown assuming the same PPB in each species.
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Similar results were acquired while applying the in vitro PPB estimates.
7.4.3 Empirical translation of in vitro effects
Drug effects were simulated using the final human drug effect models and plotted
against the in vitro effects at matched exposures to visualise the translational re-
lationships for each compound (Figure 7.13). Nonclinical effects corresponding to
10% PR prolongation in humans were extracted. PR prolongations of 10 % occurred
at unbound concentrations corresponding to 13-21 % rCav1.2 binding at the dilti-
azem site in vitro. The in vitro to clinical relationship for verapamil was slightly
steeper compared to those for AZD1305 and flecainide, although the confidence in-
tervals were largely overlapping. As for QRS translations, accounting for the PPB
was vital for consistent in vitro to human translational relationships between the
compounds.
IN VITRO
13-21%
AZD1305
Flecainide
Verapamil
95% CI
95% PI
Figure 7.13 Top-down translation to PR prolongations in humans from rCav1.2 binding in
vitro at the diltiazem site, by AZD1305 (solid lines), flecainide (dashed lines) and verapamil
(dotted lines).
7.4.4 Semi-mechanistic translation of in vitro effects
The operational model 2.10 well described AZD1305-induced PR prolongations.
However, as maximum PR prolongations were not reached in this data set, the
model was practically unidentifiable when estimating both the parameter describing
the maximum PR prolongation possible in the system (Em) and the transducer ratio
(τ). Similar to the QRS modelling, this identifiability issue led to high correlation
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between Em and τ (-0.83) and was solved by fixing Em. Different values of Em
were investigated (40-100 ms, Figure 7.14), and resulted in similar predictions up to
approximately 30 ms PR prolongation regardless of Em being 40 or 100 ms. Widen-
ings above 30 ms are unlikely to occur in a safety setting (by a drug not intended to
cause PR prolongation), where effects in the range of 10-20 ms are likely to cause
concern.
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Figure 7.14 Predicted AZD1305-PR prolongation relationship (left) and rCav1.2 binding-
PR prolongation relationship for operational models with Em fixed at 40, 60, 80 and 100
ms show that small PR prolongations are predicted similarly when Em is varied, and that
predictions up to 30 ms PR prolongations are similar for Em values above 40 ms.
An Em of 60 ms PR prolongation was selected based on the simulation results
and the highest PR prolongations reached in the clinical literature data sets (56 ms).
The estimated model well captured the observed drug-induced PR prolongation al-
though the data show large variability (Figures 7.15 and 7.16). The final estimate
for the system parameter τ was lower for PR compared to QRS and with larger
uncertainty (4.0 ± 0.7 vs. 8.0 ± 0.4), reflecting a less efficient signal transduction
and reduced precision due to more variable data (Table 7.6). The selected value of
Em influences the estimated value of τ due to the identifiability issue previously de-
scribed. Baseline and effect compartment parameters were similar to the estimated
values in the PKPD models (Chapter 5).
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Table 7.6 Parameter estimates for the human AZD1305 operational model describ-
ing baseline and drug-induced effects on PR interval durations.
Estimate (SE) BSV % (SE) IOV % (SE)
QRS0 (ms) 160 (3.53) 11.7 (1.59) 4.46 (0.69)
α 0.0819 (0.0211) 1340 (22.2) -
A (%) 2.68 (0.279) 43.8 (3.68) -
φ (h) -3.09 (0.662) 107 (2.61) -
Em (ms) 60 (fixed) - -
τ 3.99 (0.69) 59.4 (1.8) -
n 2.09 (0.22) - -
ke0 (h-1) 14.5 (3.9) 40.9 (43.2) -
Additive residual (ms) 3.73 (0.09) - -
BSV and IOV are presented as the coefficient of variation, approximated by CV%
= ω*100 for log-normal distributions.
Free AZD1305 (pred. C
e
 uM)
δP
R
 (m
s)
 
 
0 1 2
−10
0
10
20
30
Model PI
Model CI
Median
HV data
Figure 7.16 Baseline-subtracted PR data and simulated PR prolongations for the operational
model.
7.4.4.1 Simulating the in vitro to clinical relationship
The translational relationship between bound rCav1.2 and PR prolongation in hu-
mans was simulated and 95 % confidence and prediction intervals generated (Figure
7.17). These results predict that 12-22 % binding of rCav1.2 at the diltiazem site is
required to induce 10 % PR prolongation.
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Figure 7.17 Model predicted translation between rCav1.2 binding in vitro and PR pro-
longation in humans, highlighting the confidence interval for bound rCav1.2 at 10% PR
prolongation.
7.4.4.2 Predicting effects of flecainide and verapamil using the estimated
system parameters
The systems parameters were combined with in vitro potency parameters for fle-
cainide and verapamil and used to predict the PR prolongation of these compounds
in the measured range of unbound concentrations (Figure 7.18). To account for the
different potency and metabolism of the two verapamil enantiomers, the efficacy of
verapamil was assumed to be mediated only by the more potent S enantiomer. The
estimated Ki for verapamil of 0.044 µM was therefore corrected to account for the
predicted enantiomer composition in vivo by
Ki,invivo =
Ki,invitrofs,invitro
fs,invivo
(7.11)
where Ki,invitro and Ki,invivo are the in vitro and in vivo potencies and fs,invitro
and fs,invivo the fraction of the more potent S enantiomer in vitro (0.5) and in
vivo (0.18, [138]), respectively. PR prolongations induced by flecainide were slightly
over-predicted while verapamil effects were well predicted by the model.
7.5 Discussion
During preclinical drug development, both in vitro and in vivo data are generated
at AstraZeneca to assess potential safety risks, such as changes in QRS and PR
durations. Typically, in vitro Cav/Nav studies are conducted during lead identi-
fication/optimisation and obtained results (IC50) used, in the context with other
data, to drive the chemistry and select compounds to progress into in vivo stud-
ies. Early in vivo studies (e.g. anaesthetised guinea pigs) are typically run during
lead optimisation, and provide first cardiac safety information in a complete living
system, including QRS/PR, to select/terminate candidate drugs from a chemical
167
Fr
ee
 fl
ec
ai
ni
de
 (u
M)
δPR (ms)
 
 
0
0.
5
1
1.
5
020406080
M
od
el
 C
I
M
od
el
 P
I
M
ed
ia
n
Pa
tie
nt
 d
at
a
H
V 
da
ta
Fr
ee
 v
er
ap
am
il (
uM
)
δPR (ms)
 
 
0
0.
1
0.
2
0.
3
020406080
M
od
el
 C
I
M
od
el
 P
I
M
ed
ia
n
Pa
tie
nt
 d
at
a
H
V 
da
ta
Fi
gu
re
7.
18
M
od
el
pr
ed
ic
te
d
an
d
m
ea
su
re
d
eff
ec
ts
of
fle
ca
in
id
e
an
d
ve
ra
pa
m
il
in
hu
m
an
s.
Pr
ed
ic
tio
ns
we
re
ge
ne
ra
te
d
us
in
g
th
e
es
tim
at
ed
sig
na
l
tr
an
sd
uc
tio
n
pa
ra
m
et
er
s
an
d
th
e
in
vi
tro
es
tim
at
ed
po
te
nc
y
in
th
e
rC
av
1.
2
as
sa
y.
C
lin
ic
al
da
ta
we
re
co
lle
ct
ed
fro
m
lit
er
at
ur
e
st
ud
ie
s.
168
series. Prior to FTIM, ICH S7A/B guidance requires a non-rodent (typically dog)
telemetry study to assess cardiovascular risk, including QRS/PR changes, as part
of the pre-clinical safety package. Together, in vitro and in vivo data on cardiac
conduction form part of an integrated package of evidence for the safety of a poten-
tial drug, which can be further strengthened by quantitative predictions of QRS/PR
effects in humans based on nonclinical observations.
7.5.1 Small in vitro interactions lead to relevant QRS/PR prolon-
gations
Translation between in vitro effects and QRS/PR change in humans show that rela-
tively low hNav1.5 inhibition (3-7 %) and rCav1.2 binding (13-21 %) correlate with
10 % QRS/PR change (Figures 7.5 and 7.13). Translation using the middle-out ap-
proach resulted in similar thresholds, strengthening the confidence in the predicted
relationships. Using margins to IC50 of 30-100-fold have been suggested both for
unbound Cmax and hERG channel inhibition [170] and for hNav1.5 [19]. However,
the Hill (sigmoidicity) factors have large impact at the low inhibition levels that
correlate to clinical effects. For example, 10 % inhibition occurs at concentrations
9 times lower than IC50 with a Hill factor of 1, but only 4 times lower with a Hill
factor of 1.5. The chosen margins to IC50 may therefore be unnecessarily high for
compounds with high Hill factors, while potentially missing compounds with small
Hill factors. Concentrations corresponding to inhibitions leading to a meaningful
human change may therefore provide safer margins, such as 5 % hNav1.5 inhibition
and 15 % rCav1.2 binding. A limitation to using IC10 values rather than IC50 is
the higher signal-to-noise ratio at these small inhibition levels, and in vitro effects
should therefore be evaluated considering the full concentration-response curves.
In vitro to clinical translations to human QRS widenings were highly con-
sistent, although flecainide had a steeper relationship compared to AZD1305 and
quinidine (Figure 7.5). This reflects the mechanisms of action of type 1a and 1c an-
tiarrhythmics (quinidine and flecainide, respectively), which bind to the open state
of Nav1.5 [171] and dissociate to the closed states at different rates. Flecainide dis-
sociates slower compared to quinidine (>1500 ms vs. 300-1500ms, [172], and more
Nav1.5 block therefore remains at the beginning of each action potential, causing
more QRS widening. As for QRS, translations of in vitro effects to clinical PR
prolongations were relatively consistent between the investigated compounds. Ve-
rapamil had a steeper relationship, possibly resulting from AV block induced by
binding to the verapamil site on Cav1.2 in addition to the diltiazem site. Also,
while QRS prolongations are strongly linked to the block of a single ion channel,
multiple mechanisms contribute to AZD1305-, flecainide- and verapamil-induced PR
prolongations that were not taken into account in this work. For example, AZD1305
169
and flecainide prolong the P wave (by Nav1.5 block) and flecainide also reduces
intra-cellular Ca2+ release [173, 174].
While the top-down in vitro to clinical relationships provide predictions of
human effects at specific in vitro levels such as the predicted therapeutic Cmax, they
cannot directly be used to predict the effects for full PK curves. However, this is
possible with the semi-mechanistic approach using the estimated system parameters
in combination with in vitro (unbound) potency. Such predictions may be used
to predict exposure-effect relationships as exemplified in Figures 7.10 and 7.18, or
alternatively over time simulating QRS/PR effects at a predicted PK. If the true
maximum prolongations possible in the systems (Em values) are larger than the
assumed values, there is a risk of under-predicting large QRS/PR effects (>20-30ms).
However, such large side effects would most likely result in the discontinuation of
the compound despite this under-prediction, and this limitation is therefore of small
concern for the purpose of safety assessment.
7.5.2 QRS/PR effects are smaller in animals compared to humans
The translational relationships for QRS/PR effects demonstrated smaller changes at
matched exposures in the nonclinical species compared to humans (Figures 7.4 and
7.12). However, across compounds, the effects were consistent, especially for QRS
where low percentage changes were 3-4 times larger in humans compared to dogs.
PR translations were more variable, with human changes 1-4 times larger compared
to dogs. Similar relationships were found for guinea pigs, although the compound
set was incomplete.
It is important to note that the levels of effects in dogs and guinea pigs that
correspond to meaningful clinical changes of 10% (2-5% for QRS, 2-10% for PR) are
well below the effect levels that these studies are typically powered for (guinea pig:
19/21% QRS/PR [23]. However, this power analysis is based on point-wise statistics,
whereas employing a PKPD modelling approach increases sensitivity and specificity
[18] as all dose levels and time points are used simultaneously. Conducting PKPD
modelling of nonclinical in vivo data as a routine analysis is therefore recommended
to improve the power to identify small QRS/PR effects. Furthermore, nonclinical
effects should be evaluated well above the expected therapeutic exposure to ensure
that potential side effects in cardiac conduction are developed.
7.5.3 Possible mechanisms for the reduced sensitivity in animals
Several compounds with different mechanisms of action were investigated to account
for possible compound-specific differences and to achieve a broader applicability of
the recommendations and translational relationships of this work. Anatomically,
guinea pig and dog hearts are 300 and 6 times lighter than human hearts [175] and
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have smaller specialised tissues, e.g. AV node (reviewed in [176] resulting in shorter
QRS and PR intervals. Therefore, evaluating relative rather than absolute changes
from baseline reduces the translational gap between guinea pigs, dogs and humans.
A major assumption is that the in vitro, in vivo and clinical (unbound) plasma
concentrations all are equivalent to the target tissue exposure. For these compounds,
the same fractions unbound were applied as the measured PPBs were similar across
species, and considered to be within the variability of the assay. However, small
errors in these fractions have direct impact on the translational relationships, and
high quality data for the free fractions in each species could potentially improve
precision in the translational relationships. Exposures at the target sites may also
differ between species due to differences in the distribution to the heart tissue and
intra-cellular targets.
The reduced sensitivity of guinea pigs and dogs to conduction slowing is likely
to be present at the tissue level as flecainide and quinidine reduce the depolarisation
rate more in human atrial tissue compared to guinea pigs, rabbits and dogs [177].
It is not known if in vitro studies using guinea pig and dog Nav/Cav would indi-
cate reduced potency compared to human Nav/Cav. Cav1.2 is multi-functional with
many splice variants [178] which could potentially differ between species. Nav1.5 is
highly conserved between mice, rats, pigs and humans (94-98% amino acid homol-
ogy [179]), but the relative quantity of each isoform of Nav varies throughout the
conduction system (reviewed in [180]) and between species [179]. Thus, conduction
slowing may differ between species partly due to differences in the relative quantity
of ion channel isoforms and splice variants.
7.5.4 Predicting QRS and PR prolongations in humans
The results of this work may be used to improve predictions of QRS and PR pro-
longations in humans using nonclinical data in combination with the translational
relationships identified in this work (Figure 7.19).
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Figure 7.19 A. QRS widening and B. PR prolongations in humans may be predicted from
nonclinical data using the quantitative translational relationships that have been presented
in this thesis, as indicated by the arrows representing translational links in the biomarker
map [32]. Dashed lines represent compound-specific relationships that can be quantified
directly from nonclinical data to be used in combination with the quantitative translational
relationships represented by solid lines in order to predict QRS/PR prolongations in humans.
In early in vitro and in vivo studies, nonclinical effects at exposures resulting
in 10% human prolongation may be used to define a margin for acceptable levels
of effects in nonclinical studies. This acceptable level is, according to these results,
around 2-5% QRS/PR change in guinea pigs or dogs at expected therapeutic expo-
sures (Figure 7.20). Similarly, acceptable in vitro effects were around 5% hNav1.5
inhibition and 15% rCav1.2 diltiazem binding. Further, the developed models or pro-
vided translational figures (Figures 7.4, 7.5, 7.9, 7.12, 7.13, 7.17) may be easily used
to define margins related to a different human effect, such as 5 or 20 %. However,
it should be emphasized that relying on in vitro data alone is not recommended.
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As was discussed above, different mechanisms of ion channel block influences the
resulting effect on conduction. For example, a quickly dissociating Nav1.5 blocker
may not cause QRS widening, despite its potency in vitro.
Figure 7.20 Suggested safety margins in nonclinical studies at predicted clinical therapeutic
concentrations, in order to reduce risk of QRS or PR prolongations above 10%. The small
in vivo effects emphasize the importance of sensitive methods for identifying effects in the
collected data in combination with doses resulting in super-therapeutic exposures.
Before FTIM studies, a more in-depth assessment of the therapeutic dose
range may be required, such as clinical simulations of PR/QRS change over time
using the predicted human PK. Prior to this work, quantitative results on the trans-
lational relationships were not available in the literature, and a best guess for trans-
lating effects may have been for example equal (absolute or relative to baseline)
drug effect in humans compared to animals. However, in this work, the percentage
QRS/PR change was up to five times larger in humans compared to guinea pigs
and dogs. Worst case QRS/PR effects in humans at the expected PK can thus
be predicted by simulating not equal, but four times larger slopes than estimated
slopes for dogs and guinea pig, while also accounting for baseline and protein bind-
ing differences. To include a measure of uncertainty, a best case scenario may also
be predicted by a two times larger (QRS) or the same (PR) slope. Although small
distributional delays may be present, QRS and PR effects are likely to be well ap-
proximated by a direct effect model for orally administered drugs. In addition, the
in vitro system models can complete the risk assessment by predicting QRS/PR
effects over time using the system parameters estimated in this work, together with
in vitro potency, free fraction of drug in plasma and the predicted human PK. Sev-
eral independent predictions of clinical effects provide additional confidence and any
discordance offers a measure of the uncertainty regarding the human prediction.
Therefore, a combined view applying information from in vitro and in vivo studies
such as that illustrated in Figure 7.21 is vital in order to predict cardiac conduction
risks before FTIM studies.
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Figure 7.21 The resulting translational relationships from this thesis work can be used to
generate risk assessments of A. QRS widening or B. PR prolongations in humans using
nonclinical data from multiple sources, providing a combined view on the predicted risk
with increased confidence compared to any single prediction.
7.6 Summary
In this chapter, two approaches to translate nonclinical effects to clinical QRS and
PR interval prolongations were presented and used to investigate the translational
relationships for four anti-arrhythmic compounds. This is the first quantitative as-
sessment of non-clinical to clinical translation of QRS and PR intervals using math-
ematical models. The results of these analyses show that small in vitro interactions
lead to relevant QRS/PR prolongations. These small effects should preferably be
evaluated considering the full concentration-response curves as small in vitro effects
may be difficult to measure in practice. Also, QRS/PR effects are up to four times
smaller in guinea pigs and dogs compared to humans. This emphasises the impor-
tance of using sensitive techniques such as PKPD modelling to analyse routine in
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vivo data, and also the importance of evaluating nonclinical effects well above the
expected therapeutic exposure. Importantly, using data from multiple nonclinical
sources to predict human effects enables multiple independent predictions, where any
disagreement between the predicted effects can be viewed as an additional measure
of uncertainty.
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Chapter 8
Conclusions
The aim of this thesis was to increase the understanding of how drug-induced cardiac
conduction slowing in humans, reflected by QRS and PR prolongations in monitored
ECGs, may be predicted and mitigated using nonclinical in vitro and in vivo data.
Drug-induced QRS and PR prolongations are, for indications other than cardiac
arrhythmias, typically undesired and may increase CV risk [15]. Early identification
of risk is therefore important for safe and efficient drug discovery and development.
Predicting effects in humans based on observations in animals rely on the under-
standing of how sensitive animals are compared to humans. However, prior to the
work performed for this thesis, no quantitative analysis of the relative effects on QRS
and PR in animals and humans could be identified in the literature. In addition, no
systematic investigation of M&S approaches for quantifying QRS and PR intervals
in animals and humans was identified.
The first objective of this thesis was therefore to “apply and develop models
to quantify QRS and PR intervals monitored in nonclinical species and in humans
at baseline conditions and during drug treatment”. This was accomplished by col-
lecting and analysing available nonclinical (guinea pig and dog) and clinical PK
and ECG data for six compounds. In Chapter 5, PKPD models were developed
for QRS complex durations in guinea pigs (flecainide), dogs (AZD1305, flecainide
and quinidine) and humans (AZD1305) and for PR intervals in guinea pigs (fle-
cainide, verapamil), dogs (AZD1305, AZD8683, AZD9164, flecainide and verapamil)
and humans (AZD1305). In addition, in Chapter 6, regression models assessing the
concentration-effect relationships in humans using data collected in literature studies
were developed for QRS widenings (flecainide and quinidine) and PR prolongations
(flecainide and verapamil). AZD8683 and AZD9164 did not prolong QRS or PR in
humans at the evaluated exposures.
Based on the results from these compounds, small QRS and PR effects (up
to around 20%) may be modelled using proportional drug effect models, while non-
linear models such as the Emax model may be more appropriate for larger effects.
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Also, delays between plasma drug concentrations and QRS or PR effects were well
described using the effect compartment model. In addition, it was shown that the
choice of baseline model can influence the estimation of the drug effects. Resid-
ual unexplained variability of PR intervals was reduced by incorporating heart-rate
correction and a circadian rhythm to describe baseline variability. QRS intervals
required less detailed baseline models, and a constant baseline model was often suf-
ficient. In general, the baseline models had higher influence in humans compared to
dogs and least influence in guinea pigs. The results of this modelling investigation
may be used to support the design of routine modelling protocols for analysing QRS
and PR interval data. Such analyses may improve the sensitivity to detect small
QRS/PR changes potentially missed by point-wise statistical methods, which are
currently applied to analyse these data.
The second objective was to “investigate the translation between nonclinical
in vitro and in vivo effects and clinical QRS and PR prolongations”. This was
accomplished by two different translational analyses, both described in Chapter 7.
The first was an investigation into the relative effects of the in vitro and in vivo assays
compared to the clinic, and was based on the developed models from Chapters 5 and
6. This translational investigation showed that QRS and PR changes were smaller
at matched exposures in the nonclinical species compared to humans. Primarily
QRS, but also PR effects, were consistent across the investigated compounds, where
a 10% change in humans compared to a 2-5% QRS change and a 2-10% PR change
in dogs and guinea pigs. Also the in vitro to clinical translation was consistent
across compounds, where a 10% change in humans compared to 3-7% inhibition in
the hNav1.5 assay for QRS and 13-21% binding in the rCav1.2 assay for PR. The
second translational approach applied the operational model (Equation 2.10) to link
the in vitro effects of AZD1305 to the clinical effects. Using this approach, a model
describing the translational relationship was parameterised and successfully used to
predict effects of quinidine, flecainide and verapamil. Also, the predicted in vitro
effects at 10% QRS or PR prolongations were similar to those calculated from the
empirical investigation (5-7% for QRS and 12-22% for PR using the 95% confidence
interval).
The third objective was to “develop a model framework to quantitatively pre-
dict QRS and PR prolongations in humans using nonclinical data that can be adopted
by the pharmaceutical industry to improve safety assessment. This relates to how
the results of the translational analyses may be applied in practice to predict clinical
QRS and PR effects, and is discussed in detail in Chapter 7. To reduce QRS/PR risk
in early nonclinical studies, it is recommended to use the translational relationships
to define margins for acceptable levels of nonclinical effects (Figure 8.1). Applying
the 10% effect level as a human margin, the results of the translational work of this
thesis suggest that nonclinical QRS/PR changes above around 5% are indicative of
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high risk of at least 10% change in humans. Conservative nonclinical margins may
be even lower, such as 2-4% QRS or PR change in guinea pigs or dogs at expected
therapeutic exposures. Similarly, in vitro effects above 5% hNav1.5 inhibition or
15% rCav1.2 diltiazem binding indicate high risk of more than 10% QRS or PR
change in humans, respectively.
The translational relationships suggested by this work may also be used to
predict human effects by simulating QRS/PR changes over time. Without any trans-
lational knowledge, the best guess may be that the slope in humans is equal to that
in the animal species, taking differences in baseline and protein binding into account.
However, this work shows that assuming equal effects in animals and humans may
lead to highly underpredicted human effects, and potentially unsafe compounds may
appear safe and be progressed. Instead, the translational relationships identified in
this work suggest that the human slope for QRS (as percentage change from base-
line) is approximately two to four times larger compared to guinea pigs and dogs,
and equal to four times larger for PR. Although these results are based on data
for a limited number of compounds, they provide a current best estimate for the
relative sensitivities of guinea pigs, dogs and humans to drug-induced QRS and PR
interval changes. Also, compounds with different mechanisms of action were investi-
gated to account for possible compound-specific differences and to achieve a broader
applicability of the recommendations and translational relationships of this work.
Despite the relatively consistent in vitro to clinical translations for the inves-
tigated compounds, the influence of drug-ion channel kinetics and other mechanisms
on QRS/PR prolongations highlight the importance of also evaluating drug effects
in vivo. Improved sensitivity earlier in discovery does however reduce animal use,
as potentially unsafe drugs can be discontinued at an earlier stage. Importantly, the
results of the work presented in this thesis may be used to generate several indepen-
dent predictions of QRS and PR effects in humans, using the observed or estimated
effects in vitro and in guinea pigs and dogs together with the suggested translational
relationships. Several independent predictions of clinical effects provides additional
confidence and any discordance offers a measure of the uncertainty regarding the
human prediction. Therefore, a combined view applying information from in vitro
and in vivo studies is vital to predict cardiac conduction risks before FTIM studies,
using the preliminary translational relationships suggested in this work to build on
an integrated package of evidence of clinical QRS/PR risk.
8.1 Future work
This work provides a first attempt to quantitatively assess the nonclinical to clinical
translation of QRS and PR changes, in order to identify risks in nonclinical studies
and predict QRS and PR changes in humans. A limited number of compounds were
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Figure 8.1 Overview of the suggested novel risk assessment processes for A. QRS widening
and B. PR prolongations in drug discovery and early development. During lead generation
and optimisation, the suggested safety margins for the nonclinical effects can be used to
exclude compounds with high risk at the predicted human Cmax. More thorough assess-
ment of human risk using predicted PK profiles may be performed using the translational
relationships suggested in this work together with the quantified nonclinical effects.
investigated, and analyses into the translation of additional compounds is required
to improve confidence in the translation. While the full translational relationships
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between in vitro and humans were estimated in this work, visual methods were
applied to quantify the in vivo to clinical translations. Collating all data and esti-
mating the parameters of the in vivo and clinical data simultaneously, assuming a
model for the translational relationship, may further improve this quantitation.
In this work, compounds with different mechanisms of action were inves-
tigated and compared, and it was found that, despite these differences, relatively
consistent translational relationships were identified. However, detailed mechanistic
models may further advance these predictions as these differences may be incorpo-
rated in the model in order to predict drug effects. To date, these detailed models
have largely focused on the ventricular AP, limiting the possibility of predicting ef-
fects on PR which reflect atrial depolarisation and conduction through the AV node.
In such models, QRS widening is reflected by a reduced rate of depolarisation in the
upstroke of the AP. Multi-level models have also been built, simulating effects at
tissue or whole body level, such as the electrical activity across the torso, allowing
direct comparisons with measured ECGs. While these models show great promise,
and may reduce the use of animals, they must still overcome the currently missing
link between drug concentrations in vitro and at the receptor site in vivo.
Prior to this study, no quantitative information was available on the rela-
tive sensitivity to drug-induced QRS/PR effects in nonclinical species and humans.
Although this study is limited by the low number of investigated compounds, it
provides a starting point for nonclinical assessment of conduction liabilities and
predictions to humans.
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Appendix A
Example model code from
Monolix
DESCRIPTION:
Baseline with RR correction and circadian rhythm.
Proportional drug effect originating from an effect compartment.
DATA:
path = "path_to_data_folder",
file ="data_file_with_PK_parameteters.csv",
headers = {ID,OCC,ADM,X,AMT,RATE,TIME,IGNORE,X,X,X,X,X,X,X,X,X,X,X,Y,IGNORE},
columnDelimiter = ","
INDIVIDUAL:
RRref = {distribution=Normal, iiv=no},
alpha = {distribution=Normal, iiv=yes},
A = {distribution=logNormal, iiv=yes},
p = {distribution=Normal, iiv=yes},
baseline = {distribution=Normal, iiv=yes, iov=yes},
ke = {distribution=Normal, iiv=yes},
ke0 = {distribution=logNormal, iiv=yes},
STRUCTURAL_MODEL:
file = "mlxt:model_file",
path = "path_to_model_file",
output = {E}
OBSERVATIONS:
y1 = {type=continuous, prediction=E, error=constant}
181
TASKS:
; settings
globalSettings={
withVariance=no,
settingsGraphics="path_to_graphics_settings_file",
settingsAlgorithms="path_to_graphics_settings_file",
resultFolder="path_to_results_folder"},
; workflow
estimatePopulationParameters(
initialValues={
pop_RRref = 1000 [method=FIXED],
pop_alpha = 0.02,
pop_A = 0.015,
pop_p = -6,
pop_baseline = 94,
pop_ke = 0,
pop_ke0 = 1,
a_y1 = 5,
omega_alpha = 1,
omega_A = 0.2,
omega_p = 1.5,
omega_baseline = 7,
omega_ke = 1,
omega_ke0 = 1,
gamma_be = 1,
} ),
estimateFisherInformationMatrix( method={linearization} ),
estimateIndividualParameters( method={conditionalMode} ),
estimateLogLikelihood(method={linearization} ),
displayGraphics(),
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Appendix B
Collected literature data
Table B.1 Summary of the literature flecainide, quinidine and verapamil concentration-
QRS/PR data. Drug concentrations are unbound drug in µM. QRS/PR data are change
from baseline in ms. Baseline levels of 92.5 ms for QRS and 160 ms for PR were used
to convert published changes provided in percentage to ms where pre-dose intervals were
missing.
Ref Drug ECG Subjects Dosing Paired data
n Status Route History Cu (µM) δECG (ms)
[105] flecainide QRS 12 HV oral Acute 0.240381 6.29
[105] flecainide QRS 12 HV oral Acute 0.0753 5.55
[105] flecainide QRS 12 HV oral Acute 0.532892 14.7075
[105] flecainide QRS 12 HV oral Acute 0.204179 9.065
[107] flecainide QRS 10 HV iv inf Acute 0.367811 16
[108] flecainide QRS 10 HV iv inf Acute 0.362019 4
[109] flecainide QRS 6 HV iv inf Acute 0.249069 9.6
[105] flecainide QRS 12 HV oral Chronic 0.250517 6.7525
[105] flecainide QRS 12 HV oral Chronic 0.198386 6.475
[105] flecainide QRS 12 HV oral Chronic 0.641498 13.2275
[105] flecainide QRS 12 HV oral Chronic 0.519859 12.21
[110] flecainide QRS 12 HV oral Chronic 0.227348 -0.2775
[110] flecainide QRS 12 HV oral Chronic 0.502482 7.77
[111] flecainide QRS 27 Patients oral Acute 0.622673 21
[112] flecainide QRS 13 Patients oral Acute 0.655978 19
[107] flecainide QRS 12 Patients iv inf Acute 0.424286 31
[113] flecainide QRS 93 Patients iv inf Acute 0.405461 11
[114] flecainide QRS 10 Patients iv inf Acute 0.570542 14
[115] flecainide QRS 11 Patients iv inf Acute 0.333057 8.6
[116] flecainide QRS 47 Patients iv inf Acute 0.485105 22
[117] flecainide QRS 9 Patients oral Chronic 0.625569 26.8369
[112] flecainide QRS 13 Patients oral Chronic 1.34671 23.56
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Table continued from previous page
Ref Drug ECG Subjects Dosing Paired data
n Status Route History Cu (µM) δECG (ms)
[118] flecainide QRS 18 Patients oral Chronic 0.844228 27
[119] flecainide QRS 19 Patients oral Chronic 1.556681 28.4
[120] flecainide QRS 14 Patients oral Chronic 1.410426 11.7475
[106] flecainide PR 8 HV oral Acute 0.42863 23
[108] flecainide PR 10 HV iv inf Acute 0.362019 19
[109] flecainide PR 6 HV iv inf Acute 0.249069 12.2
[110] flecainide PR 12 HV oral Chronic 0.227348 7.52
[110] flecainide PR 12 HV oral Chronic 0.502482 18.88
[112] flecainide PR 13 Patients oral Acute 0.655978 32.76
[113] flecainide PR 93 Patients iv inf Acute 0.405461 12
[114] flecainide PR 10 Patients iv inf Acute 0.570542 28
[112] flecainide PR 13 Patients oral Chronic 1.34671 56.16
[119] flecainide PR 21 Patients oral Chronic 1.556681 44.7
[120] flecainide PR 14 Patients oral Chronic 1.410426 11.68
[125] quinidine QRS 8 HV oral Chronic 0.526483 11.1925
[121] quinidine QRS 21 HV oral Acute 0.274523 2
[121] quinidine QRS 27 HV oral Acute 0.297087 -4
[129] quinidine QRS 9 Patients oral Chronic 1.240995 1
[130] quinidine QRS 11 Patients oral Chronic 1.504237 18
[130] quinidine QRS 11 Patients oral Chronic 1.316207 16.2
[126] quinidine QRS 6 HV oral Chronic 0.300847 3.3
[131] quinidine QRS 20 Patients oral Chronic 1.391419 12
[127] quinidine QRS 20 Patients iv inf Acute 1.429025 8.5
[122] quinidine QRS 10 HV oral Acute 0.413665 4.3
[122] quinidine QRS 10 HV iv inf Acute 1.203389 11.8
[124] quinidine QRS 8 HV iv inf Acute 1.240995 8
[124] quinidine QRS 9 HV oral Acute 0.060169 2
[132] quinidine QRS 18 Patients oral Chronic 1.278601 7
[128] quinidine QRS 100 Patients iv inf Acute 1.203389 14
[133] quinidine QRS 10 Patients oral Chronic 0.263241 1.333333
[134] quinidine QRS 10 Patients oral Chronic 0.902542 13
[135] quinidine QRS 10 Patients oral Chronic 1.281 15
[129] quinidine PR 9 Patients oral Chronic 1.240995 2
[122] quinidine PR 10 HV oral Acute 0.413665 4.95
[122] quinidine PR 10 HV iv inf Acute 1.203389 9.92
[124] quinidine PR 8 HV iv inf Acute 1.240995 0
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Table continued from previous page
Ref Drug ECG Subjects Dosing Paired data
n Status Route History Cu (µM) δECG (ms)
[139] verapamil PR 8 HV oral Acute 0.157094 51.2
[140] verapamil PR 6 HV oral Acute 0.076953 39
[141] verapamil PR 8 HV oral Acute 0.166428 36.75676
[142] verapamil PR 16 HV oral Acute 0.020491 30.4
[142] verapamil PR 16 HV oral Acute 0.022312 32
[142] verapamil PR 16 HV oral Acute 0.047811 40
[142] verapamil PR 16 HV oral Acute 0.041436 36.8
[106] verapamil PR 8 HV oral Acute 0.073311 32
[143] verapamil PR 9 HV oral Acute 0.079685 33.6
[143] verapamil PR 9 HV oral Acute 0.053731 22.4
[144] verapamil PR 6 HV oral Acute 0.020035 7
[145] verapamil PR 8 HV oral Acute 0.078866 32.48
[146] verapamil PR 20 HV oral Acute 0.017303 10
[146] verapamil PR 20 HV oral Acute 0.030963 24
[146] verapamil PR 20 HV oral Acute 0.040981 26
[147] verapamil PR 6 HV oral Acute 0.091069 39
[148] verapamil PR 9 HV oral Acute 0.135647 34.24
[149] verapamil PR 8 HV oral Chronic 0.06557 23.84
[149] verapamil PR 8 HV oral Chronic 0.043941 8.64
[150] verapamil PR 24 HV oral Chronic 0.072855 33.6
[150] verapamil PR 24 HV oral Chronic 0.081962 33.6
[151] verapamil PR 13 HV oral Chronic 0.09289 28.15385
[151] verapamil PR 13 HV oral Chronic 0.163014 44
[148] verapamil PR 22 Patients oral Acute 0.178632 23.68
[148] verapamil PR 14 Patients oral Acute 0.340598 27.2
[152] verapamil PR 18 Patients oral Chronic 0.120211 51
[152] verapamil PR 12 Patients oral Chronic 0.118845 45
[152] verapamil PR 18 Patients oral Chronic 0.253627 45
[152] verapamil PR 12 Patients oral Chronic 0.189879 46
[152] verapamil PR 18 Patients oral Chronic 0.173031 53
[152] verapamil PR 12 Patients oral Chronic 0.140702 46
[152] verapamil PR 18 Patients oral Chronic 0.351527 45
[152] verapamil PR 12 Patients oral Chronic 0.21128 45
[153] verapamil PR 11 Patients oral Chronic 0.150719 23
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